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Abstract 
The Aim of the project was to investigate cell senescence in basal cell carcinoma (BCC). 
Although the concept of oncogene-induced senescence (OIS) was originally confined to 
cultured cells, it is now well established that this mechanism has an important role in 
tumour biology. OIS represents a physiological response that restricts the progression 
of benign tumours into their malignant counterparts e.g. nevi to melanoma or 
adenoma to adenocarcinoma. Full malignancy is associated with the loss of important 
tumour suppressor genes including RETINOBLASTOMA and/or TP53. BCC of the skin is 
the most common skin tumour and is associated with mutational inactivation of the 
PTCH1 tumour suppressor gene (and less frequently oncogenic activation of 
SMOOTHENED). Although BCC does not appear to stem from precursor lesions - 
though mouse models of BCC display areas of basaloid hyperproliferation - and it is 
relatively stable at the genomic level, we sought to determine if these unique tumours 
display any characteristics of OIS. Human BCCs were positive for Senescence-
associated β-galactosidase (SA-β-gal) activity (pH 6.0) and expressed known markers of 
senescence including DCR2, DEC1 (SHARP2) as well as the cell cycle inhibitors p15INK4b 
and p16INK4a. Interestingly, SA-β-gal activity was observed in stromal cells surrounding 
the tumour islands and this may account for why BCCs are difficult to culture in vitro as 
senescent cells are known to express increased levels of growth factors, cytokines and 
ECM proteins. To determine if OIS is associated with Hedgehog signalling in BCC, I 
employed a novel in vitro model of BCC created through PTCH1 suppression in human 
immortalised NEB1 keratinocytes. NEB1-shPTCH1 cells are viable and proliferative 
(albeit more slowly than control NEB1-shCON cells) and do not display SA-β-gal activity 
but they express higher levels of several senescent markers including DCR2 and 
p21WAF1. I also investigated senescence in a Mouse model of BCC in which one allele of 
Ptch1 is mutated and which on x-ray irradiation results in BCC formation. The 
expression of known markers of senescence including DCR2, DEC1 (SHARP2) as well as 
the cell cycle inhibitors p15INK4b, p16INK4a and p53 were all with the exception of 
p21WAF1 detected in these tumours. Together these data suggest that senescence is a 
characteristic of BCC and may explain why these tumours rarely metastasise. 
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1.1 Structure of normal skin 
The skin is the largest organ of the body, making up 16% of body weight, with a  an 
average surface area of 1.8m2 (Gawkrodger, 2002). Skin performs many vital 
functions as both a barrier and regulating influence between the outside world 
and the controlled environment within our bodies. It protects internal tissues from 
exposure to trauma, ultraviolet (UV) radiation, temperature extremes, toxins, and 
bacteria. Other important functions include sensory perception, immunologic 
surveillance, thermoregulation, and control of fluid loss. Structurally skin consists 
of three mutually dependent layers the epidermis, dermis and subcutis (Figure 
1.1) (McGrath et al., 2008). The epidermis is derived from surface ectoderm but is 
colonized by pigment-containing melanocytes of neural crest origin, antigen-
processing langerhans cells of bone marrow origin, and pressure-sensing merkel 
cells of neural crest origin. The dermis is derived from mesoderm and contains 
collagen, elastic fibres, blood vessels, sensory structures, and fibroblasts (Rinn et 
al., 2006). During the fourth week of embryologic development, the single cell 
thick ectoderm and underlying mesoderm begin to proliferate and differentiate. 
The specialized structures formed by the skin, including teeth, hair follicles, 
fingernails, toenails, sebaceous glands, sweat glands, apocrine glands, and 
mammary glands also begin to appear during this period of development. Teeth, 
hair, and hair follicles are formed by the epidermis and dermis in concert, while 
fingernails and toenails are formed by the epidermis alone. Hair follicles, 
sebaceous glands, sweat glands, apocrine glands, and mammary glands are 
considered epidermal glands or epidermal appendages, because they develop as 
down growths or diverticula of the epidermis into the dermis (Gawkrodger, 2002). 
 The skin is a dynamic organ that undergoes continuous changes throughout life as 
outer layers are shed and replaced by inner layers. It also varies in thickness among 
anatomic location, sex, and age of the individual. This varying thickness primarily 
represents a difference in dermal thickness, as epidermal thickness is rather constant 
throughout life and from one anatomic location to another. Skin is thickest on the 
palms and soles of the feet (1.5 mm thick), while the thinnest skin is found on the 
24 
 
eyelids and in the post-auricular region (0.05 mm thick). Skin exposed to sunlight is the 
main site of synthesis of vitamin D, which is essential for the growth and maintenance 
of our bones (Farage et al., 2010). Much importance is attached to the appearance of 
skin, especially in our modern society. Medical conditions affecting the skin can have 
marked effects, not only on our state of well being but also on the ways we interact 
with other people, on our suitability for certain occupations and on the sorts of 
pastimes we can enjoy. Some of the consequences of skin disease, such as rashes and 
itching, may be obvious and others, such as the psychological impact, can be more 
subtle      although just as important.   
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Figure 1.1:  Structure of Normal Skin. Normal skin consists of the three layers, 
epidermis, dermis and subcutis. Within the skin a number of glands and appendages 
are found including the hair follicle, sebaceous and apocrine gland and eccrine sweat 
glands (http://medical-dictionary.thefreedictionary.com/lax+skin).   
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1.1.1 Epidermis 
The epidermis is the thin, tough, outermost layer or epithelial layer of the skin (see 
Figure 1.2). It consists of stratified squamous epithelium that is composed primarily of 
keratinocytes. The epidermis contains no blood vessels and is entirely dependent on 
the underlying dermis for nutrient delivery and waste disposal via diffusion through 
the dermoepidermal junction. Its thickness varies according to body site and in most 
parts of the body the epidermis is about 0.1 mm thick, but on the soles of the feet and 
the palms of the hands it can be 1mm thick or more. It provides a protective barrier 
against mechanical, thermal and physical injury and hazardous substances. The 
epidermis is also important in preventing loss of moisture, it reduces the harmful 
effects of UV radiation and acts as a sensory organ (touch, detects temperature), the 
epidermis helps regulate temperature and immune organ to detect infections and 
preventing entry of substances and organisms into the body. In certain areas of the 
body that require greater protection (such as the palms of the hands and the soles of 
the feet), the outer keratinised layer of the epidermis (stratum corneum) is much 
thicker .  
Most of the cells in the epidermis are keratinocytes, named because they produce a 
tough intermediate filament (IF) protein called keratin. Keratin is also the protein from 
which nails and hair are formed. Keratin gives skin much of its resistance to physical 
wear and tear and makes skin waterproof. Keratinocytes arise in the deepest level of 
the epidermis and new cells are constantly being produced and slowly migrate up 
toward the surface of the epidermis. Once the keratinocytes reach the skin surface, 
they are gradually shed and are replaced by younger cells pushed up from below.  On 
average it takes about 60 days for a new keratinocyte to migrate to the surface and to 
be shed. As keratinocytes divide and differentiate, they move from this deeper layer to 
the more superficial layers. Once they reach the stratum corneum, they are fully 
differentiated keratinocytes or corneocytes, devoid of nuclei and are subsequently 
shed in the process of epidermal turnover. Cells of the stratum corneum are the 
largest and most abundant of the epidermis. The stratum corneum ranges in thickness 
from between 15-100 or more cells depending on anatomic location and is the primary 
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protective barrier from the external environment (McGrath et al., 2008, Farage et al., 
2010, Fuchs, 1990).   
Melanocytes (pigment-producing cells): Melanocytes, are the second most abundant 
cells type found in the epidermis and are derived from neural crest cells and are found 
in the basal layer of the epidermis as well as in hair follicles, the retina, uveal tract, and 
leptomeninges (McGrath et al., 2008). Melanocytes produce pigment called melanin, 
which is responsible for different skin colour. The amount of melanin pigment in the 
skin determines an individual's skin color (skin phototype). Skin pigment can be 
inherited genetically or can be acquired through various diseases. Hormonal changes 
during pregnancy can also vary the amount of pigmentation. The Fitzpatrick Scale is 
used to classify skin complexion and response to UV exposure (See Table 1.1 below). 
This classification is used clinically for evaluation of facial skin pigmentation before 
resurfacing procedures and is important for predicting outcomes and adverse effects. 
Melanin's primary function, however, is to filter out ultraviolet radiation from sunlight, 
which can damage DNA, resulting in numerous harmful effects, including skin cancer. 
Melanin is packaged into small parcels (or melanosomes), which are then transferred 
to keratinocytes, where they absorbs radiant energy from the sun and protects the 
skin from the harmful effects of UV radiation. Melanocytes are the cells of origin 
of melanoma. In areas exposed to the sun, the ratio of melanocytes to keratinocytes is 
approximately 1:4. In areas not exposed to solar radiation, the ratio may be as small as 
1:30. Absolute numbers of melanosomes are the same among the sexes and various 
races. Differing pigmentation among individuals is related to melanosome size rather 
than cell number. Sun exposure, melanocyte-stimulating hormone (MSH), 
adrenocorticotropic hormone (ACTH), estrogens, and progesterones stimulate melanin 
production. With aging, a decline is observed in the number of melanocytes populating 
the skin of an individual. Since these cells are of neural crest origin, they have no ability 
to reproduce. 
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                Table 1.1:  Skin types. 
 
      Skin Types 
 
          Colour 
 
              Features 
 
I.  
 
White or freckled skin 
 
Always burns, never tans 
 
II.  
 
White skin 
 
Burns easily, tans poorly 
 
III.  
 
Olive skin 
 
Mild burn, gradually tans 
 
IV.  
 
Light brown skin 
 
Burns minimally, tans easily 
 
V.  
 
Dark brown skin 
 
Rarely burns, tans easily 
 
VI.  
 
Black skin 
 
Never burns, always tans 
 
The epidermis also contains Langerhans' cells (immune cells), which are part of the 
skin's immune system and found in the epidermis. Langerhan’s cells are responsible for 
helping the body learn and later recognise new ‘allergens’ (material foreign to the 
body). Although these cells help detect foreign substances and defend the body 
against infection, they also play a role in the development of skin allergies. Langerhans 
cells originate from the bone marrow and are found in the basal, spinous, and granular 
layers of the epidermis (Farage et al., 2010).     
Merkel cells are a fourth, epidermal cell and are less visible. These cells are found in 
the basal layer of the epidermis. Their exact role and function of these cells is not well 
understood. Special immunohistochemical stains are needed to visualise Merkel cells. 
These cells are derived from neural crest cells, are found on the volar aspect of digits, 
in nail beds, on the genitalia, and in other areas of the skin. These cells are specialized 
in the perception of light touch (Farage et al., 2010). 
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The epidermis contains four distinct layers, described below from the most superficial 
to the deepest. These layers include stratum basale, stratum spinosum, stratum 
granulosum and stratum corneum. In addition, the stratum lucidum is a thin layer of 
translucent cells seen in thick epidermis. The stratum lucidum represents a transition 
from the stratum granulosum and stratum corneum and is not usually seen in thin 
epidermis. Together, the stratum spinosum and stratum granulosum are sometimes 
referred to as the Malphigian layer. 
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Figure 1.2:  Showing epidermal layers. The epidermis consists of five different layers of 
keratinocytes, stratum basale, stratum spinosum, stratum granulosum, stratum 
lucidum and stratum corneum (http://www.youthful-you-wisdom.com/structure-of-
human-skin.html) . 
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1.1.1.1 Stratum basale (basal layer): The innermost layer of the epidermis which lies 
adjacent to the dermis comprises mainly dividing and non-dividing keratinocytes, 
which are attached to the basement membrane by hemidesmosomes. This layer is 
responsible for constantly renewing epidermal cells. It is a continuous layer that is 
generally one cell thick although it can be two or three cells thick in glabrous skin. The 
basal cells are small, 10-14 nm, and cuboidal in shape (McGrath et al., 2008). These 
undifferentiated, proliferative cells are mitotically active and differentiate outward to 
form the distinctive supra-basal layers of the differentiated tissues. As well as 
keratinocytes, about 25% of the cells found in the basal layer are the melanocytes, 
they produce the melanin that provides pigmentation to skin and hair. Keratinocytes of 
the basal layer synthesize keratins K5 and K14 forming cytoskeleton filaments (keratin 
intermediate filaments) that aggregate into thin bundles (tonofilaments) (Fuchs, 1990, 
Blanpain and Fuchs, 2006). Whilst keratinocytes differentiate and progress to the skin 
surface, some cells of the basal layer remain undifferentiated and self-renew. These 
are the stem cells of the basal layer, being so defined as they do not terminally 
differentiate and with each division a daughter cell is produced which can commit to 
differentiate (McGrath et al., 2008) (Fenderson, 2008). The purpose of these cells is to 
maintain homeostasis regenerating hair and repairing the epidermis after injury. These 
stem cells are located in the basal inter follicular epidermis (IFE) and the bulge region 
of the hair follicle (Alonso and Fuchs, 2003). The stem cells in the hair follicle can give 
rise to the eight differentiated cell types within the hair follicle or either sebocytes of 
the sebaceous glands and under wound healing conditions IFE. The hair follicle cell 
types are as follow; outer root sheath (ORS), companion layers of the ORS, Henle, 
Huxley layers of the Inner Root Sheath (IRS) plus the IRS Cuticle, Cortex of the hair fiber 
and hair fiber cuticle and finally hair follicle germinative epithelium (that will give rise 
to above). Whereas the stem cells of the IFE can also be induced to give rise to hair and 
sebocyte lineages as long as they have the correct mesenchymal signals (Owens and 
Watt, 2003, Youssef et al., 2010). Epidermal stem cells strongly adhere to their 
underlying basement membrane and maintain the homeostasis of the IFE by 
replenishing the suprabasl terminally differentiated cells (Blanpain and Fuchs, 2006, 
McGrath et al., 2008). Compared to differentiated keratinocytes the undifferentiated 
keratinocyte stem cells have a greater life span, are slow cycling and divide to give rise 
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to cell that will remain in the basal layer as a stem cell and to daughter cell, known as a 
transit-amplifying cell (TAC). TA cells, initially undergo a few rounds of division 
increasing the number of cells and from there cells will go on to undergo an 
irreversible withdrawal from the cell cycle (Potten and Booth, 2002, Owens and Watt, 
2003). During this there is a loss of adhesiveness, and the cells are pushed up through 
the layers of the epidermis, undergoing gradual differentiation until they will reach the 
stratum corneum (Owens and Watt, 2003, Youssef et al., 2010). 
1.1.1.2 Stratum spinulosum (spinous, spiny or prickle cell layer): As basal cells divide 
and mature, they move towards the outer layer of skin, initially forming the stratum 
spinosum. Intercellular bridges, the desmosomes, which appear as `prickles' at a 
microscopic level, connect the cells (McGrath et al., 2008). The stratum spinosum is a 
multilayered (4-8 layered) arrangement of cuboidal cells and is the first layer of the 
differentiation compartment formed by the migration of the cells from the basal layer 
(Fuchs, 1990). The basal cells progressively weaken their attachment to the basement 
membrane and those of their neighbors and are pushed up into the spinous layer. 
Although, cells of stratum spinosum are normally post-mitotic, they are still 
metabolically active and synthesize keratins K1 and K10 forming cytoskeletal filaments 
that aggregate to form tonofibrillar bundles which are thicker than tonofilament 
bundles in basal cells (Blanpain and Fuchs, 2006, Fuchs, 1990). These keratin 
intermediate filament are anchored to the desmosomes, which are abundant in 
spinous cells than in the basal cells, joining adjacent cells to provide extra structural 
support, helping the skin resists the abrasion (Blanpain and Fuchs, 2006, Fuchs, 1990). 
As cells move upwards within the spinal layer they synthesize lamellar granules which 
contain lipids that are to be released into the intercellular spaces of the granular and 
stratum corneum cells. These lamellar granules are responsible for the barrier 
properties of the stratum granulosum and stratum corneum through avoidance of 
transepidermal water  loss (Fuchs, 1990). 
1.1.1.3 Stratum granulosum (granular layer):  Succeeding the stratum spinosum is the 
stratum granulosum or granular layer which typically contains 3 to 5 layers of 
squamous cells. Continuing their transition to the surface the cells continue to flatten, 
lose their nuclei and their cytoplasm appears granular at this level. Keratohyalin forms 
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dense cytoplasmic granules that contain profilaggrin-the precursor of the 
interfilamentous protein fillagrin. Additional structural proteins of the cornified 
envelope including loricrin and involucrin are further synthesize by granular cells and 
deposited just beneath the plasma membrane to reinforce the cornified envelope 
(Fuchs, 1990, McGrath et al., 2008). 
1.1.1.4 Stratum corneum (horny layer): This layer is the outermost portion of the 
epidermis, known as the stratum corneum and is relatively waterproof and, when 
undamaged, prevents most bacteria, viruses, and other foreign substances from 
entering the body. The cells of this layer, now referred to as corneocytes or squames, 
are flattened cells that have lost their nuclei and their cytoplasmic organelles (McGrath 
et al., 2008). As the dead cells slough off, they are continuously replaced by new cells. 
During the transition of granular cells to cornified keratinocytes profilaggrin is 
converted to filaggrin which aggregates the keratin filaments into tight bundles 
(conversion of bundling tonfibrils into macrofirillar cables) (Candi et al., 2001, Whitfield 
James and Chakravarthy, 2001). This promotes the collapse of the cell into a flattened 
shape, which is characteristic of the corneocytes of the cornified layer (Fuchs, 1990, 
McGrath et al., 2008). Therefore, corneocytes mostly consist of keratin intermediate 
filament embedded in a filaggrin matrix and surrounded by insoluble lipids (Candi et 
al., 2001).   
 
1.1.2 Dermoepidermal junction/ Basement Membrane: 
The dermoepidermal junction is an undulating basement membrane and has an 
important role in making sure the epidermis adheres to the underlying dermis. The 
dermo-epidermal junction zone (DEJZ) connects the epidermis and dermis (Villone et 
al., 2008). It is composed of a network of structural proteins, which provides a firm 
connection between the basal keratinocytes and the dermis. This structural network is 
made up of: hemidesmosome-anchoring filament complex, basement membrane with 
two layers (the lamina lucida and the lamina densa) and anchoring fibrils (Villone et al., 
2008).     
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1.1.3 Dermis 
The dermis is the fibrous connective tissue or supportive layer of the skin. It lies 
immediately underneath the epidermis and is about four times thicker. It varies in 
thickness, ranging from 0.6 mm on the eyelids to 3 mm on the back, palms and soles. 
The primary function of the dermis is to sustain and support the epidermis. Two layers 
comprise the dermis: a thin papillary layer and a thicker reticular layer (see Figure 
1.3). The papillary dermis lies below and connects with the epidermis. It contains thin 
loosely arranged collagen fibres. Thicker bundles of collagen run parallel to the skin 
surface in the deeper reticular layer, which extends from the base of the papillary layer 
to the subcutis tissue. The dermis contains nerve endings, sweat glands and oil 
(sebaceous) glands, hair follicles, and blood vessels (see Figure 1.3). Fibroblasts are the 
major cell type of the dermis and secrete procollagen and elastic fibers. Procollagen is 
terminally cleaved by proteolytic enzymes into collagen that aggregates and becomes 
cross-linked. These tightly cross-linked collagen fibers provide tensile strength and 
resistance to shear and other mechanical forces. Collagen makes up 70% of the weight 
of the dermis, primarily Type I (85% of the total collagen) and Type III (15% of the total 
collagen) (Farage et al., 2010, Bremnes et al., 2011). Elastic fibers constitute less than 
1% of the weight of the dermis, but they play an enormous functional role by resisting 
deformational forces and returning the skin to its resting shape. 
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                     Figure 1.3: The Dermis including derivatives of skin. 
 
  Figure 1.3: The dermis including derivative structures of skin. 
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1.1.4 Subcutis 
The subcutis is the fatty layer immediately below the dermis and epidermis (see Figure 
1.3). It is also called subcutaneous tissue, hypodermis or panniculus. It mainly consists 
of fat cells (adipocytes), nerves and blood vessels. It can vary considerably in thickness 
from person to person depending mostly on whether they are overweight. 
1.2 Derivative structures of the skin 
Hair: Hair (see Figure 1.3) can be found in varying densities of growth over the entire 
surface of the body, exceptions being on the palms, soles and glans penis, clitoris, labia 
minora, mucocutaneous junction, and portions of the fingers and toes (McGrath et al., 
2008). Hair follicles are most dense on the scalp and face and are derived from the 
epidermis and the dermis (Gawkrodger, 2002). The development of the hair follicle is 
dependent on a series of epithelial-mesenchymal interaction. To begin the dermis 
signals the epidermis to make an appendage, this forms a hair placode in which the 
basal epithelium becomes elongated. In response to this the epidermis signals the 
dermal cells causing them to consolidate and form the dermal papilla (DP) (Blanpain 
and Fuchs, 2009, Widelitz, 2008). Subsequently the DP signals back promoting 
differentiation and proliferation to form the appendage. The developing follicle 
extends down and encloses the DP, whilst the cells at the base still maintain a high 
proliferative state (the matrix cells). Thereafter as the follicle matures the cells begin to 
differentiate into the IRS and the outer layer of the cells differentiates into the ORS. 
The ORS is continuous with the epidermis and has an external basement membrane 
(Fuchs and Raghavan, 2002). Whereas the IRS degenerates near the skin surface which 
enable the hair to protrude on its own. The hair is comprised of terminally 
differentiated keratinocytes from the matrix. Hair follicles also contains sebaceous 
glands to ensure the hair is impermeable to water. Also attach to the follicle is tiny 
bundle of muscle fibre called errector pili, which is responsible for causing the follicle 
lissis to become more perpendicular to the surface of the skin, and causing the follicle 
to protrude slightly above the surrounding skin (Blanpain and Fuchs, 2006, Fuchs, 
1990). The body generates a constant supply of new hair throughout the lifetime 
although the purpose of this is unknown. To produce new hairs, existing follicles 
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undergo cycles of growth (anagen), regression (catagen), rest (telogen) and shedding 
(exogen). During each angen phase, follicles produce an entire hair shaft, while during 
catagen and telogen, follicles rest and prepare their stem cells so that they can receive 
the signal to start the next growth phase and make the new hair shaft (Fellous et al., 
2009, Fuchs and Raghavan, 2002). As well as the IFE, stem cell niches have also been 
implicated and reported in the upper regions of the ORS including the bulge region and 
in the germinal epithelium or matrix (Fuchs, 1990). These bulge stem cells are 
multipotent and can differentiate into all epidermal lineages. It is believed that these 
stem cells are also involved in IFE repair and contribute to wound healing (Blanpain 
and Fuchs, 2006, Fuchs, 1990, Gawkrodger, 2002, Potten and Booth, 2002, Youssef et 
al., 2010).  
Nails: These consist of a dense plate of hardened keratin between 0.3 and 0.5mm 
thick. Fingernails function to protect the tip of the fingers and to aid grasping. The nail 
is made up of a nail bed, nail matrix and a nail plate. The thickened epidermis which 
underlies the free margin of the nail at the proximal end is called the hyponychium. 
Fingernails grow at 0.1 mm per day; the toenails more slowly (Gawkrodger, 2002, 
McGrath et al., 2008). 
Sebaceous glands: Sebaceous glands (see Figure 1.3) or holocrine glands are found 
over the entire surface of the body except the palms, soles, and dorsum of the feet. 
They are largest and most concentrated in the face and scalp where they are the sites 
of origin of acne. The normal function of sebaceous glands is to produce and secrete 
sebum, a group of complex oils that include triglycerides and fatty acid breakdown 
products, wax esters, squalene, cholesterol esters, and cholesterol. Sebum lubricates 
the skin to protect it against friction and makes the skin more impervious to moisture 
(Gawkrodger, 2002). 
Sweat glands: Sweat glands (see Figure 1.3) or eccrine glands are found over the 
entire surface of the body except the vermillion border of the lips, the external ear 
canal, the nail beds, the labia minora, and the glans penis and the inner aspect of the 
prepuce. They are most concentrated in the palms and soles and the axillae. Each 
gland consists of a coiled secretory intradermal portion that connects to the epidermis 
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via a relatively straight distal duct. The normal function of the sweat gland is to 
produce sweat, which cools the body by evaporation. The thermoregulatory center in 
the hypothalamus controls sweat gland activity through sympathetic nerve fibers that 
innervate the sweat glands. Sweat excretion is triggered when core body temperature 
reaches or exceeds a set point (Gawkrodger, 2002). 
1.3 Introduction to Basal Cell Carcinoma (BCC) 
Melanoma and Non melanoma skin cancer (NMSC) are the most common skin cancers 
and NMSC is more common in the caucasian population (Czarnecki et al., 1994). Basal 
cell carcinoma of the skin is a form of non melanoma skin cancer also known as the 
basalioma, basal cell epithelioma, rodent ulcer and Jacobs ulcer; and is the commonest 
tumour affecting humans worldwide. According to the American Cancer Society, 75% 
of all skin cancers are basal cell carcinomas. BCC was first describe in 1824 by Jacobs 
and mainly arises from keratinocytes.BCC is a slow growing tumour and painless (Lo et 
al., 1991). BCC is a form of malignant tumour but it rarely metastasis (Domarus and 
Stevens, 1984). BCC is a treatable cancer but if left untreated it can cause huge 
destruction of surrounding tissues and causes a huge burden on cost of the health 
treatment worldwide. BCC mostly occurs on sun exposed areas and is common on the 
head & neck region and also occurs on trunk and limbs. Although the anatomical 
distribution varies between different types of BCC, nodular basal cell carcinoma mainly 
occurs on the head and neck and superficial is common on the trunk (Bastiaens et al., 
1998).   
1.4 Incidence of BCC  
BCC can occur at any age but it is more prevalent over 40 years of age, and rarely 
occurs at an earlier age. BCC is very rare in dark skin people because of increase in 
pigmentation and due to this have less effect of UV rays of sun. The incidence of BCC 
shows marked difference in geographical variation. In UK around 100,000 people were 
diagnosed with non-melanoma skin cancer in 2010. In the USA more than 1million 
cases occur every year. In Australia the incidence is much higher at 726 per 100,000 
(Marks et al., 1993). Comparative studies from Australia and the UK shows that this 
tumour is more common in men than in women (Diepgen and Mahler, 2002).   
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1.5 Aetiology/Risk factors of Basal Cell Carcinoma  
The main reason for developing BCC is exposure to ultraviolet radiations (UV) and this 
radiation mostly comes from sun exposure (Zanetti et al., 1996). Other risk factors for 
developing BCC include skin colour, with light coloured hair and eyes, also those more 
likely to burn than tan, are more at risk of sun damage than dark skinned people (Lear 
et al., 1997). Other risk factors for developing skin cancer include, age (Mithoefer et 
al., 2002), if you have had skin cancer before, having a family history of skin cancer 
(Vitasa et al., 1990), having had certain other skin conditions or previous radiotherapy 
(Yamada et al., 1996),  having been exposed to certain chemicals (such as arsenic) 
(Maloney, 1996) and having a weakened immune system (Hartevelt et al., 1990). 
BCC can develop either sporadically or by hereditary means (Jemal et al., 2001, Kricker 
et al., 1995). Hereditary BCC develops as a result of basal cell nevous syndrome (BCNS), 
also called Nevoid Basal Cell Carcinoma Syndrome (NBCCS), or Gorlin Syndrome 
(Gorlin, 1995). Gorlin syndrome is an autosomal dominant condition. The reason for 
this syndrome is a mutation in the patched (PTCH1) tumour suppressor gene which is 
located on 9q22.3 (Hahn et al., 1996, Johnson et al., 1996). Approximately one half of 
1% of BCC cases are attributable to the nevoid basal cell carcinoma syndrome (NBCCS), 
an autosomal dominant disorder characterized by multiple BCCs. Other tumors 
associated with the syndrome include medulloblastoma, ovarian fibroma, cardiac 
fibroma, fibrosarcoma, rhabdomyosarcoma, and meningioma. Congenital 
malformations are also features of this syndrome and include pits of the palms and 
soles of the feet, keratocysts and other dental malformations, midline brain 
malformations, strabismus, spine and rib abnormalities, ectopic calcification, 
mesenteric cysts, macrocephaly with characteristic coarse facies, and generalized 
overgrowth. 
BCC can also develop in patients with Xeroderma pigmentosum (autosomal recessive 
disease), Bazex Syndrome also called as Bazex-Dupre-Christol Syndrome (x-linked 
dominant condition) and Rombo Syndrome (autosomal dominant condition). PUVA 
(psoralens plus ultraviolet A) treatment for psoriasis can increase chances of 
developing BCC (Stern and Lange, 1988). There is also an association between infection 
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with the monogenic types of human papillomavirus (HPV) and development of BCC 
(Pfister and Schegget, Barr et al., 1989). 
1.6 Types of Basal Cell Carcinoma and clinical presentation 
Basal cell carcinoma (BCC) is the most common type of skin cancer and the least 
dangerous. It is locally invasive, slowly eating away at the surrounding tissue, and may 
eventually become an ulcerated, bleeding sore. BCC are commonly divided on the 
basis of clinical and histological appearances (Rippey, 1998) Each has a distinct clinical 
presentation as discussed below. More than twenty five different types of BCC can be 
recognised. These different types of BCC are mainly divided into aggressive and non 
aggressive types. The more common types of BCC include nodular, superficial and 
morphoeic BCC. 
1.6.1 Nodular Basal Cell Carcinoma 
 Nodular BCC is the most common form of BCC and accounts for about 60% of all BCC 
cases (Jacobs et al., 1982). These types of BCC mostly occur on the sun exposed areas 
especially on the face and ears but can involve other parts of body. Nodular BCCs 
typically present as a shiny, pearly, raised spot or nodule. Recurrent ulceration is 
frequent and this may lead to a depressed area in the central part of the lesion with a 
more raised, rolled edge. Sensory symptoms are uncommon. Unlike superficial BCCs 
though, nodular lesions will repeatedly ulcerate and bleed (see Figure 1.4 A). 
Histological this tumour is characterised by rounded mass of neoplastic cells with 
peripheral (see Figure 1.4 B).  
1.6.2 Superficial Basal Cell Carcinoma 
The second most common type of BCC (25%) (Jacobs et al., 1982) usually appears on 
the trunk but also on the head & neck or extremities. Clinically it appears as a 
Superficial BCC and presents as a bright pink, shiny, usually well-defined patch on the 
skin. The degree of redness may fluctuate greatly, and it may be more obvious when 
the skin is warm or the spot is rubbed, e.g. after a shower. Superficial BCC may 
sometimes be pigmented, as may all BCCs. It is not usually symptomatic, although it 
may sometimes be slightly itchy. Though these lesions are readily eroded by minor 
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trauma, they seldom bleed. Superficial BCC progressively enlarges over months to 
years. With time, areas of nodular or even morphoeic growth pattern may supervene 
within the original superficial BCC (see Figure 1.4 C). Histologically it is defined as one 
or more tumour foci extending from epidermis into the papillary dermis with 
peripheral palisading cells (see Figure 1.4 D) . 
1.6.3 Morphoeic Basal Cell Carcinoma 
This type of BCC also called sclerosing (resemble scar) BCC. This type of tumour is less 
common (2%) but is an aggressive type of BCC (Jacobs et al., 1982). It is often found on 
the head and neck, much like nodular BCC. Morphoeic BCCs are usually long standing 
and tend to be deeply invasive and have the appearance of a pale scar (see Figure 1.4 
E). They can be difficult to detect and sometimes the patient is unaware of it, or may 
have simply thought it was an old scar that hadn’t healed very well. They are quite firm 
to touch. Morphoeic BCCs constitute an aggressive growth pattern and are often 
associated with significant tissue destruction. Their finger-like processes often extend 
much more widely and deeply than it seems on inspection. Morphoeic BCCs are 
frequently asymptomatic, and may remain undetected for many years before being 
treated. Histologically it is defined as one or more tumour island in deep dermis with 
peripheral palisading cells (see Figure 1.4 D). 
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Figure 1.4: Showing clinical and histological images of BCC (A) Nodular BCC (B) Shows 
histology of Nodular BCC (C) Superficial BCC (D) Shows histology of Superficial BCC (E) 
Morphoeic BCC (F) Shows histology of Morphoeic BCC. Figure A, C and E were taken 
from http://www.skincancerclinic.md/skin-cancer/bcc/. Other pictures taken from BCC 
used in this study. 
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1.7 Treatment of Basal Cell Carcinoma  
BCC is a treatable cancer but if left untreated it can cause huge disfigurement of 
surrounding tissue. There are different treatment options available for this disease and 
choice of treatment is based on the type, size, location, and depth of penetration of 
the tumour, the patient’s age and general health, and the likely cosmetic effect. 
Standard surgical excisions. This is the preferred method for removing BCC. This 
method involves the removal of the whole tumour mass and surrounding normal 
tissues. After removal of the tumour tissues the wound is closed by stitching. Standard 
surgical excision is not as good and efficient than Mohs but still has cure rate near 90%. 
The basic disadvantage of this procedure is the high reoccurrence of BCC of the face, 
especially around eyelids and nose (Sigurdsson and Agnarsson, 1998, Farhi et al., 
2007).  
Mohs surgery (or Mohs micrographic surgery). This type of treatment is normally 
done in the outpatient department or clinic of doctor. By using this method 
anaesthetic is applied on the surgical area of the patient. The tumour is excised and 
immediately examined under the microscope thoroughly. If the tumour is still present 
the procedure is repeated until the last layer of tumour examined under the 
microscope is tumour free. This method of surgery is a form of pathology processing 
called CCPDMA (complete circumferential peripheral and deep margin assessment) 
and has the highest rate of cure generally 98% or better(Rowe et al., 1989a). This 
method of treatment is generally used for recurring tumours, poorly demarcated 
tumours, or in critical areas around eyes, nose, lips and ears (Rowe et al., 1989b). 
Chemotherapy/Topical Medication. Some superficial cancers can be treated with local 
therapy such as 5-flurouracil and 5% Imiquimoid cream five times a week for a few 
weeks. These are chemotherapy agents and are approved by the FDA for superficial 
BCC. The success rate of treatment is near about 70% to 90% (Romagosa et al., 2000, 
Love W, 2009).  
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Immunotherapy. Treatment using Euphorbia peplus, a common garden weed has 
been used as an immunotherapy agent in Australia for treating BCC. This is now 
commercially available in the UK and has the trade name 'Picato'.   
 Radiation. In this method x-ray beams are directed towards the tumour. This 
treatment is repeated several times per week for few weeks. This form of treatment is 
recommended for tumours that are hard to manage surgically and for elderly patients 
and those in poor health and also recommended for sites where surgical excision can 
cause disfigurement. The cure rate of this treatment is around 95% for small tumours 
and 80% for large tumours. This treatment can cause long term cosmetic problems, 
radiation risk and involve multiple visits to the clinic.  
Photodynamic therapy (PDT). This type of treatment is useful when the patient has 
more than one BCC. In this treatment a photosensitizing agent such as Methyl 
aminolevulinate is applied on the tumour after which the area of treatment is 
activated by strong light. The cure rate ranges from 70% to 90%. 
Cryosurgery. In this technique liquid nitrogen is used to destroy the tumour by 
freezing. The procedure may be repeated during the same session to remove all 
tumour tissues. It is an effective form of treatment for all forms of tumours and 
treatment of choice for patients with bleeding disorders or intolerance to anaesthesia. 
The cure rate for this treatment is less effective than excision and ranging from 80% to 
90%. The disadvantages of this treatment include lack of margin control, tissue 
necrosis, over and under treatment of tumour and long recovery time. 
 Electrodessication and curettage. In this method the doctor uses a curette to remove 
the cancerous growth and then skin is burned with an electric current to soften the 
area for further cancer removal. This technique is repeated to ensure tumour is fully 
removed. The cure rate of this technique is less effective than surgical excision. This 
technique is not recommended for treating aggressive BCC and those on high risk and 
difficult sites. 
Hedgehog Pathway Inhibitors. Vismodegib (Erivedge) is the first FDA-approved drug 
for advanced forms of basal cell carcinoma (Keating, 2012). It selectively inhibits 
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Smoothened (SMO), a key transmembrane protein involved in hedgehog signal 
transduction of cancerous epithelial cells. In a phase I dose-ranging study by Von Hoff 
et al (2011), 18 of 33 patients showed an objective response. Two of the 18 had 
complete response, and the remaining 16 showed a partial response. FDA-approval 
was based on a single, international, open-label trial (n=104). Of the 104 participants, 
96 were evaluable. Of those with metastatic BCC (n=33), 30.3% had partial response, 
but none had complete response. With locally advanced BCC (n=63), 22% showed a 
partial response and 20% showed complete response (Keating, 2012).[ 
 
1.8 Hedgehog Signalling Pathway 
 The Hedgehog (HH) family of secreted signalling proteins play a crucial role in the 
development of animal organisms from Drosophila to humans, regulating the 
morphogenesis of various tissues and organs. HH plays a major role in patterning of 
tissues including growth of digits in limbs (Towers and Tickle, 2009), spinal cord and 
organization of brain (Weedon et al., 2008). Recent studies show the HH family also 
plays an important role in adult life including maintenance of the stem cell population 
to regulate maintenance and regeneration of adult tissues (Huangfu and Anderson, 
2006). HH pathway is also involved in the development of cancers especially of lung, 
mammary glands, prostate and skin (BCC) (Velcheti and Govindan, 2007, Huang et al., 
2011, Hatsell and Frost, 2007, Li et al., 2011, Datta and Datta, 2006).  
HH was originally identified as a determinant of segment polarity in Drosophila 
melanogaster, the fruit fly (Rubin et al., 2005, Hooper and Scott, 2005).  Drosophila 
have one hedgehog gene (Hh) whereas vertebrates have a more complex signalling 
system (Dennler et al., 2007, Hooper and Scott, 2005). HH proteins are glycoproteins 
that activate a membrane-receptor complex (see Figure 1.5) and consist of three 
family members; Sonic Hedgehog (SHH), Indian Hedgehog (IHH) and Desert Hedgehog 
(DHH) (Lauth and Toftgard, 2007, Hooper and Scott, 2005).  HH precursors are cleaved 
at the C- and N- terminal regions for cholesteroylation, (a cholesterol molecule is 
covalently attached to the COOH-terminal glycine); and palmitoylation, (a palmitoyl 
moiety found on the NH2 terminal cysteine).  Subsequently mature HH proteins are 
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transported to the cell surface (Katoh and Katoh, 2008, Hooper and Scott, 2005, 
Couve-Privat et al., 2004, Yang et al., 2010). The best characterised is SHH as it is the 
most commonly expressed and potent of all the HH ligands although the binding 
affinities of all three are similar (Ruiz i Altaba et al., 2002c, Lauth and Toftgard, 2007, 
Daya-Grosjean and Couvé-Privat, 2005).  The N terminal domain of SHH is responsible 
for the signalling activities whilst the C terminal domain is responsible for the 
intramolecular precursor processing of the protein (Couve-Privat et al., 2004). HH 
signalling is mediated through incompletely described balances between activating 
and repressive forms of GLI (Bishop et al., 2010).  
HH ligand can be transported by diffusion through extracellular spaces or a 
concentration gradient. HH can also enter the cell via endocytosis which can be 
receptor mediated (Ryan and Chiang, 2012). Heparin sulphate proteoglycans (HSPG) 
have been shown to control a number of signalling pathways such as HH, Wnt, TGF-β 
and FGF signalling pathways. HSPGs are capable of retaining and stabilising HH ligands 
by facilitating ligand-receptor interactions (Ryan and Chiang, 2012). For HH to be 
released from the cell, a 12-pass transmembrane protein Dispatched (DISP) is required. 
DISP has a significant sequence similarity to PTCH in particular, the sterol sensing 
region that is implicated in lipid transport or secretion of lipid modified proteins (Lum 
and Beachy, 2004). Lipid modified HH is not secreted from cells if there is an absence 
of DISP. In D. melanogaster, DISP releases lipid modified HH from the cell compared 
to mammalian DISP which is thought to be involved in HH multimer formation (Daya-
Grosjean and Couvé-Privat, 2005). HH signalling is controlled by the tumour suppressor 
protein PTCH1 and the G-protein coupled receptor SMO (Taipale and Beachy, 2001). 
PTCH1 contains twelve transmembrane domains and two extracellular loops that bind 
to HH ligands (Marigo et al., 1996). Mutations of PTCH1 are associated with various 
birth defects as the HH pathway is heavily involved in embryonic development (Hahn 
et al., 1996). PTCH2 was discovered in vertebrates shares a 54% sequence homology to 
PTCH1 however the amino and carboxylic regions differ which confers a different 
protein function (Carpenter et al., 1998).  Not only does PTCH1 function as the HH 
receptor, PTCH1 is a negative regulator of the HH pathway by inhibiting SMO. SMO has 
been described as a proto-oncogene (Beachy et al., 2004, Couve-Privat et al., 2004, 
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Daya-Grosjean and Couvé-Privat, 2005) and is 7-transmembrane 115 kDa protein with 
structural similarity to serpentine, G-protein coupled receptors (van den Heuvel and 
Ingham, 1996, Alcedo et al., 1996).   Smoothened is responsible for triggering 
intracellular signalling and the subsequent activation of HH target genes. There is one 
known human smoothened gene (SMO) and is homologous with members of the 
‘frizzled’ (WNT receptor) family. SMO comprises of a cytoplasmic tail with a domain 
that binds to a multi-molecular series of interacting proteins which also includes 
suppressor of fused (SuFu), fused (Fu) and GLI (Beachy et al., 2004, Epstein, 2008, 
Lauth and Toftgard, 2007). In the absence of a HH signal, PTCH1 localises to the 
primary cilium and maintains SMO in an inactive form thus preventing its translocation 
to the cilia (Rohatgi et al., 2007a). Early studies of PTCH1 would suggest that it binds 
directly with SMO (Murone et al., 1999), however more recent studies indicate that 
the two proteins do not physically bind to each other (Taipale and Beachy, 2001).  
The key components of the HH signalling pathway are shown in Figure 1.5 and 
discussed in more detail in sections 1.8.1, 1.8.2 and 1.8.3. The HH receptor (see Figure 
1.5), patched (PTCH), represses HH signalling by inhibiting the signalling effecter 
smoothened (SMO). PTCH mutational inactivation leads to over expression of 
downstream HH-responsive genes, such as GLI-1 and GLI-2, which results in BCC 
development (Denef et al., 2000). Downstream of SMO, the GLI-1 transcription factors 
are activated resulting in the induction of transforming growth factor (TGF-β) 
(Heberlein et al., 1993) and platelet-derived growth factor alpha (PDGF) (Xie et al., 
2001). 
As the HH signalling pathway plays an important role in development, it is not 
surprising that dysregulation of the pathway is associated with disease including 
cancer (di Magliano and Hebrok, 2003, Ruiz i Altaba et al., 2002a, Taipale and Beachy, 
2001). HH signalling has also been shown to be required for the maintenance of 
cancers such as lung and prostate cancer despite the tumours arising from the 
dysregulation of other signalling pathways (Karhadkar et al., 2004, Watkins et al., 
2003).  HH signalling was implicated In BCC biology after the observation that Gorlin 
syndrome patients are predisposed to developing BCCs (Johnson et al., 1996). Gorlin 
syndrome patients are born with a defective PTCH1 allele and upon the loss of 
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function of the remaining allele (loss of heterozygosity, LOH) BCCs develop (Gailani and 
Bale, 1997). As a result Gorlin patients are more likely to acquire the LOH mutation of 
PTCH1 and develop BCCs at an earlier age than non-Gorlin patients. Non-Gorlin 
patients develop tumours later in life because loss of function mutations to both 
PTCH1 alleles takes longer to occur for BCCs to form (Gailani et al., 1996). PTCH1 LOH 
mutations have been observed sporadic BCCs ranging between 11-67% in various 
studies (Saran, 2010). It has been reported that approximately 90% of sporadic BCCs 
harbour loss of function mutations of PTCH1 and 10% activating mutations of SMO 
(Youssef et al., 2010). 50% of sporadic BCCs have been shown to carry mutations of 
PTCH1 that are caused by UVB radiation (Gailani and Bale, 1997). In contrast one study 
has shown that out of the BCCs examined, PTCH mRNA was over expressed in all 
samples. PTCH protein expression was found in all tumour cells and stronger in 
palisading cells but not in normal epidermal cells. Downstream of PTCH1, activating 
mutations of SMO have been described in sporadic BCCs as Arg-562-Gln in SMO-
mutant 1 (M1) and Trp-535-Leu in SMO-mutant 2 (M2). Of the two identified 
mutations the SMO-M2 mutation was found in nearly all BCCs where PTCH1 remained 
intact. Mice over expressing wild type SMO do not develop any abnormalities whereas 
SMO-M2 over expressing mice display BCC like characteristics (Xie et al., 1998). A 
number of mouse models of BCC have been developed to help understand how BCCs 
may form. As Ptch -/- mice are not viable, Ptch +/- mice were developed with a single 
allele mutation of Ptch as seen in Gorlin patients.  An in-vivo study has shown that loss 
of Ptch1 function in mouse skin is capable of inducing BCC formation (Daya-Grosjean 
and Couvé-Privat, 2005, Donovan, 2009). Further downstream of the HH pathway, 
mice over expressing GLI1 were able to develop tumours that share a resemblance to 
BCCs (Nilsson et al., 2000a). Interestingly, mice over expressing an activated mutant 
form of GLI2 which is a positive regulator of GLI1 developed multiple BCCs 
(Grachtchouk et al., 2000, Sheng et al., 2002). GLI2 studies in mice show that over 
expression of the protein in hair follicle stem cells leads to nodular BCC formation 
compared to GLI2 over expression in the IFE which leads to a more superficial BCC 
phenotype (Grachtchouk et al., 2000). 
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Figure 1.5: Overview of Sonic Hedgehog Signalling. In the absence of ligand, the HH 
signalling pathway is inactive (left). In this case, the transmembrane protein receptor 
Patched (PTCH) inhibits the activity of Smoothened (SMO), a seven transmembrane 
protein. The transcription factor GLI-1 a downstream component of HH signalling, is 
prevented from entering the nucleus. As a consequence, transcriptional activation of 
HH target genes is repressed. Activation of the pathway (right) is initiated through 
binding of any of the three mammalian ligands — Sonic hedgehog, Desert hedgehog or 
Indian hedgehog (all are represented as HH in the figure) — to PTCH. Ligand binding 
results in de-repression of SMO, thereby activating a cascade that leads to the 
translocation of the active form of the transcription factor GLI to the nucleus. Nuclear 
GLI activates target gene expression, including PTCH and GLI-1 itself, as well as Hip, a 
HH binding protein that attenuates ligand diffusion (di Magliano and Hebrok, 2003).   
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1.8.1 Patched (PTCH) 
PTCH is the component that specifically binds hedgehog (Stone et al., 1996), is 1500 
amino acids glycoprotein with 12- pass transmembrane receptor and two large 
extracellular loops that are needed for binding with hedgehog (Hooper and Scott, 
1989, Nakano et al., 1989). PTCH, a tumour suppressor gene is located on chromosome 
9 q22-q31 and encodes for the protein PTCH, a 12-transmembrane receptor (Ruiz i 
Altaba et al., 2002c, Asplund et al., 2008).  There are two PTCH genes, PTCH1 and 
PTCH2 which have similar affinities for SHH (Couve-Privat et al., 2004). PTCH1 is a 
transmembrane protein that together with Smoothened forms a receptor complex for 
SHH. This protein is expressed in the cell membrane of target tissues, where it 
represses Smoothened signalling. Binding of SHH to PTCH1 (physiological activation) or 
mutational inactivation of PTCH1 (pathological activation) suspends the inhibition of 
Smoothened, which results in the activation of the hedgehog pathway. Mutations in 
PTCH can cause tumours including BCC, medulloblastoma, meningioma, breast 
carcinoma and neuroectodermal tumours (Hahn et al., 1996, Johnson et al., 1996).   
1.8.2 Smoothened (SMO) 
 SMO has been described as a proto-oncogene (Beachy et al., 2004, Couve-Privat et al., 
2004, Daya-Grosjean and Couvé-Privat, 2005) and is 7-transmembrane 115 kDa protein 
with structural similarity to serpentine, G-protein coupled receptors (van den Heuvel 
and Ingham, 1996, Alcedo et al., 1996).   Smoothened is responsible for triggering 
intracellular signalling and the subsequent activation of HH target genes. There is one 
known human smoothened gene (SMO) and is homologous with members of the 
‘frizzled’ (WNT receptor) family. SMO comprises of a cytoplasmic tail with a domain 
that binds to a multi-molecular series of interacting proteins which also includes 
suppressor of fused (SuFu), fused (Fu) and GLI (Beachy et al., 2004, Epstein, 2008, 
Lauth and Toftgard, 2007).  The multi-molecular complex is a key regulator in shuttling 
GLI proteins between the cytoplasm and the nucleus. In the absence of hedgehog, 
patched interacts at the membrane with smoothened, rendering it inactive. When 
inactive the multi-molecule complex is bound to microtubules/ cytoskeleton and 
retains the GLI in the cytoplasm though phosphorylation of the carboxy-terminus or 
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full length GLI, which represses the translocation of GLI to the nucleus (Lauth and 
Toftgard, 2007) However, when hedgehog binds to patched, the inhibition of 
smoothened signalling is released and downstream genes are transcriptionally 
unregulated.  
1.8.3 GLI Proteins 
 GLI proteins are large multifunctional transcription proteins, initially isolated from glial 
cell tumours (Fischer et al., 1995), present either in the nucleus and in cytoplasm. 
There are three different forms of GLI. GLI-1 only occurs as a full length transcriptional 
activator and GLI-2 and GLI-3 can be processed as truncated repressors (Wang et al., 
2000, Pan et al., 2006). The over expression of GLI-1 and GLI-2 can induce  
spontaneous skin tumorigenesis (Nilsson et al., 2000b).  In the presence of HH ligand 
(Figure 1.6) the pathway is activated.  This can occur on binding to any of the HH 
ligands, SHH, DHH or IHH to the PTCH receptor.  This results in the inhibition of PTCH 
action on SMO.  Consequently SMO is activated and transduces a signal from the 
plasma membrane to the cytoplasm.  SuFu is inhibited by SMO and through an 
unknown mechanism this triggers the dissociation of GLI from the SuFu/Fu complex.  
This regulates between the full length forms and the truncated, repressive forms of GLI 
(Bishop et al., 2010).  GLI then translocates to the nucleus and subsequently binds to 
the DNA of HH-target genes with a consensus-binding site (5’-tgggtggtc-3’) (Yang et al., 
2010).  GLI zinc finger proteins are large multifunctional transcription factors that are 
the transcriptional target genes of SHH signalling (Ruiz i Altaba et al., 2002c, Lauth and 
Toftgard, 2007).  They were first identified as a gene unregulated in Glioblastoma 
(Epstein, 2008).  There are three members of the GLI family named GLI 1, 2 and 3 
which have a highly conserved DNA-binding domain with a zinc finger that binds with a 
consensus sequence although each has an independent role (Dennler et al., 2007, 
Fernandez-Zapico, 2008).  GLI is inherent in both the  nucleus and the cytoplasm and 
are part of a multi-molecular complex as previously mentioned (Figure 1.6) (Ruiz i 
Altaba et al., 2002c, Lauth and Toftgard, 2007, Ruiz i Altaba et al., 2002b).  Both GLI 2 
and 3 have C-terminus activator domains and N-terminus repressor domains and 
therefore can act as either activators or suppressors, whereas GLI1 only has a C-
terminus domain, functioning only as an activator (Epstein, 2008, Katoh and Katoh, 
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2008, Hooper and Scott, 2005, Tojo et al., 2003).  Activators GLI 2/3 function upstream 
of GLI-1 and induces the transcription of the GLI-1 gene and PTCH via direct binding to 
their promoter regions (Dennler et al., 2007, Lauth and Toftgard, 2007).  PTCH then 
negatively feeds back inhibiting the membrane signal, whereas GLI-1 positively feeds 
back inducing GLI-1 specific genes (Katoh and Katoh, 2008, Lauth and Toftgard, 2007, 
Hooper and Scott, 2005, Bonifas et al., 2001). HH-interacting protein (HIP) participates 
in a negative feedback loop by sequestering hedgehog ligands, but unlike PTCH, it has 
no effect on the activity of SMO (Hooper and Scott, 2005, Yang et al., 2010).  The SHH 
signalling cascade is believed to activate several genes including Transforming Growth 
factor β (TGFβ)/ Bone Morphogenetic Protein (BMP), and Wnt family proteins (Couve-
Privat et al., 2004, Bonifas et al., 2001). Other transcription targets of GLI are reported 
target genes such as FOXM1, CCND1, SFRP1 and PDGFRA (Katoh and Katoh, 2008, 
Asplund et al., 2008).  
1.8.4. Primary Cilia 
The primary cilium is a microtubule-based organelle which projects from the surface of 
virtually all cells in the mammalian body but is predominantly seen in stromal and 
epithelial cells (Michaud and Yoder, 2006, Hoey et al., 2011). They are immotile and 
anchored to the cell by the basal body just beneath the plasma membrane, which 
develops from the centriole of the centrosome by turning microtubules into a 
structure called the axoneme (Simpson et al., 2009, Michaud and Yoder, 2006, Rohatgi 
et al., 2007b).  The development of the cilia is regulated by the cell cycle, as such 
primary cilia are found in cells within the G0 phase of the cell cycle. The cilium forms a 
continuous membrane with the cell although the transport of proteins into the cilium 
is regulated (Michaud and Yoder, 2006, Hoey et al., 2011).  The function of the primary 
cilium is as a sensory organelle which receives both mechanical and chemical signals 
from other cells and the environment, and transmits these signals to the nucleus to 
elicit a cellular response (Hoey et al., 2011).  
The mechanism for the signal transduction cascade from SMO to GLI-1 is not fully 
defined, although increasing data suggest that the primary cilium provides a platform 
for relaying the signal from the cell membrane to the nucleus (Kasper et al., 2009).  
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The discovery that the protein components of the primary cilia are required for HH 
signalling led to the suggestion that sub cellular localisation is important in HH 
signalling (Rohatgi et al., 2007b).  Recent studies revealed that multiple components of 
the SHH, but also the platelet derived growth factor receptor-A signal transduction 
pathway is localize to the primary cilium (Michaud and Yoder, 2006, Kasper et al., 
2009).  As well as PTCH and SMO, the GLI proteins and Sufu have been shown to reside 
in the dorsal tip of the primary cilium (Michaud and Yoder, 2006, Simpson et al., 2009).  
SMO localizes to the primary cilia in response to SHH which appears to be a crucial 
step in its activation. Rohatgi et al, 2007 showed that after stimulation of cells with 
SHH, endogenous SMO was enriched in the primary cilia.  Total levels of SMO were not 
altered, but localised to the cilia (Rohatgi et al., 2007b).  Furthermore SHH triggered 
the removal of PTCH from the primary cilium, thereby allowing the binding and 
movement of SMO within the cilia (Rohatgi et al., 2007b).  The loss of the cilium blocks 
ligand-induced signalling by the SHH pathway (Michaud and Yoder, 2006, Fendrich et 
al., 2011).   
Intraflagellar transport (IFT) function in the cilia is also believed to be required for SMO 
activity as well as modulation of GLI protein activity (see Figure 1.11) (Michaud and 
Yoder, 2006, Simpson et al., 2009, Kasper et al., 2006b).  As IFT proteins do not play a 
role in Drosophila HH signalling, Kasper et al, 2006 speculate that cilia are involved in 
the relay of the mammalian HH-signal and that IFT proteins organise a structure that 
may facilitate the interaction of other HH-signalling components with latent GLI 
transcription factors (Kasper et al., 2006b). 
Genetic mutations that disrupt the function of primary cilia result in a broad spectrum 
of disorders, including cystic kidneys, hepatic and pancreatic abnormalities, skeletal 
malformations, obesity, and severe developmental defects (Michaud and Yoder, 2006).  
Defects and function mutations in IFT result in severe patterning defects of the neural 
tube similar to observations made in SHH and SMO mutated embryos (Kasper et al., 
2006b). 
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Figure 1.6: Hedgehog Signalling Through Primary Cilia An illustrative representation of 
HH signalling through the primary cilium.  Activation of the pathway is initiated upon 
HH binding to PTCH1, which leads to de-repression of SMO. Therefore the HH 
signalling cascade involving a multi-protein complex with the primary cilium acting as a 
processing platform, leads to the translocation of the active GLI transcription factors to 
the nucleus. Abbreviations: Intraflagellar proteins (IFT); Protein kinase A (PKA); 
Suppressor of fused (SuFu).   Modified from Kasper et al, 2009 (Kasper et al., 2009) 
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1.9 Hedgehog Signalling in Cancer 
It has been well documented that the aberrant activation of the HH signalling pathway 
can lead to a number of cancers. As the HH signalling pathway plays an important role 
in development, it is not surprising that dysregulation of the pathway is associated 
with disease including cancer (di Magliano and Hebrok, 2003, Ruiz i Altaba et al., 
2002a, Taipale and Beachy, 2001, Lee and Frederic, 2006). HH signalling has also been 
shown to be required for the maintenance of cancers such as lung and prostate cancer 
despite the tumours arising from the dysregulation of other signalling pathways 
(Walsh, 2005). HH signalling was implicated in BCC after the observation that Gorlin 
syndrome patients are predisposed to developing BCCs. Patients with this syndrome 
are born with a defective PTCH1 allele and upon the loss of function of the remaining 
allele (loss of heterozygosity, LOH) BCCs develop (Gailani and Bale, 1997). As a result 
these patients are more likely to acquire the LOH mutation of PTCH1 and develop 
BCCs at an earlier age than non-Gorlins patients. Non-Gorlins patients develop 
tumours later in life because loss of function mutations to both PTCH1 alleles takes 
longer to occur for BCCs to form. PTCH1 LOH mutations have been observed sporadic 
BCCs ranging between 11-67% in various studies (Lee and Frederic, 2006). It has been 
reported that approximately 90% of sporadic BCCs harbour loss of function mutations 
of PTCH1 and 10% activating mutations of SMO (Youssef et al., 2010).  
 
SHH signalling is often activated in solid tumours including BCC, but also Gastric 
Carcinoma, Melanoma, Medulloblastomas, Gliomas in brain, pancreatic and small cell 
lung cancer to name a few and are reported to have increased levels of SHH (Snijders 
et al., 2009, Yauch et al., 2008, Katoh and Katoh, 2008, Yoo et al., 2008, Daya-Grosjean 
and Couvé-Privat, 2005, Walter et al., 2010).  Activation of the pathway can be either 
by over expression of the ligand or by the alteration of the downstream signalling 
pathway within the tumour epithelium (Figure 1.7) (Snijders et al., 2009, Yauch et al., 
2008).  Predominantly mouse models have been used to study BCCs.  Over expression 
of HH in the skin of transgenic mice results in skeletal and skin anomalies and the 
development of tumour like BCCs (Daya-Grosjean and Couvé-Privat, 2005).  In mice 
over expressing GLI-1 and GLI-2, BCC like tumours also develop.   
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Perturbations in the SHH pathway can occur through the mutation or deletion of PTCH 
or SMO. (Crowson, 2006) Mutations in the PTCH gene produces a truncated form of 
the protein which is unable to bind to and inactivate SMO (Crowson, 2006).  
Heterozygous mutations in PTCH1 were first noticed in Gorlin syndrome as previously 
mentioned (Section 1.2.1) (Wong et al., 2003, Crowson, 2006). Sporadic mutations in 
other forms of cancer such as medulloblastoma, oesophageal SCC and transitional cell 
carcinoma of the bladder have also been reported with the loss of PTCH function 
(Beachy et al., 2004, Dennler et al., 2007). Downstream of PTCH1, activating mutations 
of SMO have been described in sporadic BCCs as Arg-562-Gln in SMO-mutant 1 (M1) 
and Trp-535-Leu in SMO-mutant 2 (M2). Of the two identified mutations the SMO-M2 
mutation was found in nearly all BCCs where PTCH1 remained intact. The mice over 
expressing wild type SMO do not develop any abnormalities whereas SMO-M2 over 
expressing mice display BCC like characteristics. SMO gain of function mutations have 
been documented in a subset of small cell lung carcinoma (Dennler et al., 2007).  Non-
canonical activation of the HH pathway i.e. the pathway is stimulated by another 
factor, may also contribute to BCC development. Transforming growth factor-β (TGF-β) 
has been reported to induce both GLI1 and GLI2 expression in keratinocytes (Javelaud 
et al., 2011).  
The results of these sporadic mutations leads to SHH-independent constitutive 
activation by the target genes GLI-1 and PTCH1 itself (Valin et al., 2009).  Consequently, 
there is consistent up-regulation of the transcription target family GLI.  Studies of the 
HH signalling pathway are usually performed by the activation, inhibition and 
expression of downstream targets including SMO and GLI. 
Up-regulation of GLI-1 has been seen in BCC and is thought to play a role in the 
development of BCC by activating BCL2 which therefore decreases apoptosis. 
(Crowson, 2006)  The up regulation of GLI-1 and GLI2 has also been reported in mRNA 
extractions from micro-dissected BCC cells (Asplund et al., 2008, Daya-Grosjean and 
Couvé-Privat, 2005).  PTCH1 expression was not up-regulated in their study.   Work 
with mice has shown that GLI can induce BCC like tumour formation (Ruiz i Altaba et 
al., 2002c) indicating that activation of the SHH pathway and thereby the activation of 
a single transcription factor can cause tumour formation.  Furthermore sporadic BCCs 
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frequently have GLI-1 expression unlike sporadic SCCs which show no expression (Ruiz 
i Altaba et al., 2002c).  More recently work on Oesophageal SCC has shown the HH 
signalling pathway to be active.  High levels of SHH and SMO were detected in SCC 
whereas PTCH1 levels were low.  GLI1 showed varied expression with 50% of SCC 
expressing high levels of GLI1 (Leovic et al., 2011).  It has also been reported that GLI-1 
expression is not always associated with a loss of the receptor PTCH suggesting that 
GLI-1 may have a more aggressive role in development of BCC (Micke et al., 2007).  
Furthermore recent work has shown that SHH responsive tumours have activated 
canonical pathways in the tumour stroma and in some cases this is restricted to the 
stroma (Chen et al., 2011). 
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Figure 1.7: SHH Signalling Pathway Mutations in BCC Mutations of the tumour 
suppressor gene PTCH are found in the nevoid basal cell carcinoma (NBCC) patients, 
sporadic and Xeroderma Pigmentosum (XP).  BCCs present mutations of PTCH as well 
as the proto-oncogenes SHH and SMO. Over expression of downstream target genes 
such as GLI-1 is also implicated in BCC development.  Modified from (Daya-Grosjean 
and Couvé-Privat, 2005). 
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1.10 Mouse Models of Basal Cell Carcinoma 
Basal cell carcinomas, the commonest human skin cancers, consistently have 
abnormalities of the hedgehog signalling pathway and often have PTCH gene 
mutations (Undén et al., 1997). There are so many mouse models of BCC have been 
developed to help understand how BCCs may form (Aszterbaum et al., 1999). 
The Ptch mutant mice provide the first mouse model, to our knowledge, of ultraviolet 
and ionizing radiation-induced basal cell carcinoma-like tumours, and also 
demonstrate that PTCH  inactivation and hedgehog target gene activation are essential 
for basal cell carcinoma tumorigenesis (Aszterbaum et al., 1999). In one study 
Ptch+/− mice develop primordial follicular neoplasms resembling human 
trichoblastomas, and when they expose to ultraviolet radiation or ionizing radiation 
results in an increase in the number and size of these tumours and a shift in their 
histologic features so that they more closely resemble human basal cell carcinoma 
(Mancuso et al., 2004). Like human BCCs, mouse trichoblastoma and BCC-like tumours 
are composed of nests of basaloid cells with large nuclei, scant cytoplasm and few 
mitotic figures (Mancuso et al., 2004). Some of the mouse BCC and trichoblastoma 
tumour nests also have peripheral palisading and small cysts lined by cornified cells 
reminiscent of hair follicle structures (Mancuso et al., 2004).  An in vivo study has 
shown that loss of Ptch1 function in mouse skin is capable of inducing BCC formation 
(Adolphe et al., 2006). An inducible Ptch1 knockout mouse system has demonstrated 
that the loss of Ptch1 function from the basal cell population is sufficient to induce skin 
tumour formation that resembles BCC. This system differs to Ptch+/- mouse models 
that are UV irradiated to tumours therefore there may be non-specific effects of the 
UV radiation (Donovan, 2009, Daya-Grosjean and Couvé-Privat, 2005). The Adolphe 
model shows that the targeted deletion of both PTCH1 alleles is sufficient to induce 
BCC-like tumour formation which implies that specifically the loss of PTCH1 is function 
is important for tumour formation. 
Further downstream of the HH pathway, mice over expressing GLI1 were able to 
develop tumours that share a resemblance to BCCs (Nilsson et al., 2000a). 
Interestingly, mice over expressing an activated mutant form of GLI2 which is a 
positive regulator of GLI1 developed multiple BCCs (Sheng et al., 2002, Grachtchouk et 
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al., 2000). GLI2 studies in mice show that over expression of the protein in hair follicle 
stem cells leads to nodular BCC formation compared to GLI2 over expression in the IFE 
which leads to a more superficial BCC phenotype (Grachtchouk et al., 2000). Other 
components of the HH pathway have been investigated including SUFU. SUFU 
knockdown in mice results in embryonic death but SUFU+/- mice develop 
characteristics that can be found in Gorlins patients such as jaw keratocysts. 
Fibroblasts derived from SUFU-/- mice were shown to have elevated levels of GLI1 
mediated HH signalling which implies that loss of SUFU function leads to ligand 
independent HH activity (Svärd et al., 2006). Mouse studies where GLI2 is over 
expressed reveals the development of multiple BCCs which suggests that GLI2 is a 
potent oncogene. These tumours strongly resemble human BCCs in their histology and 
express various BCC markers. HH components such as PTCH1, GLI1 and GLI2 were 
increased at the mRNA level in the tumours but not the epidermis. As HH ligand is not 
detected in human BCCs, this suggests that tumours can arise independently of the HH 
ligand (Grachtchouk et al., 2000). 
 
1.11 Cell Senescence and Basal Cell Carcinoma 
1.11.1 Cell senescence  
Cell senescence is defined as the physiological process of terminal cell growth arrest, it 
can be due to alteration of telomeres or by different forms of stress causing  DNA 
damage. This process is also called replicative senescence, it is thought to be tumour 
suppressive mechanism and underlying cause of aging and Longevity. This process is 
also known as the Hayflick Phenomena or Hayflick limit in honour of Dr. Leonard 
Hayflick. In 1961 Dr.Leonard Hayflick and his colleague Dr.Paul Morehead, discovered 
that many human cells particularly fibroblasts had a limited capacity to divide in 
culture (Hayflick and Moorhead, 1961). They found that these and many other normal 
human cells derived from fetal, embryonic or newborn tissues can divide for 40-60 
division and after that they stop growing (Dimri et al., 1995b). Senescent cells are 
characterised by an enlarged cell size, flattened morphology, inability to synthesize 
DNA and expression of the biomarker senescence associated β-galctosidase (Dimri et 
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al., 1995b). Hayflick also pointed out that there are two types of cells normal mortal 
cells and immortal cancer cells. Dr Hayflick and his colleagues only worked with 
fibroblast, a cell type found in connective tissues, but replicative senescence can be 
found in other cells of the body includes, keratinocytes, endothelial cells, lymphocytes, 
adrenocortical cells, vascular smooth muscle cells, chondrocytes cells etc. The 
exception exists in certain cancer cell lines where the cells never reach replicative 
senescence, these are said to be`` immortal cells’’ and include embryonic germ cells 
and most cell lines derived from  tumours, such as HeLa Cells. The reason for 
appearance of β-Galactosidase staining during replicative senescence is increase in the 
level of Lysosomal enzyme (Kurz et al., 2000).    
Another type of senescence is called oncogene induced senescence (OIS). This is a 
form of cellular senescence that represents a physiological response that restricts the 
progression of benign tumours into their malignant counterparts e.g. nevi to 
melanoma or adenoma to adenocarcinoma. This mechanism is very crucial for 
protection against cancer development (Serrano et al., 1997, Lowe et al., 2004). The 
two main pathways of OIS mostly involve p16INK4a-RB (retinoblastoma) and ARF-p53 
(Campisi, 2005). These two pathways are very crucial for tumour suppression and are 
often mutated in tumours (Hollstein et al., 1991, Ruas and Peters, 1998b, Sharpless 
and DePinho, 1999a). The tumour-suppressor pathway formed by the Cdkn2a locus 
(Arf) and by p53 (also called Trp53) plays a central part in the detection and 
elimination of cellular damage, and this constitutes the basis of its potent cancer 
protection activity (Ander et al., 2007). Arf was originally identified as an alternative 
transcript of the Ink4a tumour suppressor locus (Jes et al., 2006). Its expression levels 
are normally low, but transcription of Arf is highly induced when oncogenes are 
introduced into normal cells. On this basis, Arf is regarded as a protein specialized in 
communicating to p53 what has been called “oncogenic stress,” a term that 
encompasses the array of cell perturbations produced by oncogenes (Matheu et al., 
2008). The Arf/p53 pathway protects cells against several types of damage and this is 
the basis of its tumour suppressor activity. Interestingly, aging is a process associated 
with the accumulation of damage derived from chronic stresses of small magnitude. In 
agreement with its damage protection role, it has been recently described that the 
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Arf/p53 pathway not only protects mammalian organisms from cancer but also from 
aging. The ability of p53 to induce cell growth arrest and apoptosis is relatively well-
understood, and its importance in tumour suppression is firmly established. The 
activities of pRb and p53 are dramatically increased during cellular senescence and 
inactivation of these proteins in senescent mouse embryonic fibroblasts (MEFs) results 
in reversal of the senescent phenotype leading to cell-cycle re-entry, suggesting that 
pRb and p53 are required not only for the onset of cellular senescence, but also for the 
maintenance of the senescence programme in murine cells (Takahashi et al., 2007). In 
human cells, once pRb is fully engaged, particularly by its activator, p16INK4a, 
senescent growth arrest becomes irreversible and is no longer revoked by subsequent 
inactivation of pRb and p53 (Takahashi et al., 2007). The p16INK4a tumour suppressor 
protein functions as an inhibitor of CDK4 and CDK6, the D-type cyclin-dependent 
kinases that initiate the phosphorylation of the retinoblastoma tumour suppressor 
protein, RB (Ohtani et al., 2004). Thus, p16INK4a has the capacity to arrest cells in the 
G1-phase of the cell cycle and its probable physiological role is in the implementation 
of irreversible growth arrest termed cellular senescence (Ohtani et al., 2004). In 
contrast to normal cells, the function of the p16INK4a gene or its downstream 
mediators is frequently deregulated in many types of human cancers, illustrating the 
importance of cellular senescence in tumour suppression. The p16INK4a cyclin-
dependent kinase inhibitor has a key role in establishing stable G1 cell-cycle arrest 
through activating the retinoblastoma (Rb) tumour suppressor protein pRb  in cellular 
senescence. Akiko Takahashi et.al. (2007) shows the p16INK4a /Rb-pathway also 
cooperates with mitogenic signals to induce elevated intracellular levels of reactive 
oxygen species (ROS), thereby activating protein kinase C  (PKC ) in human senescent 
cells (Takahashi, 2007). This irreversible cytokinetic block is likely to act as a second 
barrier to cellular immortalization ensuring stable cell-cycle arrest in human senescent 
cells (Takahashi, 2007). 
1.10.2 What causes cell senescence 
Cellular senescence (see Figure 1.8) is a state of irreversible growth arrest and altered 
function of normal somatic cells after finite number of cell division normally after 50 
cell divisions (Dimri et al., 1995b). It’s basically a general process that occurs as 
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response to stress and DNA damage (d'Adda di Fagagna et al., 2004). The first major 
cause of senescence was telomere shortening leading to telomere dysfunction 
(Campisi, 2005, Shay and Wright, 2005, Zglinicki et al., 2005). Recent studies show that 
other stress signals cause senescence and these include oxidative stress, oncogene 
activation (Serrano et al., 1997, Lowe et al., 2004), cytotoxic drugs (Roninson, 2003, 
Schmitt, 2003) and DNA damage (Prescott and Blackburn, 1999, Ventura et al., 2007).  
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Figure 1.8:  Showing the various factors that are known to cause Cell Senescence 
(Collado and Serrano, 2006). 
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1.11.3 Markers of cell senescence 
Collado and Serrano 2006 haven identified a number of cell markers that are 
associated with cell senescence (Table 1.2) (Collado and Serrano, 2006). 
Table: 1.2:  Summary of best established Markers of Cell Senescence. Collado et    
al.(2006). 
       Marker             Assay 
SA-β-Gal Immunohistochemistry (IHC) 
p16INK4a Western Blot (WB), IHC 
p15INK4b WB, IHC 
p53 WB, IHC 
ARF WB, IHC 
p21WAF1 WB, IHC 
SAHFSs Immunofluorescence (IF) 
DEC1 WB, IHC 
DCR2 WB, IHC 
 
 
1.11.3.1 Decoy Receptor 2(DcR2) 
DcR2 (decoy receptor) also known as TRAIL-4 and TNFRSF10D is one of the tumour 
necrosis factor related apoptosis-inducing ligand (TRAIL) receptors and suppresses 
TRAIL inducing apoptosis and also has a role regulating chemosensitivity (Liu et al., 
2005). It’s expression like other TRAIL receptors including DR4, DR5 and DcR1 is 
regulated by p53. 
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1.11.3.2 Differentially Embryo-chondrocyte Expressed Gene (DEC1) 
DEC1 (differentially embryo-chondrocyte expressed gene) in humans; also known as 
SHARP2 (enhancer of split and hairy related protein) in rat, BHLHB2 and Stra13 
(stimulated with retinoic acid) in mouse is a basic helix-loop helix (bHLH) transcription 
factor (Yamada and Miyamoto, 2005). It is a member of subfamily of basic helix-loop-
helix transcription factors along with DEC2.These BHLH transcription factors are 
proteins functionally associated with development events such as cell proliferation, 
differentiation, myogenesis, neurogenesis (Villares and Cabrera, 1987), sex 
determination (Cronmiller et al., 1988), regulation of immunoglobulin genes 
(Beckmann et al., 1990), phospholipids metabolism (Nikoloff et al., 1992), xenobiotic 
response (Hirose et al., 1996) and lineage commitment (Yamada and Miyamoto, 2005). 
DEC1 functions as transcription repressor by directly binding to class B E-boxes (Li et 
al., 2003). The human DEC1 is highly expressed in many tissues including some tumour 
tissues and tumour derived cell lines (Fujimoto et al., 2001, Ivanova et al., 2001, Zawel 
et al., 2002). Yuxin et al. (2002) has shown that DEC1 is expressed in colon cancer but 
not in the surrounding normal tissues (Li et al., 2002a). 
1.11.3.3 p16INK4a 
p16INK4a is a member of cyclin-dependent kinase inhibitors (CDKIs) also known as 
CDKN2A and is tumour suppressor gene. p16INK4a is an inhibitor of CDK4 and CDK6 and 
prevents phosphorylation of pRB protein and cell-cycle arrest in the G1 phase. p16INK4a 
is an important tumour suppressor among the four INK4 family members and is 
inactivated in many human tumours. The CDK4 gene is also mutated in gliomas, 
mesotheliomas, nasopharyngeal, pancreatic, biliary tract tumours and acute 
lymphoblastic leukaemia's (Boukamp, 2005), melanomas and breast cancer (Borg et 
al., 2000). The main factor which distinguishes p16INK4a from other members of INK4 
family is its capacity to be unregulated in response to senescence and oncogene stress. 
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1.11.3.4 p15INK4b 
p15INK4b is a member of cyclin-dependent kinase inhibitor and encoded in humans by 
CDKN2 locus on chromosome 9p21.2. P15INK4b is highly homologous with p16INK4a. 
Along with p16INK4a it play major role in the regulation of cell cycle. By inhibiting the 
activity of CDK4 and CDK6 to inactivate the retinoblastoma (Rb) family of tumour 
suppressors. The expression of this gene is induced by TGF beta, which suggest a role 
in TGF beta induced growth inhibition.    
 1.11.3.5 p21WAF1 
p21 is a member of CIP/KIP family of cyclin-dependent kinase inhibitors which  also 
include INK4. It was first member of this family that was simultaneously cloned from 
different sources. These CDKIs commonly negatively regulate cell cycle. The members 
of this family of proteins are found in complex with the cyclin D, cyclin E and cyclin A-
dependent kinases.  
1.11.3.6 p53 
p53 is a tumour suppressor protein that in humans is encoded by the TP53 gene 
located on the short arm of chromosome 17 (17p 13.1). p53 regulates cell cycle and 
functions as tumour suppressor and is involved in the prevention of cancer. p53 plays 
an important role in transcription, DNA repair, genomic stability, apoptosis and cell 
senescence (Prives and Hall, 1999, Ko and Prives, 1996). Due to this quality, this 
protein is also known as the guardian of the genome and also the master watchman. 
p53 is the most commonly mutated or deleted gene in human cancer and has typical 
ultraviolet induced changes (C---T and CC—TT nucleotide changes) (Ziegler et al., 
1993). p53 has a dual role in regulating cell growth because it can induce cell cycle 
arrest and apoptosis as well.  
1.11.3.7 β-galactosidase. 
 The most widely used assay for senescence is the cytochemical detection of -
galactosidase activity at pH 6.0, termed senescence-associated β-galactosidase (SA- -
Gal) (Dimri et al., 1995a). This is derived from the increased lysosomal content of 
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senescent cells, which enables the detection of lysosomal -galactosidase at a 
suboptimal pH, pH 6.0 (pH 4.0 is optimal) (Kurz et al., 2000). -Galactosidase activity is 
generally accepted as a marker of senescence both in vitro and in vivo, although its 
biochemical basis is still unknown and there is evidence for a positive SA- -Gal 
reaction in settings of cellular stress that are unrelated to senescence, such as serum 
withdrawal or high confluence in cell culture (Yang and Hu, 2004). Its activity is 
normally assayed in cultured cells or tissue sections using the chromogenic substrate 
5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-Gal), or the fluorescent analogue 
fluorescein-di-β-D-galactopyranoside (FDG) (Severino et al., 2000).   
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1.8 Aims of Study 
 
Background:  
BCCs are relatively stable at the genomic level and although, a number of BCC subtypes 
are recognised and these can be grouped into benign and aggressive tumours very 
little is known about the molecular differences between these subtypes. OIS is known 
to play an important role in tumorigenesis and is a characteristic of pre-malignant 
lesions of many cancers. Although pre-malignant lesions have not been described for 
BCC it is possible that OIS may be a key feature of more benign BCCs and that loss of 
OIS may explain the more aggressive subtypes. 
Hypothesis: 
That over-expression of the  HH signalling pathway in BCC results in OIS and that loss 
or down regulation of OIS may characterise more aggressive from benign BCC 
subtypes.   
Aim:  
The aim of the work in my thesis is to determine the expression pattern of senescent 
markers in non-aggressive and aggressive subtypes  and using in vitro cell culture see 
whether this is associated with up regulation of HH signalling 
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Chapter 2: Materials and Methods 
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2.1 Tissues collection and Sectioning 
2.1.1 Paraffin Embedded Human BCC and Normal Human Skin Tissue Blocks 
BCC tumour and normal human facial skin sample blocks were taken from the tissue 
archive of the Department of Dermatology, Royal London Hospital and ethical 
permission for this study was obtained from the East London and The City Local 
Research Ethics Committee (Ethics NO: 08/H0704/65) with  informed consent from all 
patients. The average age of the patients was 63.5 and out of this 7 patients were male 
and 8 were female (SEE Appendix 1). The blocks were randomly selected from the 
archive. The diagnosis of these blocks was checked by looking at the histopathological 
report of the patients and this was carried out by a qualified dermatopathologist 
Professor Rino Cerio. The inclusion criteria for this project was to include only nodular 
(non aggressive) and morphoeic (aggressive) BCC subtypes. The tumour and normal 
skin sections were cut by the Pathology core facility Blizard Institute, Queen Mary 
University of London on a Shandon Finesse E+ microtome (Thermo Scientific, 
Germany). 3μm sections were cut and placed on superfast plus glass slides (VWR). 
2.1.2 Fresh Frozen BCC Samples 
Fresh biopsies of BCC tissues were taken from department of dermatology of Royal 
London Hospital from patients being treated for excisional surgery to remove BCC. The 
patients were contacted before surgery for donation of their tissues for this project. 
After excisional surgery biopsy specimens were snap frozen in liquid nitrogen for 
better preservation and then kept at -80Ċ until required for use. The average age of 
the patients was 63 and out of this 11 patients were male and 10 were female (SEE 
Appendix 2). Before cutting the tissues, embedding was performed using a Bright 
Cryospray 134 (Bright Instrument, Huntingdon, UK).  The sections were cut by the 
Pathology core facility Blizard Institute of Cell and Molecular Sciences, Queen Mary 
University of London on a Shandon cryotome E product number 0620E(Thermo 
Scientific). 4μm sections were placed on superfast plus glass slides (VWR). 
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2.1.3 Mouse BCC, wild type Ptch +/+ Skin and Ptch +/- Skin 
Mouse BCC tumour and Ptch1 Mouse +/+ and +/- skin sample blocks were provided by 
Mariateresa Mancuso from Biotechnology Unit and Radiation Protection Unit, ENEA-
Ente per le Nuove Tecnologie, l’Energia e l’Ambiente, Centro Ricerche, Casaccia, Rome, 
Italy. This group have generated Mice lacking one Ptch1 allele, through targeted 
disruption of exons 6 and 7 in 129/SV ES cells and maintained on CD1 background 
(Mancuso et al., 2004). Mancuso et al performed X-ray irradiation (HVL _ 1.6 mmCu) 
on these mice using a Gilardoni CHF 320G X-ray generator (Gilardoni S.p.A.; Mandello 
de Lario Lecco, Italy) operated at 250 kVp, 15 mA, with filters of 2.0 mm of A1 and 0.5 
mm of Cu. PTCH1neo67/+ mice and wild-type littermates of both sexes were whole-body 
irradiated with 3 Gy of X-rays as newborns (4 days of age) or adults (90 days of age). In 
addition, 2-month-old mice were subjected to local irradiation of the dorsal skin with a 
single dose of 4 Gy of X-rays. Briefly, anesthetized mice were radially positioned on a 
lead plate, and shaped lead shields were placed on each mouse to provide protection 
to the body parts to be spared. A dorsal skin area of 3 cm2 was irradiated through a 
central trapezoidal window of a lead shield (4-mm thickness, 60 mm in length). The 
shield was accurately positioned on the anesthetized mouse using its tail insertion as 
reference. Mice were inspected daily and at the first sign of morbidity or when 
tumours were visible were sacrificed and complete autopsies performed. A piece of 
grossly normal appearing dorsal skin with an area of 5 cm2, corresponding to the site of 
local irradiation or an equivalent area of macroscopic-tumour-bearing skin, was fixed 
in 4% buffered formalin.  Normally tumours appear in irradiated mice 60 to 90 weeks 
post irradiation. Skin biopsies from these mice were sent to the Centre for Cutaneous 
Research for use in this project and sections were cut by Pathology core facility Blizard 
Institute, Queen Mary University of London on a Shandon Finesse E+ (Thermo 
Scientific, Germany). 3μm sections were placed on superfast plus glass slides (VWR). 
 
 
 
73 
 
2.2 β -Galactosidase Assay  
β-galactosidase assay was carried out using either a commercial kit supplied by cell 
signalling technology (Senescence β-Galactosidase Staining Kit Cell 
SignallingTechnology, 166B Cumming Center, Beverly, MA 01915). In addition to the 
commercial kit we also carried out β-galactosidase assay using individual reagents. The 
reason for carrying out the β-galactosidase assay using individual reagents was one of 
cost. The β-galactosidase assay is a simple assay but the kits are expensive. In contrast 
the individual reagents are more cost effective and as a result most groups within my 
Institute prepare their own reagents. 
2.2.1 β-Galactosidase assay for cell senescence carried out using the commercial β-
galactosidase Staining Kit 
β-galactosidase staining using the commercial kit (Appendix 3) was carried out 
according to the manufacturers instruction as follows:- 
Frozen tissue sections on glass slides were taken from -80c freezer and kept at room 
temperature for 15 minutes. Then the slides were put in cold acetone for 15 minutes. 
After this slides were fixed in 1X Fixative Solution for 10-15 minutes at room 
temperature. Then the slides were washed for two times with 1X PBS. After that β-
Galactosidase Staining Solution was placed on the tissue sections and the slides were 
incubated at 37°C overnight in a dry incubator (no CO2). While the β-Galactosidase 
Staining Solution is still on the tissue sections, the slides were checked under a 
microscope for the development of blue colour. Once blue colour was seen the slides 
were washed in PBS to remove the β-Galactosidase Staining Solution and then counter 
stained with haematoxylin after which the slides were kept at room temperature. 
 
2.2.2 β-galactosidase assay using individual laboratory reagents.  
The basis of the β-galactosidase assay is straightforward. β-Gal is an essential enzyme 
that catalysis β-galactosidase into monosaccharides. When it is expressed it reacts with 
X-gal which forms a blue precipitate. When β-Gal activity is observed at pH 6 it is 
characteristic of senescent cells and is not found in pre-senescent, quiescent or 
immortal cells. To save cost we therefore decided to use commercially available 
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reagents to develop our town β-galactosidase assay. The reagents used are shown in 
Appendix 4. 
8µM frozen sections were cut by the pathology core facility Blizard Institute and kept 
in the -80 freezer until required for future work. The sections were taken out from the 
-80c freezer and left at room temperature for 15 minutes. Sections were fixed with 
0.2% (v/v) glutaraldehyde (1ml of 25% (v/v) glutaraldehyde) mixed with PBS (125ml) 
(PAA Laboratories GmbH) for 5 minutes at room temperature. Slides were then 
washed with PBS (PAA Laboratories GmbH) for 5 minutes. After that tissue sections 
were incubated with x-gal solution for 24-72 hr at 37°c without CO2. Tissues were 
checked every 6hr to detect any blue staining of the tissues. In senescent tissues blue 
staining normally appears after 24 hr. When the blue staining appeared the X-Gal 
solution was removed and sections washed in PBS. After that tissues were 
counterstained with Haematoxylin mounted with glass cover slips. 
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2.3 Immunohistochemistry (IHC) for Human and Mouse BCC tissues.  
2.3.1 Immunohistochemistry Protocol 
Reagents used for immunohistochemistry are shown in Table 3.1. Tissue sections were 
washed in Xylene twice (2X) for two minutes for dewaxing. After that tissue sections 
were washed in Alcohol (Industrial Methylated Spirits (IMS) 2X for two minutes. Then 
the tissue sections were washed in tap water for five minutes. Antigen retrieval (see 
Table 2.2) was carried out using the Antigen Unmasking solution (VECTOR 
Laboratories) at pH 6.0 in microwave oven at different times for different antibodies, 
as follows GLI-1, DEC1, p53 (35 minutes microwave oven) and for p15INK4b the pH was 
9.0 (35 minutes in microwave oven) and p16INK4b, p21WAF1 (35 and 30 minutes in 
microwave oven respectively).  
After antigen retrieval tissue sections were washed in tap water for 5 minutes. 
Endogenous peroxidise was blocked with Hydrogen Peroxide 3% (v/v) for 15 minutes in 
distilled water. Tissue sections were then washed in tap water for 5 minutes and then 
further washed with wash buffer (Dako wash buffer 10x,Dako) for 5 minutes. Normal 
Horse Serum R.T.U. VECTASTAIN Universal Elite ABC KIT (VECTOR Laboratories) was 
used for blocking tissue sections and was applied to the slides for 20 minutes. Primary 
antibodies for human skin sections (see Table 2.3) and mouse skin sections (see Table 
2.4) were then applied to the slides and incubated at room temperature for 1 hour.  
Tissue sections were then washed in wash buffer (Dako wash buffer 10x, Dako) twice 
(2X) for two minutes. Secondary antibodies were then applied to the slides as shown in 
Table 2.3 for human skin sections and Table 2.4 for mouse skin sections and incubated 
for 45 minutes at room temperature. Tissue section were then washed with Dako wash 
buffer 10x (Dako) twice (2X) for two minutes. ABC Reagent R.T.U. VECTASTAIN 
Universal Elite ABC KIT (VECTOR Laboratories) was applied to the slides for 30 minutes 
at room temperature. Tissue sections were then washed with Dako wash buffer for 2X 
for two minutes. Liquid DAB substrate was added to the slides (1ml substrate buffer + 
1 drop of DAB chromogen) for DAB staining for 5 minutes. Slides were washed in tap 
water for 5 minutes. Sections were counter stain with Haematoxylin on immuno 
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program in staining machine (Thermo Scientific Shandon Varistain® Gemini ES) 
(running tap water 2 minutes, Gills HX 2 minutes, running tap water 5 minutes, acid 
alcohol 10 seconds, running tap water 5 minutes, IMS 2 minutes 3X and Xylene 2 
minutes for 3X). Cover slips were then placed on the slides and sections observed using 
light microscopy.  
 
 
  Table 2.1: Reagents used for the immunohistochemistry 
1 Xylene 100% 
2 Alcohol 100% 
3 Antigen Unmasking Solution H-3300 and H-3301, Vector Laboratories, UK 
4 Tris Citrate EDTA Buffer PH8.1 (See Appendix-5)  
5 Pap PEN 
6 3% Hydrogen Peroxide, Product VWR-BDH Prolabo, UK 
7 Dako RealTM Antibody Diluent, Code S2022 
8 R.T.U Vectastain® Universal Elite ABC Kit, PK-7200, Vector Laboratories,  UK  
9 Dak Wash Buffer 10X, S3006 Immunohistochemistry, Dako UK Ltd 
10   Liquid DAB Substrate, HK130-5K, HK542-XAK, BioGenex, U.S.A. 
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Table 2.2:  Antigen Retrieval Solution and Conditions 
 
Proteins Antigen Retrieval Solution and Conditions 
 
  GLI-1 
Antigen Unmasking Solution H-3300 Vector Laboratories, UK, 
35min MW. 
 
  DcR2 
Antigen Unmasking Solution H-3300 Vector Laboratories, UK, 20 
minMW.   
 
  DEC1 (SHARP2) 
Antigen Unmasking Solution H-3300 Vector Laboratories, UK, 
35min MW. 
 
   p53 
Human Tissues: Tris Citrate EDTA Buffer PH8.1, 35min MW. 
Mouse Tissues: The section were incubated in 0.1% trypsin in 0.1% 
CaCl2 (pH 7.8) for 10 minutes at 37
•C.  
   
  p16INK4a 
Antigen Unmasking Solution H-3300 Vector Laboratories, U.S.A, 
30min MW. 
 
  p15INK4a 
Antigen Unmasking Solution, H-3301 Vector Laboratories, U.S.A, 
35min MW.  
 
  p21WAF1 
Antigen Unmasking Solution H-3300 Vector Laboratories, U.S.A, 
30min MW 
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Table 2.3:  Primary and Secondary Antibodies used for Immunohistochemistry on 
Human BCC and Human Skin.  
Proteins Primary Antibody and 
Dilution 
Secondary Antibody and 
Dilution 
 
  GLI-1 
GLI-1 , rabbit polyclonal IgG, 
200 µg/ml, (H-300): sc-
20687, Santa Cruz, U.S.A, 
1:500 overnight incubation 
Prediluted Biotinylated 
Universal Secondary Antibody 
(recognize mouse and rabbit), 
Vector Laboratories, U.S.A. 
 
  DcR2 
DcR2 rabbit polyclonal 
antibody, AAP-371, Assay 
Designs, U.S.A, 1:50 1hour 
incubation. 
Prediluted Biotinylated 
Universal Secondary Antibody 
(recognize mouse and rabbit), 
Vector Laboratories, U.S.A. 
 
  
DEC1(SHARP2) 
Anti-SHARP2 Rabbit, S 8443, 
S-8443, Sigma Aldrich, U.S.A, 
1:100 1hour incubation. 
Prediluted Biotinylated 
Universal Secondary Antibody 
(recognize mouse and rabbit), 
Vector Laboratories, U.S.A. 
 
  p53 
Anti-p53(Ab-6)(Pantropic) 
Mouse mAb (DO1), OP43, 
Merck4Biosciences, UK, 1:50 
1hour incubation. 
Prediluted Biotinylated 
Universal Secondary Antibody 
(recognize mouse and rabbit), 
Vector Laboratories, U.S.A. 
  
  p16INK4a 
p16INK4a (C-20)Rabbit 
Polyclonal Antibody, sc-468, 
Santa Cruz, U.S.A, 1:100 
1hour incubation. 
Prediluted Biotinylated 
Universal Secondary Antibody 
(recognize mouse and rabbit), 
Vector Laboratories, U.S.A. 
 
  p15INK4b 
   
p15INK4b Polyclonal Antibody, 
4822, Cell Signalling, U.S.A, 
1:100 1hour incubation 
Prediluted Biotinylated 
Universal Secondary Antibody 
(recognize mouse and rabbit), 
Vector Laboratories, U.S.A. 
 
  p21WAF1 
Purified Mouse Anti-Human, 
p21WAF1 BD Pharmingen™ 
1:100 dilution, 1 hour 
incubation  
Prediluted Biotinylated 
Universal Secondary Antibody 
(recognize mouse and rabbit), 
Vector Laboratories, U.S.A. 
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Table 2.4:  Primary and Secondary Antibodies use for Immunohistochemistry on 
Mouse BCC and Mouse Ptch1 +/+ and +/- Skin.  
Proteins Primary Antibody and 
Dilution 
Secondary Antibody and 
Dilution 
 
  GLI-1 
GLI-1 rabbit polyclonal IgG, 
200 µg/ml, (H-300): sc-
20687, Santa Cruz, U.S.A, 
1:500 overnight incubation 
Biotinylated Anti-Rabbit IgG 
(H+L) Goat , Catalog Number 
BA-1000, Vector Laboratories, 
1:200 1 hour incubation 
 
  DcR2 
DcR2 rabbit polyclonal 
antibody, AAP-371, Assay 
Designs, U.S.A, 1:50 1hour 
incubation. 
 Biotinylated Anti-Rabbit IgG 
(H+L) Goat , Catalog Number 
BA-1000, Vector Laboratories, 
1:200 1 hour incubation  
 
  
DEC1(SHARP2) 
Anti-SHARP2 Rabbit, S 8443, 
S-8443, Sigma Aldrich, U.S.A, 
1:100 1hour incubation. 
Biotinylated Anti-Rabbit IgG 
(H+L) Goat , Catalog Number 
BA-1000, Vector Laboratories, 
1:200 1 hour incubation 
 
  p53 
Rabbit Polyclonal Antibody 
p53 Protein (CM5), NCL-p53-
CM5p, Leica Microsystem, 
UK, 1:100 1hour incubation. 
Biotinylated Anti-Rabbit IgG 
(H+L) Goat , Catalog Number 
BA-1000, Vector Laboratories, 
1:200 1 hour incubation  
  
  p16INK4a 
p16INK4a (C-20)Rabbit 
Polyclonal Antibody, sc-468, 
Santa Cruz, U.S.A, 1:100 
1hour incubation. 
Biotinylated Anti-Rabbit IgG 
(H+L) Goat , Catalog Number 
BA-1000, Vector Laboratories, 
1:200 1 hour incubation 
 
  p15INK4b 
   
p15INK4b Polyclonal Antibody, 
4822, Cell Signalling, U.S.A, 
1:100 1hour incubation 
Biotinylated Anti-Rabbit  IgG 
(H+L) Goat , Catalog Number 
BA-1000, Vector Laboratories, 
1:200 1 hour incubation 
 
   p21WAF1 
p21WAF1  (DCS60) Mouse 
mAb, Cell Signalling, U.S.A, 
1:100 1hour incubation 
Prediluted Biotinylated 
Universal Secondary Antibody 
(recognize mouse and rabbit), 
Vector Laboratories, U.S.A. 
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2.3.2 Visual Analogue Score 
The intensity of staining was analysed by visual analogue score which is normal 
practice of  histopathologists (see Table 2.5 and 2.6) (Harvey et al., 1999). The scoring 
was carried out blind by Professor Rino Cerio (Dermatopathologist) of Royal London 
Hospital. Statistical analysis of this score was carried out using GraphPad Prism 
Software (La Jolla, CA 92037 USA) and data was plotted on excel sheet to compare 
Morphoeic with Nodular BCC.   The same criteria were used for visual analogue scoring 
between mouse and human samples. Scoring was carried out as follows 0 is no 
staining, 1 is up to 30% staining (weak), 2 is between 30% to 60% (moderate) 3 is 
staining greater than 60% (strong). 
Table 2.5 Visual Analogue Scoring of Immunohistochemical staining for human tissues.  
0 No Staining 
1 Weak Staining 
2 Moderate Staining 
3 Strong Staining 
  
Table 2.6 Visual Analogue Scoring of Immunohistochemical staining for mouse tissues. 
No Staining        0 
Weak Staining        1 
Moderate Staining        2 
Strong Staining        3 
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2.4 NEB-1 Cell Culture  
2.4.1 Cell Culture 
All cell culture was performed in a laminar flow cabinet hood under aseptic conditions 
in accordance with standard tissue culture technique. All sterile disposable tissue 
culture flasks, plates and dishes were purchased from thermo fisher scientific (NY, 
USA). For tissue culture all centrifuge steps were using an IEC Centra-3C Centrifuge 
(International Equipment Company, Dunstable, U.K). Reagents used for the culture of 
NEB-1 keratinocytes are shown in Table 2.7. 
NEB1 immortalised keratinocytes were used to generate the in vitro BCC model. NEB1 
cells originate from early epidermal keratinocytes and are immortalised using HPV16 
(Morley et al., 2003). NEB1 cells were retrovirally transduced with PTCH shRNA 
construct 189A that targets exon 24 of PTCH mRNA. A scramble control vector was 
used as a control. NEB1 GLI-1 cells were generated using the pBabePuro retrovirus, 
with NEB1 pBP cells used as an empty vector control. All cell lines were made by 
Muhammad Rahman PhD Student Center for Cutaneous Research.  
NEB1 cells were cultured in keratinocyte growth medium (KGM) consisting of Alpha 
MEM (450ml) and heat inactivated foetal bovine serum 10% (Lonza, Slough, UK), L-
glutamine (7ml) and penicillin/streptomycin (5ml) (PAA Laboratories, Somerset, UK). 
The KGM supplement was made up of epidermal growth factor (EGF) 10µg/ml, 
hydrocortisone 0.5µg/ml, insulin (bovine pancreas) 5µg/ml, adenine (5ml) and cholera 
toxin (0.5mls) (Sigma, Poole, UK). Cells were incubated at 37°c in an atmosphere 5% 
CO2/95% air. For growing these cells the tissue culture media was changed after the 
3rd or 4th day. When the cells reached 70% confluence they were washed once with 
sterilised PBS. After washing with the PBS the cells were trypsinised to count and split 
for other procedures or frozen down for future work. For trypsinisation 3ml 
trypsin/EDTA (PAA Laboratories) was added to each flask which was left in the 370c 
incubator to detached the cells from flask. When cells were detached, 5ml KGM media 
was added to inhibit the trypsinisation. After that cells were transferred to a falcon 
tube and centrifuged at 1300rpm for 5 minutes at room temperature, then 
supernatant was discarded and the cell pellet was re-suspended in PBS and cells were 
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counted and divided for different experimental procedures including, cell staining, 
qPCR while remaining cells were frozen down in freezing media (10% (v/v) DMSO in 
FBS) for future work. 
 
 
   Table 2.7: Reagents used for the culture of NEB-1 keratinocytes. 
       Materials used for cell culture                         Company 
αMEM  Lonza, Switzerland 
 
KGM Supplement (See Appendix 6) 
 
 
Penicillin, Streptomycin and L-
Glutamine  
Sigma-Aldrich, St. Louis, MO  
 
Trypsin-EDTA  PAA, Dartmouth, MA  
 
Foetal Bovine Serum (FBS)  Lonza, Switzerland  
 
Haemocytometer  Kisker Biotech GmbH, Germany  
 
Inverted semi confocal Microscope  Nikon, Japan  
 
6 well plates, pipettes, T75 and T25 
flasks  
Thermo Fisher scientific, NY,USA  
 
NEB1 Keratinocytes Cells   1. Cancer Research UK Cell Structure 
Research Group, Dundee University 
School of Life Sciences and  
2. Centre for Cutaneous Research, Bart’s 
and the London Queen Mary’s School of 
Medicine and Dentistry, UK 
 
All plastic ware and culture flasks  Nunc/Thermo Fisher scientific, NY, USA  
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2.4.2 Cell Counting 
 After trypsinisation cells (10µl of cell suspension) were counted using a 
haemocytometer. The Haemocytometer 4x4 grid and each square contains sixteen 
squares. The cells within these squares were counted. The formula used for counting 
cells per ml is to multiply the number of cells counted by 104. 
 
2.5 Immunofluorescence (IF) Microscopy. 
2.5.1 Protocol for Immunofluorescence Microscopy 
Reagents used for immunofluorescence are shown in Table 2.8. Cells were washed in 
PBS for 2X for 5 minutes. Then the cells were fixed in 4% (v/v) Para formaldehyde for 
15 minutes. The cells were washed for 3X for 5 minutes with PBS. Cells were then 
permiablised in PBS-Triton (0.1% (v/v) triton x 100) for 10 minutes. After that cells 
were blocked with 3% (v/v) BSA at room temperature for 30 minutes. Primary and 
secondary antibodies used for immunofluorescence are shown in Table 2.9. All these 
antibodies (dilution 1:1000 in 3% (v/v BSA) were applied and the control was left in 3% 
(v/v) BSA in cold room for overnight. The cells were washed in PBS three times for 5 
minutes. Secondary antibody was applied (dilution 1:1000) and left at room 
temperature for 1 hour and kept in dark. The cells were washed with PBS three times 
for 5 minutes and kept in dark. Cells were counter stained with DAPI (dilution 1ul of 
DAPI with 5 ml of dH2O) for 5 minutes. The cells were washed once with PBS. Slides 
were mounted and cover slips applied. Analysis was carried out using a confocal 
microscope. 
Images were quantified using Image J software. Cells were selected and analysed 
based on the intensity of pixels taking into account the size of the cell. The relative 
density was then calculated which indicates the intensity of staining. 
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  Table 2.8: Reagents Used for IF are shown below. 
1 PBS 
2 4% Paraformaldehyde 
3 Triton (0.1% Triton X100) permiablised in 
PBS 
4 3% BSA 
5 DAPI 
6 Mount Medium 
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Table 2.9: Primary and Secondary Antibodies for Immunofluorescence Microscopy.   
Proteins Primary Antibody and 
Dilution 
Secondary Antibody and 
Dilution 
 
  GLI-1 
GLI-1 Goat Polyclonal 
Antibody, (H-300): sc-20687, 
Santa Cruz, U.S.A, 1:500 
overnight incubation 
Alexa Fluor® 488 Rabbit anti-
goat A-11078, Invitrogen, UK, 
1:1000 1hour dilution 
 
  DcR2 
DcR2 rabbit polyclonal 
antibody, AAP-371, Assay 
Designs, U.S.A, 1:500 
overnight incubation. 
  Alexa Fluor® 488 Goat anti-
rabbit A-11008, Invitrogen, UK, 
1:800 1hour incubation.          
 
  
DEC1(SHARP2) 
Anti-SHARP2 Rabbit, S 8443, 
S-8443, Sigma Aldrich, U.S.A, 
1:500 overnight incubation. 
Alexa Fluor® 488 Goat anti-
rabbit A-11008, Invitrogen, UK, 
1:800 1hour incubation.          
 
  p53 
Anti-p53(Ab-6)(Pantropic) 
Mouse mAb (DO1), OP43, 
Merck4Biosciences, UK, 
1:500 overnight incubation. 
Alexa Fluor® 488 goat anti-
mouse IgG2b,  Invitrogen, UK, 
1:800, 1 hour incubation.  
  
  p16INK4a 
p16INK4a (C-20)Rabbit 
Polyclonal Antibody, sc-468, 
Santa Cruz, U.S.A, 1:500 
overnight incubation. 
 Alexa Fluor® 488 Goat anti-
rabbit A-11008, Invitrogen, UK, 
1:800 1hour incubation.          
 
   p15INK4b 
   
p15INK4b Polyclonal Antibody, 
4822, Cell Signalling, U.S.A, 
1:500 overnight incubation 
Alexa Fluor® 488 Goat anti-
rabbit A-11008, Invitrogen, UK, 
1:800 1hour incubation.          
 
   p21WAF1 
Purified Mouse Anti-   Human 
p21WAF1,  BD Pharmingen™, 
UK, 1:500 overnight dilution. 
Alexa Fluor® 488 goat anti-
mouse IgG2b,  Invitrogen, UK, 
1:800, 1 hour incubation.  
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2.6 RNA Extraction and cDNA Synthesis 
2.6.1 RNA Extraction 
 
Reagents for RNA extraction are shown in Table 2.10. For total RNA extraction cells 
were grown in 6cm dishes. When the cells had reached enough (75% confluence), the 
medium was removed and cells were washed with PBS (PAA Laboratories GmbH). After 
that 350 µl of RLT buffer from RNeasy Plus mini kit (QIAGEN) & Beta-mercaptoethanol 
(10µl) were added, to lyse the cells. The cells and supernatant were removed from dish 
and placed in the QIAshredder spin column (QIAGEN) and centrifuged for 2 minutes at 
maximum speed. The lysate was transferred to a gDNA eliminator spin column 
(QIAGEN), and centrifuged for 30sec at 10,000rpm. After that the column was 
discarded and the flow through saved and added to 1 volume (350µl) of 70% (v/v) 
ethanol. I transferred 700 µl of this flow through to an RNeasy spin column and 
centrifuged at 10,000rpm for 15seconds. The flow through was discarded and the 
RNeasy spin column saved I then added 700µl of buffer RW1 to the column and 
centrifuged at 10,000rpm for 15seconds. The flow through was discarded and I saved 
the RNeasy spin column and added 500µl of buffer RPE to the column and centrifuged 
it for 2 minutes at 10,000rpm speed to wash the spin column. Finally, the RNeasy spin 
column was put in a new 1.5ml collection tube and I added 50µl of RNease free water 
and centrifuged it for 1minute at 10,000rpm to recover the RNA.  
The concentration of RNA was quantified using a Nanodrop Spectrophotometer ND 
1000 (Labtech International Ltd, East Sussex, UK). First of all I used 1 µl RNAse DNA 
free water to clean and take a standard blank reading. After that 1µl RNA was used to 
measure the concentration (ng/µl) of RNA. 
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2.6.2 cDNA synthesis 
Reagents for cDNA synthesis are shown in Table 2.10. For making cDNA a SuperScript ® 
VILOTM cDNA synthesis kit (InvitrogeneTM)was used. This kit contains 5X VILO Reaction 
mix (4µl), 10X Superscript Enzyme mix (2µl). The other reagents needed for making 
cDNA included RNA (up to 2.5µg) and DEPC treated water. The total reaction volume 
for making cDNA was 20µl.  The following protocol was employed using a thermal 
cycler (PTC-100 Peltier-Effect Cycling, MJ Research Inc, USA) shown below (see Table: 
2.11). 
 
  Table 2.10: Reagents for RNA extraction and cDNA synthesis are shown below.  
1 RNeasy Mini kit QIAGEN, WS, UK 
2 RNase free-DNase kit QIAGEN, WS, UK 
3 NanoDrop® UV spectrophotometer Thermo-Scientific, 
DE, USA  
4 SuperScript® VILO™ cDNA Synthesis kit Invitrogen, 
Paisley, UK 
5 DNA engine PCR machine MJ Research(Bio-
Rad),Hercules, CA 
 
   Table 2.11: Conditions for cDNA reaction.             
                  Temperature (Ċ) 
 
                  Time (minutes) 
                   25 Ċ (initial heating) 
 
                      10 
                   42 Ċ  (cDNA synthesis) 
 
                      1 hrs 
                   85 Ċ (RT inactivation) 
 
                      5 
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2.7 Quantitative real time-polymerase chain Reaction (qPCR) 
 
2.7.1 qPCR Protocol 
Quantitative Real Time-Polymerase Chain Reaction (qPCR) is a method based upon the 
principles of the Polymerase Chain Reaction (PCR). The primers were designed by using 
the primer 3 online tool (Table 2.12) (Rozen and Skaletsky, 1999). For qPCR a 
fluorescent dye is used, such as SYBR Green. The master mix used for the reaction is 
bought from Sigma (SYBER® Green JumpStartTM Taq Ready Mix Cat# S4438) and 
protocol performed using guidelines provided by the manufacturer of the kit. . For all 
the qPCR experiments the master mix was prepared using the following components 
tabulated in Appendix 7. The program for all the PCR varied only with the annealing 
and extension times all the other parameters are the same.   
              1. 95 0C for 15min (Enzyme activation). 
              2. 95 0C for 15sec (Denaturation). 
              3. X 0C for 20 sec (X-varies according to primers. (Tm Annealing step). 
              4. 72 0C for Xsec (X-varies depending on the product size (extension step- For 
normal   PCR a final extension step at 72 0C for 10min was used) b, c and d steps were 
repeated for 40times.  
               5. For qPCR melting curve parameters was set from 55 0C to 95 0C at a 1 sec 
rampage.  
Each sample or standard was performed in triplicate. An amplification curve for each 
sample is obtained based on the levels of fluorescence present in each amplification 
cycle.  The software detects the fluorescence threshold cycle (Ct) during the PCR when 
the level of fluorescence provides a signal over the background and is in the linear 
portion of the amplified curve. This Ct value is responsible for the accurate 
quantification of qPCR. The final stage of the run is a dissociation curve, which is used 
to assess the homogeneity of the PCR products, including the presence of primer 
dimers, thereby determining the specificity of the PCR reaction.  During the melting 
analysis the green fluorescence signal is acquired continuously as the samples are 
melted at 95oC, cooled to 60oC and then quickly heated again to 95oC.  As a result of 
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the melting, SYBR Green molecules are released from the denatured DNA, drastically 
decreasing fluorescence signal.  In order to visualise the dissociation curve as a peak, 
the negative first derivatives are also plotted. 
2.7.2 Primers 
The mRNA sequences were taken from the NCBI Gene database for the human variant. 
If there  are multiple isoforms for a single gene, all sequences were analysed using the 
Clustal W  program (http://www.ebi.ac.uk/Tools/msa/clustalw2/) which is a sequence 
alignment tool. Primers would then be designed for an area where mRNA sequences 
match between all the isoforms. The sequence is then put into the Primer 3 software 
(http://frodo.wi.mit.edu/)  which generates a number of primer pairs. These primer 
sequences were then checked  manually with the mRNA sequence and also via a 
nucleotide BLAST search  (http://blast.ncbi.nlm.nih.gov/) to determine if the primers 
are specific to gene of interest. Primers used are shown in Table 2.12. 
  
Table 2.12:  Primers and their sequences 
Gene Forward  Reverse  Temperature  Product Size 
 
GAPDH 
GTGAACCATGAGAA
GTATGACA 
 CATGAGTCCTTCCACG
ATACC 
60 123 
DcR2 
 
AGCTGAAGGGTGTC
AGAGGA 
GACTGTTTCTTCCAGG
CTGC 
63 254 
DEC1 
 
CTCTTCAGTTTGGG
AGCTGG 
AACCACTACCGTGCTA
TGCC 
63 194 
p16INK4a TGCCTTTTCACTGTG
TTGGA 
GCCATTTGCTAGCAGT
GTGA 
60 184 
p21INK4b 
 
TTAGCAGCGGAACA
AGGAGT 
GCCGAGAGAAAACAG
TCCAG 
58 1296 
p53  GTCACTGCCATGGA
GGAGCCGCA 
GACGCACACCTATTGC
AAGCAAGGGTTC 
58 225 
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2.8 Statistical Analysis 
Statistical analysis was performed using Excel and GraphPad Prism and calculated as a 
Student's t-test and Two-way Analysis of Variance (ANOVA) for three independent 
Variants. The significance level was assessed as a probability value of P<0.05 (95% 
confidence).    
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Chapter 3: Expression of senescence markers and their 
quantification in normal human skin and in BCC. 
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3.1 Expression of β-Galactosidase in normal human skin and BCC. 
β-galactosidase staining was carried out on frozen tissue sections of basal cell 
carcinoma (BCC) collected from the dermatology clinics at The Royal London 
Hospital. Frozen sections were used for β-galactosidase assay as formalin fixation 
denatures the β-galactosidase enzyme and as a result the colorimetric assay would 
not work. When cells undergo senescence they normally change their morphology 
and β-galactosidase staining at pH6, is widely recognized as an accepted marker of 
senescent cells (Dimri et al., 1995a). BCCs have a number of different 
morphological sub-types (see introduction) and I have attempted to investigate β-
galactosidase staining on these different types of BCC to determine whether 
senescence is characteristic of all BCC types or perhaps only restricted to specific 
groups. One aspect of my hypothesis being that the more benign BCC subtypes 
would exhibit senescence and that this is lost in more aggressive subtypes. To 
investigate this I used a panel of 21 BCC samples of different BCC types; these are 
summarised in Table 3.1 and full demographics shown in Appendix 2, in addition I 
used 7 normal skin biopsies in order to enable me to compare β-galactosidase 
staining between normal skin and BCC. The staining when present took 24 hours to 
develop. Results of these experiments are shown in Figure 3.1 which shows β-
galactosidase staining in normal skin (including epidermis and hair follicle), Nodular 
BCC (see Figure 3.2), Morphoeic BCC (see Figure 3.2) and Infiltrative BCC (see 
Figure 3.2). The staining protocol was the same for all BCC samples. The slides 
were visually analysed to observe the pattern of staining. The staining for β-
galactosidase was observed in most of BCC samples investigated but in normal skin 
was mainly restricted to the hair follicles and especially the outer root sheath 
(ORS). Staining for β-galactosidase was also observed in the sebaceous and eccrine 
sweat glands of normal skin. In BCC sections the staining was mostly seen in the 
stroma of BCC when compared to the epithelium and this was the same for the 
different types of BCC. However, in nodular BCC the β-galactosidase staining was 
also seen in the epithelial palisading cells when compared to morphoeic and 
infiltrative BCC types in which the tumour epithelium was mainly negative for β-
galactosidase. 
93 
 
 
 
 
 
Table 3.1: Summary of BCC Samples used for β-Galactosidase Staining 
         BCC Type       Numbers of Tumours 
Nodular BCC                   10 
Morphoeic BCC                    3 
Infiltrative BCC                    3 
Superficial BCC                    3 
Micronodular BCC                    1 
Nodular/Micro Nodular BCC                    1 
Normal Skin                    7 
 
β-galactosidase assay was carried out on frozen section of different BCC types as 
shown above. The demographic details of the individual patients are shown in 
Appendix 2. Normal skin was redundant from cosmetic surgery and as far as we 
are aware the patients had no skin disease.  
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Figure 3.1: Expression of β-Galactosidase in normal human skin. (A) is Negative 
control (B) Normal human skin. β-galactosidase staining is seen mostly in hair 
follicles and eccrine sweat gland (ESG). In the hair follicle β-galactosidase staining is 
restricted to the outer root sheath (ORS) of the hair follicle and secondary hair 
germ (HG) of the resting telogen hair follicle. 
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Figure 3.2: Representative images showing β-galactosidase staining in different BCC 
subtypes including (A) Negative Control (B) Nodular BCC (C) Morphoeic BCC and (D) 
Infiltrative BCC. Results show that β-galactosidase staining appears to be restricted to 
the stroma of different BCC subtypes and only occasionally expressed in tumour 
epithelium. 
 
 
 
C 
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3.2 Immunohistochemical Analysis of Senescence Markers in Basal Cell Carcinoma of 
Skin. 
Using β-galactosidase assay on frozen sections of different BCC types I observed that 
staining for β-galactosidase was mainly restricted to the stroma. To investigate this 
further immunohistochemical analysis of senescence markers was carried out on 
paraffin wax embedded BCC. I chose to investigate two of different types of BCC, 
Nodular BCC is non aggressive and whereas, Morphoeic BCC is considered an 
aggressive sub-type of BCC. To determine whether these BCC subtypes shows 
expression of cell senescence and also whether senescence may be more characteristic 
of either benign or aggressive BCC subtypes.   The senescence markers used for this 
study-included p16INK4a, p15INK4b, p21WAF1, p53, DcR2 and DEC1 as they have previously 
been reported to be good markers of senescence in tumours (Collado et al., 2005).    
For the staining of BCC tissue I collected 15 different samples of nodular and 
morphoeic BCC and 7 normal skin. Expression of markers in BCC was also compared 
with normal human skin. Data was analysed by visual analogue scoring and was carried 
out blind by Professor Rino Cerio (see section 2.3.4). Data was plotted on an excel 
spreadsheet, Statistical analysis was carried out using GraphPad Prism Software (La 
Jolla, CA 92037 USA)  with 95% confidence interval calculated as a Student's t-test (two 
variants) and Two-way Analysis of Variance (ANOVA) for three independent Variants. 
Raw data for visual analogue scoring of human BCC is shown in Appendix 8 
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3.2.1 GLI-1 Expression in BCC types 
Initially I carried out staining for GLI-1 on these tissue sections. The results for GLI-1 
are shown in Figure 3.3. GLI-1 staining was quite strong on the BCC samples. GLI-1 
was detected on both the tumour epithelium and in the stroma of both nodular 
and morphoeic BCC subtypes. I have used normal skin as a control and that shows 
staining in epidermis and hair follicles.  
Visual analogue scoring of the staining for GLI-1 in these tumours was carried out 
and the data analysed as mentioned in chapter 2 (section 2.3.2) by plotting the 
mean staining results with 95% confidence limits by subtype. Figure 3.3 E shows 
the results of data analysis comparing nodular with morphoeic BCC and as can be 
seen from this figure there was no significant difference between GLI-1 expression 
in nodular and morphoeic BCC subtypes.  
I also compared differences in nuclear and cytoplasmic expression and epithelial 
with stroma staining for both Morphoeic (see Figure 3.4) and Nodular (see Figure 
3.5) BCC subtypes. As can be seen from Figure 3.4 there was no significant 
difference between nuclear and cytoplasmic GLI-1 in morphoeic BCC (see 
Figure3.4A) and from Figure 3.4B there was also no difference between epithelial 
and stromal expression of GLI-1. 
Comparison between nuclear and cytoplasmic expression and epithelial with 
stroma for nodular BCC (see Figure 3.5) also showed no significant difference 
between nuclear and cytoplasmic expression of GLI-1 (see Figure 3.5A) or between 
epithelial and stroma staining in nodular BCC (see Figure 3.5B).  
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Figure 3.3: Representative images showing GLI-1 expression in (A) Negative Control (B) 
Normal skin (C) Nodular BCC (D) Morphoeic BCC. Visual analogue (E) scoring of total 
GLI-1 staining between nodular and  morphoeic BCC showed no significant difference 
in GLI-1 expression between nodular and morphoeic BCC. Visual analogue scoring was 
carried out n=15 nodular and n=15 morphoeic BCC. Statistical analysis was carried out 
using student's t-test. 
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Figure 3.4: GLI-1 visual analogue scoring comparing (A) Nuclear versus Cytoplasm and 
(B) Epithelial versus Stroma expression of GLI-1 in Morphoeic BCC. The analysis shows 
no significant difference between nuclear and cytoplasmic GLI-1 and also no difference 
between epithelia and stroma. Statistical analysis was carried out using student's t-test 
(n=15 Morphoeic, n=15 Nodular). 
                                                                        
 
 
 
 
 
 
Figure 3.5: GLI-1 visual analogue scoring comparing (A) Nuclear versus Cytoplasm and 
(B) Epithelial versus Stroma expression of GLI-1 in Morphoeic BCC. The analysis shows 
no significant difference between nuclear and cytoplasmic also no difference between 
epithelial and stromal GLI-1. Statistical analysis was carried out using student's t-test 
(n=15 Morphoeic, n=15 Nodular). 
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3.2.2  Expression of DCR2 in normal skin and BCC 
DcR2 (Decoy Receptor 2) stained positive on all BCC tissue sections of nodular and 
morphoeic BCC (see Figure 3.6 C and D) when compared with normal skin and 
negative control (see Figure 3.6 A and B). In both nodular and morphoeic BCC DcR2 
staining is quite clearly seen in both the tumour epithelium of morphoeic BCC and in 
particular the palisading cells of nodular BCC. DcR2 was also seen in the stroma of both 
morphoeic and nodular BCC. With regards its subcellular localization DcR2 was seen in 
the nucleus and cytoplasm of both BCC subtypes. 
Results of visual analogue scoring of DcR2 staining of these tumours were analysed (as 
mentioned in chapter 2 section 2.3.2) by plotting the mean staining results (with 95% 
confidence interval) by subtype. Visual  analogue scoring between nodular and 
morphoeic BCC (see Figure 3.6E) shows that there was no significant difference in 
staining intensity between nodular and morphoeic BCC, but there was significant 
difference between BCC and normal skin (P<0.05) indicating a significant up regulation 
of DcR2 in BCC compared to normal skin. 
In addition to the comparison between nodular and morphoeic BCC and normal skin I 
also compared by visual analogue scoring nuclear and cytoplasmic expression of DcR2 
(see Figure 3.7A) and epithelial versus stroma expression in morphoeic BCC (see Figure 
3.7B) and in nodular BCC (see Figure 3.8A and 3.8B respectively). Figure 3.7 shows 
that in morphoeic BCC there was no significant difference between nuclear and 
cytoplasmic DcR2 staining. However, when epithelial versus stromal expression was 
analysed there was a significantly higher level of DcR2 expression (P<0.05) in the 
stroma of morphoeic BCC compared to epithelial expression. In the nodular BCC there 
was no significant difference between nuclear and cytoplasmic expression of DcR2 (see 
Figure 3.8A) or between epithelial and stromal expression (see Figure 3.8B). These 
data therefore, indicate up-regulation of DcR2 in the stroma of morpheic BCC.  
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Figure 3.6: Representative images showing DcR2 expression in (A) Negative control (B) 
Normal Skin (C) Nodular  and (D) Morphoeic BCC. Visual analogue (E) scoring of total 
staining between nodular and morphoeic BCC showed no significant difference of DcR2 
expression, but there was a clear difference between normal skin and BCC types.  
Visual analogue scoring was carried out n=7 normal skin, n=15 nodular and n=15 
morphoeic BCC. Statistical analysis was carried out using Two-way Analysis of Variance 
ANOVA. 
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Figure 3.7: DcR2 visual analogue scoring comparing (A) Nuclear versus Cytoplasm and 
(B) Epithelial versus Stroma DcR2 expression in Morphoeic BCC. The analysis shows no 
significant difference between nuclear and cytoplasmic but there is a significant 
increase in stroma DcR2 when compared with epithelia expression. Statistical analysis 
was carried out using student's t-test.                                                                  
 
 
 
 
 
 
 
Figure 3.8: DcR2 visual analogue scoring comparing (A) Nuclear versus Cytoplasm and 
(B) Epithelial versus Stromal DcR2 expression in Nodular BCC. The analysis shows no 
significant difference between them. Statistical analysis was carried out using student's 
t-test. 
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3.2.3 Expression of DEC1 in normal skin and BCC 
DEC1 stained positive on all BCC tissue sections of nodular and morphoeic BCC (see 
Figure 3.9 C and D) when compared with normal skin and negative control (see Figure 
3.9 A and B). In both nodular and morphoeic BCC DEC1 staining is quite clearly seen in 
the both tumour epithelium of morphoeic BCC and in particular the palisading cells of 
nodular BCC. DEC1 was also seen in the stroma of both morphoeic and nodular BCC. 
With regards its subcellular localization DEC1 was seen in the nucleus and cytoplasm of 
both BCC subtypes. 
Results of visual analogue scoring of DEC1 staining of these tumours were analysed (as 
mentioned in chapter 2) by plotting the mean staining results (with 95% confidence 
interval) by subtype. Visual  analogue scoring between nodular and morphoeic BCC 
(see Figure 3.9E) shows that there was no significant difference in staining intensity 
between nodular and morphoeic BCC, but there was significant difference between 
BCC and normal skin (P<0.05) indicating a significant up regulation of DcR2 in BCC 
compared to normal skin. 
In addition to the comparison between nodular and morphoeic BCC and normal skin I 
also compared by visual analogue scoring nuclear and cytoplasmic expression of DEC1 
(see Figure 3.10A) and epithelial versus stroma expression in morphoeic BCC (see 
Figure 3.10B) and in nodular BCC (see Figure 3.11A and 3.11B respectively). Figure 
3.10 shows that in morphoeic BCC there was no significant difference between nuclear 
and cytoplasmic DEC1 staining. However, when epithelial versus stromal expression 
was analysed there was a significantly higher level of DEC1 expression (P<0.05) in the 
stroma of morphoeic BCC compared to epithelial expression. In the nodular BCC there 
was no significant difference between nuclear and cytoplasmic expression of DEC1 
(see Figure 3.11A) or between epithelial and stromal expression (see Figure 3.11B). 
These data therefore, indicate and up-regulation of DEC1 in the stroma of morpheic 
BCC.          
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Figure 3.9: Representative images showing DEC1 expression in (A) Negative control (B) 
Normal Skin (C) Nodular (D) Morphoeic BCC and (E) Visual analogue. Visual analogue 
scoring of total staining between nodular and morphoeic BCC showed no significant 
difference in DcR2 expression, but there was a clear difference with normal skin when 
comparing with BCC types. Visual analogue scoring was carried out n=7 normal skin, 
n=15 nodular and n=15 morphoeic BCC. Statistical analysis was carried out using Two-
way Analysis of Variance ANOVA. 
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Figure 3.10: DEC1 visual analogue scoring comparing (A) Nuclear versus Cytoplasm and 
(B) Epithelial versus Stroma expression of DEC1 in Morphoeic BCC. The analysis shows 
no significant difference between nuclear and cytoplasmic expression but there is a 
significant increase in stromal DEC1 expression when compared to epithelial 
expression. Statistical analysis was carried out using student's t-test.                                                                 
 
 
 
 
 
 
 
Figure 3.11: DEC1 visual analogue scoring comparing (A) Nuclear versus Cytoplasm and 
(B) Epithelial versus Stroma DEC1 expression in Nodular BCC. The analysis shows no 
significant difference between them. Statistical analysis was carried out using student's 
t-test. 
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3.2.3 Expression of p16INK4a in normal skin and BCC 
p16INK4a stained positive on all BCC tissue sections of nodular and morphoeic BCC (see 
Figure 3.12 C and D) when compared with normal skin and negative control (see 
Figure 3.12 A and B). In both nodular and morphoeic BCC. p16INK4a staining is quite 
clearly seen in the both tumour epithelium of morphoeic BCC and in particular the 
palisading cells of nodular BCC. p16INK4a was also seen in the stroma of both morphoeic 
and nodular BCC. With regards its subcellular localization p16INK4a was seen in the 
nucleus and cytoplasm of both BCC subtypes. 
Results of visual analogue scoring of p16INK4a staining of these tumours were analysed 
(as mentioned in chapter 2) by plotting the mean staining results (with 95% 
confidence interval) by subtype. Visual  analogue scoring between nodular and 
morphoeic BCC (see Figure 3.12E) shows that there was no significant difference in 
staining intensity between nodular and morphoeic BCC, but there was significant 
difference between BCC and normal skin (P<0.05) indicating a significant up regulation 
of p16INK4a in BCC compared to normal skin. 
In addition to the comparison between nodular and morphoeic BCC and normal skin I 
also compared by visual analogue scoring nuclear and cytoplasmic expression of 
p16INK4a (see Figure 3.13A) and epithelial versus stroma expression in morphoeic BCC 
(see Figure 3.13B) and in nodular BCC (see Figure 3.14A and 3.14B respectively). 
Figure 3.13 shows that in morphoeic BCC there was no significant difference between 
nuclear and cytoplasmic p16INK4a staining and also there was no difference between 
epithelial versus stromal expression. In the nodular BCC there was no significant 
difference between nuclear and cytoplasmic expression of p16INK4a (see Figure 3.14A). 
However, when epithelial versus stromal expression was analysed there was a 
significantly higher level of p16INK4a expression (P<0.05) in the stroma of nodular  BCC 
compared to epithelial expression (see Figure 3.14B). These data therefore, indicate 
and up-regulation of p16INK4a in the stroma of nodular BCC.          
 
 
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Representative images showing p16INK4a expression in (A) Negative control 
(B) Normal Skin (C) Nodular and (D) Morphoeic BCC. Visual analogue (E) scoring of total 
staining between nodular and morphoeic BCC showed no significant difference in 
p16INK4a expression, but there was a clear difference when comparing BCC subtypes 
with normal skin. Visual analogue scoring was carried out n=7 normal skin n=15 
nodular and n=15 morphoeic BCC. Statistical analysis was carried out using Two-way 
Analysis of Variance ANOVA. 
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Figure 3.13: p16INK4a visual analogue scoring comparing (A) Nuclear versus Cytoplasm 
and (B) Epithelial versus Stroma p16INK4a expression in Morphoeic BCC. The analysis 
shows no significant difference between them. Statistical analysis was carried out 
using student's t-test. 
                                                                     
 
 
 
 
 
 
Figure 3.14: p16INK4a means of visual analogue scoring comparing (A) Nuclear versus 
Cytoplasm and (B) Epithelial versus Stroma p16INK4a expression in Nodular BCC. The 
analysis shows no significant difference between nuclear and cytoplasmic p16INK4a 
expression but there is a significant increase in stromal p16INK4a when compared to 
epithelial expression. Statistical analysis was carried out using student's t-test. 
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3.2.4 Expression of p15 INK4b in normal skin and BCC  
p15INK4b stained positive on all BCC tissue sections of nodular and morphoeic BCC (see 
Figure 3.15 C and D) when compared with normal skin and negative control (see 
Figure 3.15 A and B). In both nodular and morphoeic BCC p15INK4b staining is quite 
clearly seen in the both tumour epithelium of morphoeic and nodular BCC and in 
particular the palisading cells of nodular BCC. p15INK4b was also seen in the stroma of 
both morphoeic and nodular BCC. With regards its subcellular localization p15INK4b was 
seen in the nucleus and cytoplasm of both BCC subtypes. 
Results of visual analogue scoring of p15INK4b staining of these tumours were analysed 
(as mentioned in chapter 2) by plotting the mean staining results (with 95% 
confidence interval) by subtype. Visual  analogue scoring between nodular and 
morphoeic BCC (see Figure 3.15E) shows that there was no significant difference in 
staining intensity between nodular and morphoeic BCC, but there was a significant 
difference between BCC and normal skin (P<0.05) indicating a significant up regulation 
of p15INK4b in BCC compared to normal skin. 
In addition to the comparison between nodular and morphoeic BCC and normal skin I 
also compared by visual analogue scoring nuclear and cytoplasmic expression of 
p15INK4b (see Figure 3.16A) and epithelial versus stroma expression in morphoeic BCC 
(see Figure 3.16B) and in nodular BCC (see Figure 3.17A and 3.17B respectively). 
Figure 3.16 shows that in morphoeic BCC there was no significant difference between 
nuclear and cytoplasmic p15INK4b staining. However, when epithelial versus stromal 
expression was analysed there was a significantly higher level of p15INK4b expression 
(P<0.05) in the stroma of morphoeic BCC compared to epithelial expression. In the 
nodular BCC there was no significant difference between nuclear and cytoplasmic 
expression of p15INK4b (see Figure 3.17A). However, when epithelial versus stromal 
expression was analysed there was a significantly higher level of p15INK4b expression 
(P<0.05) in the stroma of nodular BCC compared to epithelial expression (see Figure 
3.17B). These data therefore, indicate and up-regulation of p15INK4b in the stroma of 
morpheic BCC.          
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Figure 3.15: Representative images showing p15INK4b expression in (A) Negative control 
(B) Normal Skin (C) Nodular and (D) Morphoeic BCC. Visual analogue (E) scoring of total 
staining between nodular and morphoeic BCC showed no significant difference in 
p15INK4b expression, but there was a significant difference when comparing BCC types 
with normal skin. Visual analogue scoring was carried out on n=7 normal skin, n=15 
nodular and n=15 morphoeic BCC. Statistical analysis was carried out using Two-way 
Analysis of Variance ANOVA. 
 20 X  
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Figure 3.16: p15INK4b visual analogue scoring comparing (A) Nuclear versus Cytoplasm 
and (B) Epithelial versus Stroma p15INK4b expression in Morphoeic BCC. The analysis 
shows no significant difference between nuclear and cytoplasmic p15INK4b but there is 
a significant increase in stromal p15INK4b when compared to epithelial expression. 
Statistical analysis was carried out using student's t-test. 
                                                                      
 
 
 
 
 
Figure 3.17: p15INK4b visual analogue scoring comparing (A) Nuclear versus Cytoplasm 
and (B) Epithelial versus Stroma p15INK4b expression in Nodular BCC. The analysis shows 
no significant difference between nuclear and cytoplasmic p15INK4b but there is a 
significant increase in stromal p15INK4b when compared to epithelial expression. 
Statistical analysis was carried out using student's t-test. 
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3.2.5 Expression of p53 in normal skin and BCC 
p53 stained positive on all BCC tissue sections of nodular and morphoeic BCC (see 
Figure 3.18 C and D) when compared with normal skin and negative control (see 
Figure 3.18 A and B). In both nodular and morphoeic BCC p53 staining is quite clearly 
seen epithelium of morphoeic   nodular BCC. p53 was also seen in the stroma of both 
morphoeic and nodular BCC. With regards its subcellular localization p53 was mostly 
seen in the nucleus when compared with cytoplasm of both BCC subtypes. 
Results of visual analogue scoring of p53 staining of these tumours were analysed (as 
mentioned in chapter 2) by plotting the mean staining results (with 95% confidence 
interval) by subtype. Visual  analogue scoring between nodular and morphoeic BCC 
(see Figure 3.18E) shows that there was no significant difference in staining intensity 
between nodular and morphoeic BCC, but there was significant difference between 
BCC and normal skin (P<0.05) indicating a significant up regulation of p53 in BCC 
compared to normal skin. 
In addition to the comparison between nodular and morphoeic BCC and normal skin I 
also compared by visual analogue scoring nuclear and cytoplasmic expression of p53 
(see Figure3.19A) and epithelial versus stroma expression in morphoeic BCC (see 
Figure 3.19B) and in nodular BCC (see Figure 3.20A and 3.20B respectively). Figure 
3.19 shows that in morphoeic BCC there was a increase expression of p53 in nucleus 
when compared with cytoplasmic p53 staining (P<0.05). However, when epithelial 
versus stromal expression was analysed there was a significantly higher level of p53 
expression (P<0.05) in the epithelia of morphoeic BCC compared to stroma expression. 
In the nodular BCC there was a increase level of p53 in  nucleus when compared with 
cytoplasmic expression of p53  (see Figure 3.20A) and also increase of p53 in epithelia 
when compared with stromal expression (see Figure 3.20B) (p<0.05). These data 
therefore, indicate and up-regulation of p53  in the epithelia  of both morpheic and 
nodular BCC.          
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Figure 3.18: Representative images showing p53 expression in (A) Negative control (B) 
Normal Skin (C) Nodular and (D) Morphoeic BCC. Visual analogue (E) scoring of total 
staining between nodular and morphoeic BCC showed no significant difference of p53 
expression, but there was a clear difference with normal skin when compared with 
BCC types.  Visual analogue scoring was carried out on n=7 normal skin, n=15 nodular 
and n=15 morphoeic BCC. Statistical analysis was carried out using Two-way Analysis of 
Variance ANOVA. 
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Figure 3.19: p53 visual analogue scoring comparing (A) Nuclear versus Cytoplasm and 
(B) Epithelial versus Stroma p53 expression in Morphoeic BCC. The analysis shows 
significant difference between nuclear and cytoplasmic and also between epithelial 
and stromal p53 expression. Statistical analysis was carried out using student's t-test. 
 
 
 
 
 
 
 
 
Figure 3.20: p53 visual analogue scoring comparing (A) Nuclear versus Cytoplasm and 
(B) Epithelial versus Stroma p53 expression in Nodular BCC.  The analysis shows 
significant difference between nuclear and cytoplasmic and also between epithelial 
and stromal p53 expression. Statistical analysis was carried out using student's t-test. 
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3.2.5 Expression of p21WAF1 in normal skin and BCC  
p21WAF1 staining is negative on all nodular and morphoeic types of BCC (see figure 3.16 
C, D) as compared with normal skin. (see figure 3.16 A, B).There is only some staining 
in sweat gland in normal skin.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21:  Representative images showing p21WAF1 expression in (A) Negative 
control (B) Normal Skin (C) Normal skin showing eccrine sweat glands and (D) Nodular 
BCC  
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Discussion 
The concept of senescence was first applied to the irreversible growth arrest of cells 
after prolonged proliferation under in vitro, non-physiological conditions (Hayflick, 
1965). Now this concept is applied in general to the irreversible arrest of cell 
proliferation caused by various stresses, including oxidative damage, telomere 
dysfunction, DNA damage and several chemotherapeutic drugs such as doxorubicin or 
cisplatin, which affect DNA structure, or taxol and vincristine, which target 
microtubules (Serrano and Blasco, 2001, Chang et al., 1999).  
Recent studies have shown that oncogene-induced senescence (OIS) occurs during the 
early stages of tumorigenesis (Braig et al., 2005, Chen et al., 2005). These studies show 
that senescent tumour cells are abundant within premalignant neoplastic lesions such 
as adenomas, but not in malignant tumours (Collado et al., 2005). This association of 
senescence cells with the premalignant stages of tumour progression opens up the 
possibility of using senescence markers as diagnostic and prognostic tools. As some 
chemotherapeutic treatment  such as retinoids induce senescence in tumour cells 
(Roninson, 2003). Senescence markers could help to monitor treatment response. 
There is a lot known about BCC with regards to their histopathological structure, 
clinical features and to an extent their underlying cause, however much remains 
undefined with regards the mechanism of development and especially with regards 
different BCC subtypes e.g. benign versus more aggressive BCC. In the work presented 
in this chapter I have investigated senescence markers on formalin-fixed paraffin-
embedded sections of BCC using standard immunohistochemistry techniques. The 
work presented in this chapter shows clearly that senescence is characteristic of 
human BCC. In particular the data presented in this chapter has shown that a number 
of senescence markers identified in other tumours (Collado et al., 2005, Zhang et al., 
2006) are also expressed in BCC. These markers include the cyclin-dependent kinase 
inhibitor p15INK4b, the decoy receptor (DcR2) and the transcription factor differentiated 
embryo-chondrocyte expressed (DEC1). In the study of Collado et al (2005) these 
markers showed an increased level of expression specifically in premalignant 
neoplastic lesions of the skin, lung and pancreas, but not in malignant tumours. The 
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high levels of these markers correlated well with the presence of SA- -Gal activity, 
which confirms their value in identifying the occurrence of OIS in vivo. 
Senescence associated β-Gal (SA-β-Gal) is widely used as an assay for senescence both 
in vitro and in vivo tissue sections(Dimri et al., 1995a). The assay involves the 
cytochemical detection of β-galactosidase activity at pH 6.0, termed senescence-
associated β-galactosidase (SA-β-Gal). Senescence associated β-Gal activity is derived 
from the increased lysosomal content of senescent cells, which enables the detection 
of lysosomal β-galactosidase at a suboptimal pH, pH 6.0 (pH 4.0 is optimal). The β-
Galactosidase assay has been accepted as a marker of senescence both in vitro and in 
vivo, although its biochemical basis is still unknown (Dimri et al., 1995a). SA-β-Gal 
activity is normally assayed in cultured cells or tissue sections using the chromogenic 
substrate 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-Gal), or the fluorescent 
analogue fluorescein-di-β-D-galactopyranoside (FDG). In this chapter I observed that 
human BCC shows positive staining for SA-β-Gal in both the epithelial tumour mass 
and in the stroma (see Figure 3.2). This may be important as tumorigenesis is a 
multistep process, whereby genetic changes lead to growth advantage in a subset of 
cells paving way to progression from normal to malignant cells (Axelrod et al., 2006). 
Tumour progression is not achieved solely by the evolving cancer cells, but stromal 
components or the microenvironment of the tumour play a key role. The knowledge 
that stromal cells have the ability to stimulate oncogenenesis has been taken a step 
further by recent data showing that stromal fibroblasts present in invasive human 
breast carcinomas promote tumour growth and angiogenesis through elevated Sdf1 
secretion (Orimo et al., 2005). In another study, it has been shown that extensive gene 
expression changes occur in all breast cell types, including fibroblasts (Allinen et al., 
2004). Kiaris et al. have shown an association between TP53 mutations in the stromal 
component of epithelial tumours and carcinogenesis (Kiaris et al., 2005). Together, 
these findings indicate that stroma influence the initiation and tumour progression of 
carcinomas and most of the cells present in stroma are fibroblasts and they have an 
active role in tumorigenesis (Mueller and Fusenig, 2004, Beacham and Cukierman, 
2005). In fact, several findings from different laboratories have suggested that cancer 
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cells themselves can alter their adjacent stroma to form a permissive and supportive 
environment for tumour progression (Bhowmick and Moses, 2005). 
In addition to human BCC I also carried out staining for SA-β-Gal in normal human skin. 
The staining for β-galactosidase was observed in most of skin samples investigated 
mainly in hair follicles and especially in outer root sheath (ORS) and hair germ. The 
staining for β-galactosidase was also observed in the sebaceous and eccrine sweat 
glands. The significance of β-galactosidase expression in the ORS and hair germ is 
unclear. Both the ORS and hair germ contain stem cells (Tumbar et al., 2004) however, 
it is very unlikely they are truly senescent as these population of cells undergo marked 
cell proliferation during the hair cycle (Morrison and Spradling, 2008). However, it is 
also important to note that while β-galactosidase is considered a good marker for cell 
senescence the basis for this is not fully understood. Therefore, it is very likely that 
cells that are not senescent may also be positive for β-galactosidase. 
Investigation of the signalling pathways leading to OIS has shown that two main 
pathways are involved, p16INK4a-RB (retinoblastoma) and ARF-P53, which are 
responsible for the execution of the proliferative arrest that characterizes senescence 
(Campisi, 2005). These two pathways are thought to be crucial for tumour suppression 
and are often mutated in tumours (Hollstein et al., 1991, Ruas and Peters, 1998a, 
Sharpless and DePinho, 1999b). 
Having shown by SA-β-Gal staining that both tumour epithelium and stroma may be 
senescent in human BCC. I decided to carry out further analysis of my BCC samples 
using a panel of senescent markers previously reported to be involved in OIS including 
p53, DcR2, DEC1, p16INK4a, p15INK4b and P21WAF1. In order to investigate in more detail 
expression of these markers I have looked at both benign nodular BCC and aggressive 
morphoeic BCC. I have quantified immunostaining using a standard analogue scoring 
system (Hsu and Raine, 1981). DcR2 has not been reported in BCC before. In my study I 
observed DcR2 was expressed in both nodular and morphoeic BCC (see Figures 3.6, C, 
D) although based on visual analogue scoring system there was no significant 
difference between nodular and morphoeic BCC. However, in comparison with normal 
skin I did observed a significant difference between normal skin and BCC subtypes (see 
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Figure 3.6 E). These data shows that compared to normal skin DcR2 is significantly 
higher in BCC. I have shown a significant increase in stroma staining compared to 
epithelia expression for DcR2 in morphoeic BCC (see Figure 3.7 B) but no difference in 
nodular BCC (see Figure 3.8B). The reason for this difference is unclear without access 
to cell cultures that would allow further downstream signalling to be investigated. 
However, increased expression of DcR2 in the stroma of morphoeic BCC may reflect 
increased stromal resistance to apoptosis. Also there was no significant difference 
between nuclear and cytoplasmic expression in both nodular and morphoeic BCC 
subtypes (see Figure 3.7A,3.8A). DcR2 is the member of tumour necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) receptor family and is also known as TRIAL-
R4. DcR2 is classical type 1 transmembrane protein with an extracellular domain, 
which shows 58-70%homology with TRAIL-R1/R2, and itself has a truncated non-
functional death domain. Consequently, these decoy receptors are able to compete for 
binding with the activators DR4 & DR5, thereby negatively regulating TRAIL-induced 
apoptosis. DcR2 expression has reported to protect cells from trail induced apoptosis 
and is regulated by p53. There is also a functional cytoplasmic signalling region which is 
believed to be involved in the activation of NF-kB, which leads to the induction of 
protective genes and increase the anti-apoptotic threshold of the cells. 
DEC1 has not been reported in BCC before and indeed does not appear to have been 
investigated in skin cancer.  In my study DEC1 was expressed in nodular and morphoeic 
BCC (see figures 3.9 C, D). There was no difference between nodular and morphoeic 
BCC but there was a significant difference between normal skin and BCC tumor types 
(see Figure 3.9 E). Therefore, in BCC there is an increase in DEC1 expression compared 
to normal skin. I have also shown significant difference between nuclear to 
cytoplasmic and epithelial to stroma in nodular and morphoeic BCC. There was an 
increase in stromal DEC1 expression in morphoeic BCC (see Figure 3.10 B) but no 
difference in nodular BCC (see Figure 3.11B). The reason for this difference is not clear 
as it may be expected that as nodular BCC are less aggressive than morphoeic BCC and 
as the stroma is known to play a role in tumour development that more senescence 
would be associated with the stroma of less aggressive BCC. However, it must also be 
remembered that senescence cells are still very active metabolically and can secrete a 
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wide range of growth regulatory factors (Coppe et al., 2010). Therefore, it is possible 
that the senescence stroma of morphoeic BCC may in fact be involve in promoting the 
more aggressive nature of these BCC. This could be investigated by culturing the 
stroma from nodular and BCC and investigating their influence on keratinocyte 
invasion in three-dimensional organotypic models. There was no significant difference 
between nuclear to cytoplasmic in nodular and morphoeic BCC (see Figure 3.10 A, 3.11 
A).  DEC1 is a basic helix-loop helix protein (bHLH). DEC1 is also known as, enhancer of 
split and hairy related protein 2 (SHARP2) in rats, or stimulated with retinoic acid 13 
(SRA13) in the mouse. This transcription factor is involved in a variety of cellular 
processes such as cell differentiation, lipid metabolism, proliferation and regulation of 
the molecular clock. DEC1 is widely expressed in normal tissues such as testis, lymph 
node,  endothelial cells placenta, spleen, thymus, cervix, and ovary but is abundant in 
various carcinomas in breast cancer, colorectal, pancreatic and non-small cell lung 
cancer (Turley et al., 2004). Hypoxia a state where tissue is deprived of normal oxygen 
levels is associated with microenvironment of a tumour. There is little known about 
how DEC1 mediates cell proliferation, it does initiates G1 cell cycle arrest and it has 
been shown that DEC1 is a target of tumour suppressor p53 which binds to the 
promoter on the DEC1 gene. 
Mutations in the p16INK4a gene have been previously identified in sporadic melanomas 
and NMSC resulting in a breakdown of tumour suppression mechanisms (Wagner et 
al., 1998). Under conditions of stress, and oncogenic stimuli, expression of p16INK4a 
increases as does p15INK4b expression (Malumbres et al., 2000). p15INK4b has a structural 
and functional homology with p16INK4a and is transcriptionally activated by 
transforming growth factor-beta (TGF-β) (Hannon and Beach, 1994). Many cells 
constitutively express p15INK4b and with the loss p16INK4a, p15INK4b will maintain 
inhibition of CDK4. p15INK4b has been previously described as being involved in the 
growth arrest that is imposed during Ras-induced senescence (Malumbres et al., 
2000). In cancer the influence of p15INK4b is not clear and work with p15INK4b deficient 
mice has only shown a subtle predisposition to tumours whereas loss of p16INK4a 
causes a wide range of tumors. The increased expression of these genes results in the 
suspension of the cell cycle and counteracts the excessive proliferation or the 
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replication of damaged DNA. Under normal physiological conditions p16INK4a is 
expressed in low levels but if cells are under stress such as oncogenic stress p16INK4a 
levels increase. This protein is usually inactive in cancers such as melanoma, leukemia 
and head and neck cancer, whether by mutation, methylation or deletion which results 
in the inactivation of the tumour suppressor system. p16INK4a has been previously 
shown to be expressed in BCC before and stained positive but not as senescence 
marker. In my study p16 along with p15INK4b was expressed in both BCC subtypes (see 
Figures 3.12 C, D and 3.15 C, D). There was no significant difference between BCC 
subtypes but there was significant difference between normal skin and BCC tumor 
types (see Figure 3.12 E and 3.15 E). I have also shown difference between nuclear and 
cytoplasmic and epithelial to stroma in nodular and morphoeic BCC. There was 
increase in stroma then epithelia in p16INK4a in nodular BCC (see Figure 3.14 B) but no 
difference in morphoeic BCC (see Figure 3.13 B) along with nuclear to cytoplasm in 
nodular and morphoeic BCC (see Figure 3.13 A, 3.14 A). For p15INK4b there was 
increase in stroma then epithelia in both nodular and morphoeic BCC (see Figure 3.16 
B, 3.15 B), but no difference between nuclear to cytoplasmic (see Figure 3.16 A, 3.15 
A). Eshkoor et al. (2008) found significant expression of p16INK4a protein and mRNA 
expression in BCC cells when compared with normal skin tissue  and staining was in the 
nucleus and cytoplasm (Eshkoor et al., 2008). This data supports my results showing 
that there is clear difference in p16INK4a expression between BCC and normal skin (see 
Figure 3.12E).   Svensson et al. (2003), did not observe any difference in the expression 
of p16INK4a among different histological types of carcinoma suggesting that p16INK4a 
expression does not correlate with malignancy or proliferation (Svensson et al., 2003). 
My data confirms the observations of Sevensson et al (2003) as I also did not observe 
any significant difference in the  expression of p16INK4a between benign nodular and 
aggressive morphoeic BCC. 
p53 has been previously reported as senescence marker (Barbareschi et al., 1992, 
Suzuki et al., 2001). In my study p53 was expressed in both nodular and morphoeic 
BCC (see figures 3.18 C, D), but not in normal skin. I have also shown difference 
between nuclear to cytoplasmic and epithelial to stromal expression in nodular and 
morphoeic BCC. There was a significant increase of p53 in nuclear and epithelial 
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compartments when compared with cytoplasmic and stromal expression (see figure 
3.19 and 3.20 A,B).  p53 protein is encode by the gene TP53 on the short arm of 
chromosome 17 (17p3) and is mediated response to DNA damage, telomere 
shortening, oxidants, hypoxia and a variety of stresses. There are four major functions 
of p53 1) promotes transient arrest and repair of DNA, 2) defective repair, the repair 
attempt fails there by promoting the development of cancer, 3) apoptosis, in the case 
of severe damage p53 up regulates effectors of apoptosis and 4) senescence, initiation 
of cellular senescence (Vogelstein et al., 2000). In senescence it functions through 
increasing the expression of CDK inhibitor p21 and there by halting cell progression at 
G1 (Kramer et al., 2001). P53 expression is often associated with oncogenic RAS and is 
often seen alongside p16INK4a expression. P53 is the most commonly altered gene in 
cancer through its loss or mutation which results in an inability to bind target genes 
(Hanahan and Weinberg, 2000). Barrett  et al (1997) shows p53 expression in BCC, also 
show nuclear staining of p53 this correlates with my study as well (Barrett et al., 1997). 
I have also stained for p21WAF1 but observed no expression in BCC. In normal human 
skin there is some staining in sweat glands (see figure 3.21). In previous studies also 
p21WAF1 was also negative in BCC (Ahmed et al., 1997). p21WAF1, encoded by CDKN1a, 
was first identified in normal human fibroblasts (Herbig et al., 2003, Roninson, 2002). 
Expression of p21WAF1 can be induced by a number of cell growth regulatory signals 
including; DNA damage, tumour suppressor p53 and TGFB to affect cellular senescence 
and cell differentiation (Roninson, 2002). Of all the mechanisms that p53 is involved in 
p21WAF1 only plays a role in cell cycle regulation and senescence (Levine, 1997). 
Ultimately p21WAF1, like p16INK4a, maintain pRB in a hypophoshorylated state 
preventing its inactivation in G1 phase by binding to CDK2/cyclin E (Stein et al., 1999). 
In my study β-galactosidase staining along with DcR2, DEC1, p15INK4b, p16INK4a and p53 
were observed in both tumour epithelium and tumour stroma. The stroma has been 
shown to play very important role in tumour formation and constitutes the 
microenvironment of the tumour (Mueller and Fusenig, 2004). Normal stroma consists 
of a wide range of molecules that act as a supportive framework for tissues and 
organs. Among all the stromal components, fibroblasts are essential for the synthesis 
and deposition of the extracellular matrix (ECM) by producing a variety of collagens 
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and fibronectin (Blankenstein, 2005). Fibroblasts not only maintain the integrity of the 
ECM and basement membrane, in some cases, they also contribute to the ECM 
remoulding by secreting proteases such as matrix metalloproteinase (MMPs) which 
effectively degrade ECM (Orimo and Weinberg, 2006, Östman and Augsten, 2009). 
Another important role of fibroblasts is wound healing. During wound healing, 
fibroblasts are activated and become a specialized type of fibroblast, myofibroblast, 
which is endowed with a higher capability of ECM synthesis (Schaffer and Nanney, 
1996, Marsh et al.). Along with fibroblasts, other types of cells such as inflammatory 
cells and endothelium also contribute to the integrity and homeostasis of the stroma. 
Among the components of the stromal cells, an increasing number of Cancer 
associated fibroblasts (CAFs) which share a similar morphology with myofibroblasts 
observed in wound healing are often found in the cancer (Cirri and Chiarugi, 2012). 
CAFs are believed to actively participate in the growth and invasion of the tumour cells 
by providing a unique tumour microenvironment (Cirri and Chiarugi, 2012). CAFs found 
in different cancers are highly heterogeneous, and they are possibly derived from 
resident fibroblasts, epithelial cells, endothelial cells or mesenchymal cells (Pietras and 
Östman, 2010). The results of several in vitro and in vivo experiments indicate that 
CAFs promote cancer (Shekhar et al., 2001, Chung et al., 2003). In breast cancer, cells 
of the stromal-epithelial component are able to confer tumourgenic properties 
(Shekhar et al., 2001). The stromal-epithelial interaction is also important to the 
normal development of the mammary gland and it has been reported that adjacent 
cancer cells can alter the stroma to provide a more supportive environment (Shekhar 
et al., 2001).  
In vivo, senescent cells have been observed in association with aging but also with the 
early phases of tumourgenesis (Beausejour and Campisi, 2006, Collado et al., 2005). 
Cells in premalignant tumours undertake OIS, but cells of malignant tumours do not, 
due to the loss of senescence effectors such as p16. BCC is a malignant cancer but it 
very rarely metastasizes and it also doesn't have premalignant type. The presence of 
these senescence cells in BCC might have role in restricting BCC and preventing 
metastasize.   
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In conclusion, in this chapter I have shown that cell senescence is seen in both the 
tumour epithelium and stroma of human BCC. However, I did not observe any 
significant difference between non aggressive nodular BCC and more aggressive BCC 
types. This suggests that while up-regulation of senescence in BCC is characteristic of 
this tumour and may explain why they rarely metastasise; cell senescence does not 
explain difference between subtypes. 
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Chapter 4: Expression of senescence markers in an in vitro 
BCC model. 
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Introduction 
In Chapter 3 of this thesis I investigated the expression of cell senescence in nodular 
and morphoeic BCC. I showed that while markers of cell senescence were significantly 
up-regulated in nodular and morphoeic BCC compared to normal human skin there 
was no significant difference between BCC sub types. From this data I concluded that 
cell senescence is involved in human BCC but this does not explain different BCC 
subtypes. 
 
However, although I have shown up-regulation of senescence markers in BCC, these 
data do not tell me whether their expression is a direct or indirect result of 
dysregulation of the Hedgehog signalling pathway and therefore, whether they arise as  
a direct effect of up-regulation of GLI-1.  To investigate this further I decided to use an 
in vitro model. Currently keratinocytes from BCC have proven very difficult to culture. 
In the introduction to this thesis I have described how Hedgehog signalling is crucial to 
the development of BCCs, and that irrespective of the site of the upstream genetic 
mutation, up-regulation of the GLI-1 transcription factor gene and protein is 
characteristic of BCC. Transgenic experiments in mice have shown us that GLI proteins 
may have differing roles in both the early stages of tumour development and the later 
stages of tumour persistence and survival. Clearly the initiation of BCC formation and 
persistence of the tumour relies on both of the molecules to an extent. However, as 
described in the introduction to this thesis. There is limited knowledge of what 
happens downstream of these GLI proteins. Regl et al (2002) have previously used a 
keratinocyte culture model to examine the interaction of GLI-1 and GLI-2 and have also 
examined the expression of both GLI-1 and GLI-2 factors in human BCCs. They 
demonstrated a degree of inter dependence between the two genes, suggesting that 
the expression of these genes were mutually controlled. 
 
A Medline search for cell culture in basal cell carcinoma provides only seven published 
reports where the culture of BCC cells has been successfully achieved and has yielded 
results in the investigation of BCC cell biology. Of note, Asada mentioned that there 
were only some cellular characteristics of the BCC tumours preserved in culture (Asada 
et al., 1992).  This, and the small number of reports of BCC cell culture being successful 
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implies that the difficulty in culturing these cells is due to the fact that the cells require 
a milieu such as the stroma to grow efficiently, and that without it, growth is limited. 
As a result of such difficulties, many of these reports state that the cultures were short 
term only, and that although a small number of passages may have been possible, few 
of these studies go beyond the technical aspects of cell culture to derive useful 
information from the cell analysis. 
 
It is well accepted that cell culture techniques have been of limited use in terms of 
culturing keratinocytes from BCC. Although it is not clear why keratinocytes from BCC 
have been difficult to culture it is possible that growth of BCC is dependent upon its 
stroma. Therefore, culture of keratinocytes from BCC may require fibroblasts from the 
tumour stroma to act a feeder layer. However, there have been no reports to data of 
the use of stromal cells from BCC and indeed in my own group it was observed that 
fibroblasts from BCC were also difficult to culture in vitro (Jane Elliott PhD thesis). 
Therefore, a cell culture system that gives insight to the molecular mechanisms of BCC 
would be a significant development in the investigation of BCC pathogenesis.  
 
To get around this difficulty of growing and manipulating BCCs cells for the purpose of 
molecular biology investigation, a model system using keratinocytes has been used in 
the laboratory in which I performed this work. Given the importance of GLI-1 
expression in the development of BCC, the group I have worked with has developed a 
model in which keratinocytes are retrovirally transduced to over-express GLI-1 
transcription factor. However, a potential limitation of this model is that while it 
replicates the up-regulation of GLI-1 seen in BCC normal human keratinocytes have 
wild-type PTCH. PTCH is well established as a downstream target of GLI-1 and a 
consequence when GLI-1 is over-expressed in cells with wild-type PTCH the 
subsequent up-regulation of PTCH results in down-regulation of GLI-1 and damping 
down of these GLI-1 signals. In contrast in BCC PTCH is mutated GLI-1 is up-regulated 
but because PTCH is mutated negative feedback cannot happen. Therefore, PTCH 
knockdown in human keratinocytes may be a better model representative of BCC. 
In this chapter I have made use of both retroviral expression of GLI-1 in human NEB1 
keratinocytes (GLI-1 NEB1) as well as an in vitro model of BCC currently being develop 
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by Mr. Muhammad Rahman. Using a small hairpin RNA (shRNA) sequence that target 
PTCH1, NEB1 immortalised keratinocytes have been retrovirally transduced in order to 
knockdown PTCH1 expression (NEB1 189A). Figure 4.1A shows qPCR for PTCH1 and 
confirms strong suppression in NEB1-189A cells and as a result, GLI-1 expression was 
increased (Figure 4.1B). A non-targeting scrambled control (shCON) sequence was 
used as control. Both the retrovirally over expressing GLI-1 NEB1 cells and NEB1-189A 
cells were then used to investigate changes in expression of senescence markers 
investigated in chapter 3.  
  
Therefore, the aim of this chapter is to investigate the expression of cell senescence 
markers in in vitro models of BCC (PTCH1 knockdown Cells and GLI-1 over expressing 
cells) to determine whether over-expression of GLI-1 up-regulates the expression of 
cell senescence markers identified in chapter 1 of this thesis.       
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Figure 4.1: qPCR for PTCH1 and GLI-1 in NEB1-shCON and NEB1-189A cells. (A) shows 
level of PTCH mRNA expression in both control (shCON) NEB1 keratinocytes and in the 
NEB1 189-A-β1 showing that PTCH was significantly reduced in the NEB1 cells (B) 
shows that as a result of PTCH knockdown there was an over 6 fold increase in GLI-1 
expression in the NEB1 189A-β1 cell line. Results are mean +/- SEM, n=3 separate 
experiments. Statistical analysis was carried out using Student's t-test. 
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4.1 Immunofluorescence staining and Quantitative Real Time-Polymerase Chain 
Reaction (qPCR) of GLI-1 in an in vitro model of BCC 
In order to investigate GLI-1 regulation of cell senescence markers seen in BCC and 
reported in Chapter 3, immunofluorescence staining was carried out on NEB1 
keratinocytes retrovirally over expressing GLI-1 and on NEB1 keratinocytes in which 
PTCH has been knockdown using shRNA technology resulting in up-regulation of GLI-1. 
Immunofluorescence staining was carried out for known markers of senescence 
(Collado and Serrano, 2006) as investigated in chapter 3. Staining was quantified by 
ImageJ software and each experiment was repeated three times. Along with this 
Quantitative Polymerase Chain Reaction (qPCR) was also performed to quantify levels 
of mRNA expression for senescence markers in these cells. 
GLI-1 stained positive on all in vitro models of BCC including NEB1 GLI-1 cells and NEB-
1 189A cells along with NEB1-pBP vector control cells and NEB1 shCON cells as control. 
GLI-1 immunofluorescence staining was generally more apparent in the cytoplasm of 
both our NEB1 GLI-1 over expressing and NEB1 189A cells although faint staining can 
also be seen when looking at nucleus of the cell although when seen against the DAPI 
stained nuclei this appears as pale blue dots (see Figure 4.2 A and B). In Figure 4.2A 
there is small increase in fluorescence in the NEB1 GLI-1 over expressing cells when 
compared to control cells in the top panel. However, the difference in GLI-1 
immunofluorescence staining is more apparent in Figure 4.2B in the NEB1 189A cells 
when the top control panels are compared with bottom panel it can be seen that in 
PTCH knockdown cells (bottom panels) there is an increase in GLI-1 staining. 
In order to quantify changes in GLI-1 expression I also analysed GLI-1 
immunofluorescence staining of both GLI-1 over-expressing cells (NEB1 GLI-1) and 
PTCH1 knockdown (NEB1 189A) cells using by ImageJ software as discussed in chapter 
2. The fluorescence levels for GLI-1 was significantly higher in NEB1 GLI-1 cells (see 
Figure 4.2C) compared to NEB1 pBP control cells (P<0.05) and in NEB1 189A cells (see 
Figure 4.2C), GLI-1 immunofluorescence was significantly higher (P<0.05) when 
compared with NEB1 shCON vector control cells (see Figure 4.2C).   
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In addition to quantifying immunofluorescence levels I also carried out GLI-1 qPCR 
(Figure 4.2D). The expression of GLI-1 mRNA level was significantly increased (P<0.05) 
in NEB1 GLI-1 cells (see Figure 4.2D) and NEB1 189A cells (P<0.05) (see Figure 4.2D), 
when compared with NEB1 pBP vector control cells (see Figure 4.2D) and NEB1 shCON 
cells (see Figure 4.2D). This data confirms the up-regulation of GLI-1 at protein and 
mRNA level in both our NEB1 GLI-1 cells and NEB1 189A cells. These cells were then 
further analysed for expression of cell senescence markers in investigated in chapter 
three.    
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Figure 4.2: Immunofluorescence staining for GLI-1 on in vitro BCC models (A) NEB1 pBP 
vector Control Cells top panels showing GLI-1 immunofluorescence staining and then 
image merged with DAPI stained cells to show nuclei and NEB1 GLI-1 cells in bottom 
panel showing GLI-1 immunofluorescence staining and then image merge with DAPI 
stained cells to show nuclei (B) NEB1 shCON Control cells top panels showing GLI-1 
immunofluorescence staining and then image merged with DAPI stained cells to show 
nuclei and NEB1 189A cells bottom panel showing GLI-1 immunofluorescence staining 
and then image merge with DAPI stained cells to show nuclei (C) ImageJ quantification 
of GLI-1 immunofluorescence in both NEB1 GLI-1 and NEB1 189A and NEB1 controls 
cells (D) Quantitative polymerase chain reaction (qPCR) expression of GLI-1 in NEB1 
Cells. Results are mean +/- SEM, n=3 separate experiments. Statistical analysis was 
carried out using Student's t-test.      
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4.2 Immunofluorescence staining and Quantitative Real Time-Polymerase Chain 
Reaction (qPCR) of DcR2 in an in vitro model of BCC. 
DcR2 (Decoy Receptor 2) immunofluorescence was detected  in  both the NEB1 GLI-1 
cells and NEB-1 189A cells along with NEB1-pBP vector control and NEB1 shCON 
control cells. As I observed with GLI-1, Immunofluorescence staining for DcR2 was 
generally more apparent in the  cytoplasm of both our NEB1 GLI-1 and NEB1 189A cells 
although weak staining can also be seen when looking at nucleus of the cell although 
when seen against the DAPI stained nuclei this appears as pale blue (see Figure 4.3 A 
and B). In Figure 4.3A it is possible to see an increase in fluorescence in the NEB1 GLI-1 
cells bottom panel when compared to control cells in the top panel. However, there 
were no apparent differences in DcR2 immunofluorescence staining in the NEB1 189A 
cells (Figure 4.3B) as can be seen when comparing the top panels (shCON) with the 
bottom panels (NEB1 189A). 
In order to quantify DcR2 expression I also analysed DcR2 immunofluorescence 
staining by ImageJ software as discussed in chapter 2. The immunofluorescence 
staining for DcR2 in the NEB1 GLI-1 cells (see Figure 4.3C), was significantly higher 
(P<0.05) when compared with NEB1 pBP vector control cells (Figure 4.3C). However, 
there was no significant difference between NEB1 189A cells (see Figure 4.3C) when 
compared with NEB-1 shCON cells (see Figure 4.3C) for DcR2.   
In addition to quantifying immunofluorescence I also carried out carried out qPCR to 
quantify the expression of DcR2 mRNA level, there was no significant difference 
between NEB1 GLI-1 cells (see Figure 4.3D) when compared with NEB1 pBP vector 
control cells (see Figure 4.D). However, there was a significant difference (P<0.05) 
between NEB1 189A cells (see Figure 4.3D), when compared with NEB1 shCON cells 
(see Figure 4.3D). This data indicates an up-regulation of DcR2 in NEB1 GLI-1 cells at 
protein level and NEB1 189A cell at mRNA level.     
 
 
 
134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Immunofluorescence staining for DcR2 on in vitro BCC models. (A) top 
panels showing DcR2 immunofluorescence staining and then image merged with DAPI 
stained cells to show nuclei for NEB1 pBP vector Control Cells and in bottom panel 
showing DcR2 immunofluorescence staining and then image merged with DAPI stained 
cells to show nuclei in NEB1 GLI-1 cells (B) top panels showing DcR2 
immunofluorescence staining and then image merged with DAPI stained cells to show 
nuclei for NEB1 shCON Control cells and in bottom panel showing DcR2 
immunofluorescence staining and then image merged with DAPI stained cells to show 
nuclei in NEB1 189A cells (C) ImageJ quantification of DcR2 immunofluorescence in 
both NEB1 GLI-1 over expressing and NEB1 189A Cells and controls (D) Quantitative 
polymerase chain reaction (qPCR) analysis of DcR2 mRNA expression in NEB-1 Cells.  
Results are mean +/- SEM, n=3 separate experiments . Statistical analysis was carried 
out using Student’s t-test.         
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4.3 Immunofluorescence staining and Quantitative Real Time-Polymerase Chain 
Reaction (qPCR) of DEC1 in an in vitro model of BCC. 
 DEC1 immunofluorescence was detected in both the NEB1 GLI-1 cells and NEB1 189A 
cells along with NEB1 pBP vector control and NEB1 shCON control cells as control. As I 
observed with GLI-1, Immunofluorescence staining for DEC1 was generally more 
apparent in the  cytoplasm of both our NEB1 GLI-1 and NEB1 189A cells although weak 
staining can also be seen when looking at nucleus of the cell although when seen 
against the DAPI stained nuclei this appears as pale blue (see Figure 4.4 A and B). In 
Figure 4.4A it is possible to see a marked decrease in fluorescence in the GLI-1 over 
expressing cells bottom panel when compared to control cells in the top panel. 
However, in contrast there was a marked increase in DEC1 immunofluorescence 
staining in the NEB1 189A cells (Figure 4.3B) as can be seen when comparing the top 
panels (shCON) with the bottom panels (NEB1 189A). 
In order to quantify DEC1 expression I also analysed DEC1 immunofluorescence 
staining by ImageJ software as discussed in chapter 2. There was a significant 
difference of the staining of DEC1 in NEB1 GLI-1 cells (see Figure 4.4C), when 
compared with NEB1 pBP vector control cells (see Figure 4.4C). The staining was 
increased in control cells than in NEB1 GLI-1 cells. However, there was no significant 
difference between NEB1 189A cells (see Figure 4.4C) when compared with NEB1 
shCON cells (see Figure 4.4C) for DEC1.   
In addition to quantifying immunofluorescence I also carried out carried out qPCR to 
quantify the expression of DEC1 mRNA level, there was a significant difference 
between NEB1 GLI-1 cells (see Figure 4.4D) when compared with NEB1 pBP vector 
control cells (see Figure 4.D). The mRNA level was more prominent in control cells 
than in NEB1 GLI-1 cells. However, a significant difference (P<0.05) was seen in NEB1 
189A PTCH knockdown cells (see Figure 4.4D), when compared with control NEB1 
shCON cells (see Figure 4.4D). This data indicates an up-regulation of DEC1 in PTCH 
cells at mRNA level but this was not reflected in protein expression as determined by 
immunofluorescence staining.    
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Figure 4.4:  Immunofluorescence staining for DEC1 on in vitro BCC models (A) Top 
panels showing immunofluorescence staining and then image merged with DAPI 
stained cells to show nuclei for NEB1 pBP vector Control Cells and in bottom panel 
showing DEC1 immunofluorescence staining and then image merged with DAPI 
stained cells to show nuclei in NEB1 GLI-1 cells (B) top panels showing DEC1 
immunofluorescence staining and then image merged with DAPI stained cells to show 
nuclei for NEB1 shCON cells and in bottom panel showing DEC1 immunofluorescence 
staining and then image merged with DAPI stained cells to show nuclei in NEB 189A 
cells (C) ImageJ quantification of DEC1 immunofluorescence in both NEB1 GLI-1 and 
NEB1 189A cells and controls  (D) Quantitative polymerase chain reaction (qPCR) 
analysis of DEC1 mRNA expression in NEB1 Cells. Statistical analysis was carried out 
using Student's t-test on 3 separate experiments.   
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4.4 Immunofluorescence staining and Quantitative Real Time-Polymerase Chain 
Reaction (qPCR) of p16INK4a in an in vitro model of BCC. 
p16INK4a immunofluorescence was detected in both NEB1 GLI-1 cells and NEB1 189A 
cells along with NEB1 pBP vector control and NEB1 shCON control cells. As with 
previous immunofluorescence staining carried out in this chapter staining was more 
prominent in the  cytoplasm of all cells when compared to the nucleus of the cell (see 
Figure 4.5 A and B). However, from looking at fluorescent images there were no clear 
differences between cell types. 
In order to quantify p16INK4a expression and determine whether there were any 
significant differences in immunofluorescence that could not be seen by eye I also 
analysed p16INK4a immunofluorescence staining by ImageJ software as discussed in 
chapter 2. There was no significant difference in immunofluorescence staining for 
p16INK4 in either NEB1 GLI-1 cells (see Figure 4.5C), when compared with NEB1 pBP 
vector control cells (see Figure 4.5E). There was also a significant difference between 
NEB1 189A cells (see Figure 4.5C) when compared with NEB1 shCON cells (see Figure 
4.5C) for p16. The staining was more in control cells than in NEB1 189A cells. 
In addition to quantifying immunofluorescence I also carried out carried out qPCR to 
analyse the expression of p16INK4a mRNA level. There was no significant difference 
between NEB1 GLI-1 cells (see Figure 4.5D) when compared with NEB1 pBP vector 
control cells (see Figure 4.D). However, there was a significant difference between 
NEB1 189A cells (see Figure 4.5D), when compared with control NEB1 shCON cells (see 
Figure 4.5D). This data indicates an up-regulation of p16 level in NEB1 189A cells at the 
mRNA level but not in NEB GLI-1 cells. These changes in mRNA expression were not 
however, reflected at the protein level with regards to immunofluorescence staining.   
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Figure 4.5:  Immunofluorescence staining for  p16INK4a on in vitro BCC models (A) 
Top panels showing immunofluorescence staining and then image merged with 
DAPI stained cells to show nuclei for NEB1 pBP vector Control Cells and in bottom 
panel showing p16INK4a immunofluorescence staining and then image merged with 
DAPI stained cells to show nuclei in NEB1 GLI-1 cells (B) top panels showing p16INK4a 
immunofluorescence staining and then image merged with DAPI stained cells to 
show nuclei for NEB1 shCON cells and in bottom panel showing p16INK4a 
immunofluorescence staining and then image merged with DAPI stained cells to 
show nuclei in NEB1 189A cells (C) ImageJ quantification of p16INK4a 
immunofluorescence in both NEB1 GLI-1, NEB1 189A cells and controls (D) 
Quantitative polymerase chain reaction (qPCR) analysis of p16INK4a mRNA 
expression in NEB1 Cells. Statistical analysis was carried out using Student's t-test 
on 3 separate experiments.     
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4.5 Immunofluorescence staining and Quantitative Real Time-Polymerase Chain 
Reaction (qPCR) of p53 in an in vitro model of BCC. 
p53 stained positive on NEB1 GLI-1 cells and NEB1 189A cells along with NEB1 pBP 
vector control and NEB1 shCON cells as control. The staining was seen in both the 
cytoplasm and  in the nucleus of the cells (see Figure 4.6 A and B). 
ImageJ software was used to analyse immunofluorescence as above and as discussed 
in chapter 2. There was no significant difference in the immunofluorescence staining 
for p53 in NEB1 GLI-1 cells (see Figure 4.6C), when compared with NEB1 pBP vector 
control cells (see Figure 4.6C). However, there was a significant difference (P<0.05) 
between NEB1 189A cells (see Figure 3.6C) when compared with their NEB1 shCON 
cells (see Figure 4.6C). 
In addition to quantifying immunofluorescence I also carried out carried out qPCR to 
analyse the expression of p53 mRNA level, there was a significant difference between 
NEB1 GLI-1 cells (see Figure 4.6D) when compared with NEB1 pBP vector control cells 
(see Figure 4.6D). The mRNA level was more prominent in control cells compared to 
NEB1 GLI-1 cells However, the significant difference was seen in NEB1 189A cells (see 
Figure 4.6D), when compared with NEB1 shCON cells (see Figure 4.6D) in p53. This 
data indicates in up-regulation of p53 level in NEB1 189A cell at mRNA level.     
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 Figure 4.6:  Immunofluorescence staining for p53 on in vitro BCC models (A) Top 
panels showing immunofluorescence staining and then image merged with DAPI 
stained cells to show nuclei for NEB1 pBP vector Control Cells and in bottom panel 
showing p53 immunofluorescence staining and then image merged with DAPI 
stained cells to show nuclei in GLI-1 cells (B) top panels showing p53 
immunofluorescence staining and then image merged with DAPI stained cells to 
show nuclei for NEB1 shCON cells and in bottom panel showing p53 
immunofluorescence staining and then image merged with DAPI stained cells to 
show nuclei in NEB1 189A cells (C) ImageJ quantification of p53 
immunofluorescence in both NEB1 GLI-1 and NEB1 189A cells and controls (D) 
Quantitative polymerase chain reaction (qPCR) analysis of p53 mRNA expression in 
NEB1 Cells. Statistical analysis was carried out using Student's t-test on 3 separate 
experiments.   
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4.6 Immunofluorescence staining and Quantitative Real Time-Polymerase Chain 
Reaction (qPCR) of p21WAF1 in an in vitro model of BCC. 
p21WAF1 stained positive on NEB1 GLI-1 cells and NEB1 189A cells along with NEB1 pBP 
vector control and NEB1 shCON cells as control. Immunofluorescence staining for 
NEB1 GLI-1 cells and their NEB1 pBP controls were higher than for the NEB1 189A cells 
and their control. In NEB1 GLI-1 cells immunofluorescence appeared to be higher in 
the NEB1 GLI-1 cells compared to control cells. However, in the control cells 
immunofluorescence appeared more localised in the nucleus as determined by pale 
blue dots. NEB1 189A cells display weak immunofluorescence for p21WAF1 detected in 
the cytoplasm of control cells and this appeared higher in NEB1 189 cells  (see Figure 
4.7 A and B). 
ImageJ software was used as discussed in chapter 2 to quantify immunofluorescence 
staining. There was no significant difference in immunofluorescence staining for 
p21WAF1 in NEB1 GLI-1 cells (Figure 4.7C), when compared with NEB1 pBP vector 
control cells (Figure 4.7C). However, there was a significant difference (P<0.05) 
between NEB1 189A cells (see Figure 3.7C) when compared with NEB1 shCON cells 
(see Figure 4.7C) for p21WAF1. 
I also carried out qPCR to quantify the expression of p21WAF1 mRNA level, there was no 
significant difference between NEB1 Gli-1 cells (see Figure 4.7D) when compared with 
NEB1 pBP vector control cells (Figure 4.7D). However, there was a significant 
difference (P<0.05) in NEB1 189A cells (4.7D), when compared with NEB1 shCON cells 
(Figure 4.7D) in p21WAF1. 
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Figure 4.7: Immunofluorescence staining for p21WAF1 Antibody on in vitro BCC models 
(A) Top panels showing immunofluorescence staining and then image merged with 
DAPI stained cells to show nuclei for NEB1 pBP vector Control Cells and in bottom 
panel showing p21WAF1 immunofluorescence staining and then image merged with 
DAPI stained cells to show nuclei in NEB1 GLI-1 cells (B) top panels showing p21WAF1 
immunofluorescence staining and then image merged with DAPI stained cells to show 
nuclei for NEB1 shCON cells and in bottom panel showing p21WAF1 
immunofluorescence staining and then image merged with DAPI stained cells to show 
nuclei in NEB1 189A cells (C) ImageJ quantification of p21WAF1 immunofluorescence in 
both NEB1 GLI-1 and NEB1 189A and control cells (D) Quantitative polymerase chain 
reaction (qPCR) analysis of p21WAF1 mRNA expression in NEB1 Cells. Statistical analysis 
was carried out using Student's t-test on 3 separate experiments.    
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Discussion 
There has been much debate about the physiological relevance of senescence in vivo, 
particularly as this response was originally identified as an in vitro phenomenon. 
Ultimately, much data have emerged that demonstrate the relevance of cellular 
senescence in vivo in both mouse and human tumours (Collado et al., 2007, Collado et 
al., 2005, Michaloglou et al., 2005, Itahana et al., 2004). In recent years the 
understanding of the pathology of cancer has highlighted the relevance and role of 
senescence as a physiological barrier against tumour initiation and progression (Prieur 
and Peeper, 2008, Decottignies and d’Adda di Fagagna, 2011). The first description of 
'cellular senescence' dates to 1965 when Leonard Hayflick observed that cells undergo 
a replicative senescence in culture (Hayflick, 1965, Hayflick and Moorhead, 1961). It is 
now well established that premature forms of cellular senescence can be triggered 
through either the activation of oncogenes (a type of senescence that is termed 
oncogene-induced senescence (OIS)) or the loss of tumour suppressor genes (Nardella 
et al., 2011, Saretzki, 2010). This phenomenon can also be observed in response to 
other stimuli, such as oncogenic stress, DNA damage or cytotoxic drugs (Maruyama et 
al., 2009, Dimri, 2005). Cells displaying senescent characteristics have not only been 
observed in cell culture but also in their maternal tissue environment. A number of 
reports have been related to reduced cellular lifespan with metabolic disease, stress 
sensitivity, progeria syndromes, and impaired healing, indicating that entry into 
cellular senescence may contribute to human disease (Vergel et al., 2011, Smith et al., 
2005). It has been suggested now that cellular senescence is in part responsible for the 
pathogenesis of a number of human diseases, such as atherosclerosis, osteoarthritis, 
muscular degeneration, ulcer formation, Alzheimer’s dementia, diabetes and immune 
exhaustion (Vergel et al., 2011). 
In chapter 3 of this thesis I confirmed the expression of senescence markers in human 
BCC this suggests that senescence may play an important role in BCC. In this chapter I 
wanted to further investigate these markers in BCC cells and to determine whether 
these markers were direct targets of hedgehog signalling and GLI-1. Because there are 
virtually no BCC cell lines I have employed a cell model in which GLI-1 is retrovirally 
over expressed in human keratinocyte cell lines and as such has been widely published 
144 
 
by my group (Gore et al., 2009) and a second model involving shRNA to knockdown 
PTCH in keratinocytes.. The reason I used two separate in vitro models is that although 
retroviral over expression of GLI-1 has been widely used in hedgehog research (Ruiz i 
Altaba et al., 2002b) the major limitation with this model is keratinocytes express wild-
type PTCH. Because PTCH is a downstream target and  a negative regulator of GLI-1 
(Mancuso et al., 2004) the consequence of over expressing GLI-1 is up-regulation of 
PTCH and potential down-regulation of GLI-1 this damping down any GLI-1 response. 
Because of this I have also used a new model being developed by Muhammed Rahman 
a PhD student in the Centre in which he uses shRNA to knockdown PTCH expression. 
This model is thought to be a closer replication of BCC in which PTCH mutations are the 
common mutation (Kim et al., 2002, Reifenberger et al., 2005) and as a result of PTCH 
knockdown GLI-1 is up regulated in BCC (Mancuso et al., 2004). 
I have confirmed that the loss of PTCH1 in NEB1 189A cells leads to the increase of GLI-
1 protein and mRNA expression compared to NEB1 shCON cells (Figure 4.1). This is as 
expected as GLI-1 is downstream of PTCH1 in the pathway and also, BCCs have been 
shown to have increased levels of GLI-1 (Hatta et al., 2005).  
I used both the retroviral GLI-1 over-expression and PTCH knockdown models to 
investigate expression of senescence markers using immunofluorescence staining and 
qPCR analysis where up regulation of p16INK4a, p53, p21WAF1, DcR2 and DEC1 was 
observed. Data from these experiments showed variation between protein expression 
as determined by immunofluorescence staining and qPCR. However, overall the 
experiments carried out in this chapter showed especially at the mRNA level that there 
was an increase in senescence marker expression in response to increased GLI-1 
expression. The cells did not changed their morphology as seen in typically senescence 
cells, however, change in morphology is most likely a late event in cell senescence and 
had I maintained my cells in culture for longer I may have seen the classical 'fried egg' 
morphology associated with senescence and which describes the appearance of 
senescent cells as they become flattened and enlarge (Chen and Goligorsky, 2006). 
However, maintaining cells for longer may have resulted in down-regulation of the 
markers of interest. The presence of senescence has been previously described in 
other diseases as well, such as venous ulcers (Braig et al., 2005, Collado et al., 2005, 
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Michaloglou et al., 2005, Mendez et al., 1998). Cells cultured from venous ulcers have 
been shown to have a reduced replicative life span with increased β-gal compared to 
cells form unaffected areas (Mendez et al., 1998). 
Decoy receptor 2 (DcR2) is a member of the tumour necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) receptor family and is also known as TRAIL-R4.  DcR2 
is bound by the TRAIL ligand which is an inducer of apoptosis in cells and acts through 
binding to the TRAIL receptor family which consists of two death domain receptors, 
DR4 (TRAIL-R1) and DR5 (TRAIL-R2) (Degli-Esposti et al., 1997, Johnstone et al., 2008).  
The other two receptors, DcR1 (TRAIL-R3) and DcR2, are referred to as decoys as 
although they bind to the TRAIL ligand they do not signal downstream.  DcR2 itself has 
a truncated non functional death domain (Liu et al., 2005).  Consequently, these decoy 
receptors are able to compete for binding with the activators DR4 & DR5, thereby 
negatively regulating TRAIL-induced apoptosis.  DcR2 expression has been reported to 
protect cells from TRAIL-induced apoptosis and is regulated by p53 (Liu et al., 2005).  
p53 is the most commonly altered gene in cancer through its loss (Liu et al., 2005). 
In my study I have seen an increase in expression of DcR2 showing a strong positive 
stain in the cytoplasm of the cells. This has also been reported in melanoma cell lines 
and it is suggested that the expression of this receptor may involve regulated 
movement from the intracellular compartments to the membrane (Zhang et al., 2000, 
Qian et al., 2008). In some studies, DcR2 was seen in the nucleus but then sub cellular 
localisation to the cytoplasm was seen in the melanoma cells on their exposure to the 
TRAIL ligand (Zhang et al., 2000). In this study I have shown by qPCR up regulation of 
DcR2 mRNA in the NEB1 189A cells and a slight but not significant increase in DcR2 
mRNA in the NEB1 GLI-1 cells. I also saw an  increase at the protein level in NEB1 GLI-1 
cells but not in the NEB1 189A cells. The reason for these differences is difficult to 
explain. However, they may reflect differences in the cell model with GLI-1 cells having 
wild type active PTCH whereas in NEB1 189A cells this has been knocked down. These 
differences may reflect complexity in the Hedgehog signalling pathway in these two 
cells types and also may reflect differences in the degree of cell senescence brought 
about by over-expression of GLI-1 versus up-regulation of GLI-1 in PTCH null cells. In 
addition it is increasingly accepted that mRNA and protein levels do not always 
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correlate (Ideker et al., 2001, Nishizuka et al., 2003). However, these data do suggest 
that DcR2 is regulated by GLI-1 expression in human keratinocytes and supports the 
data in chapter 3 showing increased DcR2 expression in BCC. Moreover, the expression 
of DcR2 in cells that over express GLI-1 as well as the well established up regulation of 
Bcl-2 (Regl et al., 2004, Yoon et al., 2002) may also explain why these cells are more 
resistant to apoptosis in vitro (Harrison, 2013).  
Human Differentially Expressed in Chondrocytes (DEC1) is a basic helix-loop-helix 
protein (bHLH). DEC1 is also known as, enhancer of split and hairy related protein 2 
(SHARP2) in rats, or stimulated with retinoic acid 13 (STRA13) in the mouse (Qian et al., 
2008).  This transcription factor is involved in a variety of cellular processes such as cell 
differentiation, lipid metabolism, proliferation and regulation of the molecular clock (Li 
et al., 2006).  The mouse homologue STRA13 is involved in cell growth arrest and is a 
transcriptional repressor promoting neuronal differentiation (Yoon et al., 2001).  DEC1 
expression is abundant in carcinomas but not in the adjacent tissues.  Hypoxia, a state 
where tissue is deprived of normal oxygen levels, is associated with the 
microenvironment of a tumour.  DEC1 expression has been found in response to the 
hypoxic state (Li et al., 2006, Yoon et al., 2001).   Furthermore, over expression of DEC1 
in the mouse fibroblast cell line NIH3T3 inhibited cell proliferation (Qian et al., 2008).  
Although little is known about how DEC1 mediates cell proliferation, it does initiate G1 
cell cycle arrest and it has been shown that DEC1 is a target of the tumour suppressor 
p53 which binds to the promoter on the DEC1 gene (Qian et al., 2008). 
DEC1 has been shown to be over expressed in carcinomas and is usually expressed 
when cells are in a hypoxic state (Qian et al., 2012, Collado et al., 2005). It has been 
previously demonstrated that DEC1 transcriptionally activates a gene called survivin 
which is a member of the Inhibitor of the Apoptosis family (IAF) and inhibits caspase 
and therefore negatively regulates apoptosis (Li et al., 2002b). In this chapter I have 
shown an increase in DEC1 mRNA and protein expression in NEB1 189A cells. In NEB1 
GLI-1 cells there was a significant down-regulation of DEC1 protein as determined by 
immunofluorescence staining and a slight but not significant decrease in mRNA. These 
differences between GLI-1 and PTCH knockdown cells may again reflect differences in 
the models used and perhaps in GLI-1 over-expressing cells the influence of wild type 
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PTCH. However, the data in PTCH knockdown cells would suggest that DEC1 is a target 
of GLI-1. There is a correlation between DEC1 expression and tumour grade and 
prevention of apoptosis in mouse mammary epithelial cells (Ehata et al., 2007). Like 
DcR2, DEC1 has an anti apoptotic role in senescence and cancer (Qian et al., 2008, 
Qian and Chen, 2008). This expression of DEC1 might reflect non aggressiveness of 
cancers. It has been previously published that DEC1 was expressed in premalignant 
tumours and is involved in senescence.     
Although senescence cells are no longer able to proliferate, they are still metabolically 
active and can survive for extensive periods of time in this state (Kuilman et al., 2010). 
The inactivation of more than one pathway is normally required to bypass senescence. 
In keratinocytes the inhibition of both p16INK4a and p53 is required for the replicative 
lifespan of the keratinocytes to increase (Kiyono et al., 1998, Rheinwald et al., 2002). 
p16INK4a is very important in determining the  lifespan of keratinocytes, but also 
mammary epithelial and urothelial cells, increasing serially with passage and 
preventing the immortalisation of cells (Dickson et al., 2000). In contrast Rheinwald et 
al. (2002) showed that senescence in fibroblasts was not necessarily dependent on the 
inhibition of p16INK4a and p53 and that mutant p53 in fibroblast was sufficient to 
extend their lifespan. Fibroblasts normally maintain senescence through two 
pathways, p53 and/or p16INK4a, depending on whether p16INK4a is present and that it is 
presence of p16INK4a that determines the irreversible nature of the senescence 
(Campisi, 2005, Sharpless and DePinho, 2004).  Senescence caused by telomere 
dysfunction and maintained by p53 is a reversible state; however p16INK4a expression in 
this scenario is a dominant irreversible effect that forms a second barrier against cell 
proliferation (Bond et al., 2004, Beausejour et al., 2003, Chin et al., 1999). Although 
p16INK4a upregulation can be seen at the same time as p53 and p21WAF1, it is triggered 
and acts independently (Zindy et al., 1998). If one pathway is up regulated (i.e. 
p16INK4a) this does not prevent the cells from responding to the other pathways (i.e. 
p53/p21WAF1) at a subsequent time (Ben-Porath and Weinberg, 2005). 
In this chapter I observed a significant increase in p16INK4a expression in NEB1 189A 
cells although saw no significant difference in protein level and saw no significant 
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effect at either protein or mRNA level in NEB1 GLI-1 cells. This data suggests that 
p16INK4a is most likely a target of GLI-1 in PTCH null cells. 
The role of p53 can vary depending on the cell type; sometimes it is important in 
initiating senescence whilst in others it is important in maintaining senescence. 
Previously in our group Jane Elliott a PhD student investigating senescence in BCC 
derived fibroblasts showed that expression of p53 was not increased in BCC derived 
fibroblasts compared to normal dermal fibroblasts at either early or late passage. This 
suggests that p53 was not significant in either the establishment or maintenance of the 
senescence. Nevertheless, p16INK4a expression was increased in BCC derived fibroblast, 
suggesting that in these cells p16INK4a is playing a dominant role and would account for 
the irreversible nature of senescence in the cells despite low passage numbers and 
access to nutrients and good culture conditions. In my experiments p53 mRNA and 
protein was up-regulated in NEB1 189A cells but not in GLI-1 cells although GLI-1 
mRNA was significantly down-regulated. My data showing an increase in p53 in the 
NEB1 189A cells suggests that this protein is a target of GLI-1 and is involved in 
senescence in BCC in vivo. Moreover, it is well established that p53 is mutated in 
between 30-70% of BCC (Reifenberger et al., 2005, Lacour, 2002). 
Since senescence is characterised by a permanent cell-cycle block, signiﬁcant emphasis 
has been placed on the p53 targets that mediate cell-cycle arrest and especially on the 
CDK inhibitor p21WAF1 (Castro et al., 2004). The protein levels of p21WAF1 are elevated 
at senescence in several cellular systems and, indeed, the p21WAF1 gene was found in a 
screening for senescence-inducing genes by one of the groups that ﬁrst identiﬁed p21 
(Ruan et al., 2012). Nevertheless, the question of whether p21 WAF1 is essential or not 
for the establishment of senescence has yet to be unambiguously answered. Activation 
of p53 induces the up regulation of the cyclin-dependent kinase (CDK) inhibitor 
p21WAF1, which has a direct inhibitory action on the cell-cycle machinery and correlates 
well with the declining growth rate observed in senescing cultures (Vergel et al., 2011). 
In mouse embryo fibroblasts, however, the absence of p21WAF1 does not overcome 
senescence (Castro et al., 2004). This suggests that at least one additional downstream 
effector is needed for p53-induced growth arrest in senescence. In contrast, 
elimination of p21WAF1 by a double round of homologous recombination is sufficient to 
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bypass senescence in human cells. In my experiments p21WAF1 was up-regulated in 
PTCH knockdown cells at both the mRNA and protein level. In contrast in GLI-1 over-
expressing cells I saw no significant difference. However, in vivo (chapter 3) I saw no 
staining of p21WAF1 in BCC suggesting that this protein is not up-regulated in BCC. 
Therefore, the  up regulation of p21WAF1 in PTCH1 null cells does not appear to reflect 
the expression patterns seen in BCC in vivo. The reason for this difference is not clear 
however, it might reflect the complexity of sonic hedgehog signalling in BCC and the 
involvement of other signalling pathways such as TGF-β and involvement of the stroma 
(Taipale and Beachy, 2001, Lange et al., 1999). Indeed it has recently been reported 
that BCC has one of the highest mutation rates of all human cancers (Jayaraman et al., 
2013) and that because of this they are unlikely to be homogenous and that it is very 
unlikely that one pathway alone is contributory although clearly mutation plays a 
central role. 
Mutations in the p16INK4a gene have been previously identified in sporadic melanomas 
and NMSC resulting in breakdown of tumour suppression mechanisms (De Zwaan and 
Haass, 2010). Under conditions of stress, and oncogenic stimuli, expression of both 
p16INK4a and p15INK4b increases (Kim et al., 2010, Serrano et al., 1997). The increase 
expression of these genes results in the suspension of cell cycle and counteracts 
excessive cell proliferation or the replication of damaged DNA. Work by Rheinwald et 
al, (2002) has shown that normal keratinocyte proliferation is limited by p16INK4a 
regardless of culture conditions or telomerase expression. There are number of 
possible reasons for the up regulation of p16INK4a and p15INK4b seen in these cell lines 
(Rheinwald et al., 2002).   
As mentioned in earlier studies telomere initiated senescence and DNA damaged 
senescence depend on p53 expression which is accompanied by p21WAF1 expression 
(Roninson, 2003). However p16INK4a expression can be induced by DNA damaged albeit 
delayed as a second barrier to prevent the growth of damaged cells. Moreover, 
treatment of normal human fibroblasts with various DNA damaging agents including 
ionizing radiation result in the rapid activation of p53 and long term induction of 
p21WAF1 (Di Leonardo et al., 1994).   
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The signaling pathways of p16INK4a and p15INK4b both differ but each acts on cyclin D 
which is involved in G1/S phase regulation (Maddika et al., 2007). The SHH pathway, a 
key player in BCC development has also been noted as a potential regulator of the 
cyclin D family and ultimately is important in G1/S phase regulation (Daya-Grosjean 
and Couvé-Privat, 2005). These observations were made in the cerebellum of mice but 
it has also been reported that SHH signaling opposes epithelial cell cycle arrest by 
p21WAF1 in human keratinocytes transduced with SHH and p21WAF1 (Fan and Khavari, 
1999). Furthermore, Bishop et al. (2010), saw depression and modulation of p16INK4a by 
the SHH and IHH genes and the HH signaling pathway. The downstream target of HH 
signaling, GL1-2 accumulated in the nucleus and directly binds to the promoter of 
p16INK4a. Examination of p16 promoter revealed a previously unreported GL1 binding 
site and only differs by one base mismatch from the recognised GLI binding site.   
In vivo, senescent cells have been observed in association with aging but also with the 
early phases of tumourgenesis (Pardue and DeBaryshe, 2001). Cells in premalignant 
tumours undergo OIS, in contrast cells of malignant tumours have overcome 
senescence due to loss of senescence effectors such as p16INK4a (Nardella et al., 2011, 
Collado et al., 2005).  
In this study I have shown increased level of senescence markers in both NEB1 GLI-1 
cells and NEB1 189A cells. Overall there was a greater correlation between expression 
of senescence markers and GLI-1 in the PTCH knockdown model compared to GLI-1 
over expressed cells. The reason for this is most likely the fact that wild type PTCH is 
present in the GLI-1 over expressed model and via negative feedback can dampen 
down the GLI-1 effect. In contrast in the PTCH knockdown model we observe an 
increase in the GLI-1 but as PTCH has been knockdown negative feedback cannot 
happen. Therefore, the PTCH knockdown model may be a better model representative 
of BCC. 
I did observe variability in response to PTCH knockdown with regards protein and 
mRNA expression. These differences are always difficult to explain but most likely 
reflect the effects of cell culture condition, timing of expression. It is also important to 
emphasise that protein was quantified in cells by fluorescence and the relative density 
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measurement are much less sensitive than measuring fold changes in mRNA. This is 
clearly seen in Figure 4.2 with regard GLI protein and mRNA expression. Therefore, our 
qPCR data may be more reliable as a measurement of effects of GLI-1 on senescence 
markers. Based on these data but also considering protein expression. I conclude that 
DcR2, DEC1, p16INK4a, p53 and p21WAF1 are probably early targets of GLI activation.       
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Chapter 5: Investigation of senescence in a mouse model of BCC 
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Introduction 
In the chapter 3 of this thesis I showed that senescence is associated with human BCC 
and in chapter 4 I showed up-regulation of senescence at both the mRNA and protein 
level in human keratinocytes over expressing GLI-1. These data therefore, suggested 
that the senescence seen in human BCC may be associated with activation of the HH 
pathway. 
Mouse models of BCC are widely used to investigate the role of HH signalling in BCC 
(see Chapter 2; section 1:10). However, it is not known whether cell senescence plays 
a role in mouse BCC. The principal aim of this chapter was to investigate the expression 
of senescence markers in a mouse model of basal cell carcinoma and to determine 
whether OIS was also observed in mouse BCC. BCC is a disease of ageing (over 40 
years) and rare in younger people. The main cause of this disease is UV radiation. I 
have already described the expression of a well characterised panel of senescence 
markers in human BCC (Chapter 3) and also in an in-vitro model of BCC (Chapter 4). 
The expression of senescence markers in mouse basal cell carcinoma has not 
previously been described in the medical or scientific literature. The markers to be 
used are those described in Chapter 3 and Chapter 4 and include p53, p16INK4a, 
p15INK4b, p21WAF1, DEC1 and DcR2. Although some of these markers have been 
described previously not all have been investigated in mouse skin and not in 
relationship to a possible role in senescence (Zhang et al., 2005, Mitsunaga et al., 
1995). In this chapter I have examined the expression of both -galactosidase as well 
as p53, p16INK4a, p15INK4b, p21WAF1, DEC1 and DcR2 in a murine model of BCC. The 
murine model I have used is that developed by Mariateresa Mancuso from 
Biotechnology Unit and Radiation Protection Unit, ENEA-Ente per le Nuove Tecnologie, 
l’Energia e l’Ambiente, Centro Ricerche, Casaccia, Rome, Italy (Mancuso et al., 2004). In 
this model the mice lack one Ptch1 allele (+/-) and have previously been shown to be 
susceptible to x-ray (ionizing radiation) induced BCC (Pazzaglia et al., 2004, Mancuso et 
al., 2009). Moreover, these mice have been shown to develop both a nodular type BCC 
as well as more aggressive variant BCC. I have therefore, used this model to determine 
whether mouse BCC also undergo senescence and also whether differences in cell 
senescence can be detected between Nodular and variant murine BCC’s. The 
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expression of senescence markers were assessed by visual analogue scoring as 
described in the Chapter 2. 
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5.1 Expression of β-Galactosidase in Ptch1 wild-type (+/+) mouse skin and mouse 
skin lacking one Ptch1 Allele (+/-) and in mouse BCC derived from x-ray irradiated 
Ptch1 +/- Mice. 
β-galactosidase staining was carried out on the frozen tissue sections of mouse basal 
cell carcinoma given by the Mariateresa Mancuso from Biotechnology Unit and 
Radiation Protection Unit, ENEA-Ente per le Nuove Tecnologie, l’Energia e l’Ambiente, 
Centro Ricerche, Casaccia, Rome, Italy . When cells undergo senescence they normally 
change their morphology and show β-galactosidase staining, which is recognized as 
marker of senescent cells (Dimri et al., 1995a). The tissues used by me in this study 
includes homozygous wild-type Ptch1 mouse skin (+/+), mouse skin lacking one Ptch1 
allele (+/-) and mouse BCC derived from x-ray irradiated Ptch1 +/- mice. I have 
investigated β-galactosidase staining on these different types of mouse tissues to 
determine whether senescence is characteristic of all these tissues types or perhaps 
only restricted to specific groups and whether senescence is related to  ionising 
radiation. 
To carry out this study I have used a panel of murine skin biopsies as described above. 
Details of the mouse skin and BCC samples are shown in Table 5.1. The staining took 
24 hours to develop. Results of these experiments are shown in Figure 5.1 and 5.2. 
Figure 5.1A and B shows that in Ptch1 homozygous (+/+) mouse skin β-galactosidase 
was mostly in the sebaceous glands with very faint probably non-specific staining in 
the supra basal layers of the epidermis. In Ptch1 +/- mouse skin (see Figure 5.1C and D) 
β-galactosidase was again restricted to the sebaceous glands. In mouse BCC derived 
from Ptch1 +/- irradiated mice (see Figure 5.2) no staining for β-galactosidase was 
detected in any of the tumour islands or stroma. The staining protocol was same for all 
BCC sample. 
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Figure 5.1: Representative images showing β-Galactosidase expression in mouse 
tissues (A and B) Ptch1 wild-type (+/+) Mouse skin (C and D) Mouse skin lacking one 
Ptch1 allele (+/-). The staining was mostly seen in the sebaceous glands.   
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Figure 5.2: Representative images showing β-galactosidase expression in Mouse BCC 
derived from x-ray irradiated Ptch +/- Mice (A and B) Mouse BCC like tumours (C and 
D) Mouse BCC variants. β-galactosidase staining was negative in all samples 
investigated. 
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5.2 Expression of p53 in Ptch1 wild-type (+/+) and Mouse skin lacking one Ptch1 
allele (+/-) and in Mouse BCC derived from  x-ray irradiated Ptch1 +/- Mice  
 A panel of mouse skin and mouse BCC were stained for p53. The tissues included both 
Ptch1 wild-type (+/+) and Ptch1 null (+/-) skin as well as  nodular BCC and BCC variant 
tumours derived from the Ptch1 null mice following irradiation, (see Figure 5.3 and 
5.4). The intensity of staining was assessed by visual analogue scoring. 
In both the Ptch1 wild-type (+/+) mice and Ptch1 null (+/-) mice p53 in non-irradiated 
skin (Figure 5.3) was strongly expressed in the cytoplasm of both the epidermis and in 
the hair follicles and sebaceous glands of both wild-type (Figure 5.3B) and Ptch1 null 
(Figure 5.3C) mice. 
In irradiated mouse skin p53 stained positive and was very strong on all nodular mouse 
BCC tissue sections (see Figure 5.4 A, B and C), however in mouse BCC variant tumours 
the staining was very weak (see Figure 5.4 D). In nodular mouse BCC p53 staining is 
quite clearly seen in the epithelial compartment of tumours when compared with the 
stroma. With regards its subcellular localization p53 was mostly seen in the nucleus of 
the nodular BCC when compared to expression in the cytoplasm. For the variant BCC 
types p53 was weakly cytoplasmic and was not observed in the nucleus. Results of 
visual analogue scoring of staining of these tumours were analysed (as shown in Table 
5.1).   
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Table 5.1: Showing Visual Analogue Scoring of Senescence Markers.  
Sample Number    p53 p16INK4a p21WAF1 p15INK4b DEC1 DcR2 
Mouse skin wild type Ptch1 +/+ 
(sample 1) 
  3   1     0   2   1     1 
Mouse skin wild type Ptch1 +/+ 
(sample 2) 
  3   1     2   2   1     1 
Mouse skin wild type Ptch1 +/+ 
(sample 3) 
  3   1     0   2   1     1 
Mouse Skin Ptch1 +/- (sample 1)   3   1     0   2    1    1 
Mouse Skin Ptch1 +/- (sample 2)   3   1     0   2    1    1 
Mouse Skin Ptch1 +/- (sample 3)   3   1     0   2    1    1 
Mouse Nodular BCC (sample 7)   3   3     0   2   2    2 
Mouse Nodular BCC (sample 8)   3   3     0   2    2    2 
Mouse Nodular BCC (sample 9)   3   3     0   2   2    2 
Mouse BCC Variant (sample 3)   1     0      0    1   1    0 
Mouse BCC Variant (sample 4)   1        0      0   1   1    0  
Mouse BCC Variant (sample 5)    1      0      0   1   1    0 
 
 
 
 
 
160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Representative images showing p53 expression in Mouse tissues (A) Mouse 
skin negative control (B) Ptch1 wild-type (+/+) Mouse skin (C) Mouse skin lacking one 
Ptch1 allele (+/-). p53 protein expression was mostly seen in epidermis, sebaceous 
glands and hair follicles in all investigated samples. 
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Figure 5.4: Representative images showing p53 expression in Mouse BCC derived from  
irradiated Ptch1 +/- Mice (A, B and C) Mouse Nodular BCC (D) Mouse BCC variant. The 
p53 staining was very strong on all tissues samples of mouse nodular BCC but not on 
mouse BCC variant. The staining was mostly seen in epithelial region, hair follicles and 
on epidermis. The cellular localization of staining was mostly seen in nucleus of 
nodular BCC but weakly cytoplasmic in the variant tumours.     
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5.3 Expression of DcR2 in Ptch1 wild-type (+/+) and mouse skin lacking one Ptch1 
allele (+/-) and in mouse BCC derived from x-ray irradiated Ptch1 +/- Mice. 
A panel of mouse skin and mouse BCC were stained for DcR2. The tissues included 
both Ptch1 wild-type (+/+) and Ptch1 null (+/-) skin as well as  nodular BCC and BCC 
variant tumours derived from the Ptch1 null mice following irradiation, (see Figure 5.5 
and 5.6). The intensity of staining was assessed by visual analogue scoring. 
In both the Ptch1 wild-type (+/+) mice and Ptch1 null (+/-) mice DcR2 in non-irradiated 
skin (Figure 5.5) was weakly expressed in the cytoplasm of both the epidermis and in 
the hair follicles and sebaceous glands of both wild-type (Figure 5.3B) and Ptch1 null 
(Figure 5.5C) mice. 
In irradiated mouse skin DcR2 stained positive and was of moderate in intensity on all 
nodular mouse BCC tissue sections (see Figure 5.6 A, B and C), however in mouse BCC 
variant the staining was negative (see Figure 5.6 D). In nodular mouse BCC staining is 
quite clearly seen in epithelial compartment and also in the stroma of tumour. With 
regards its subcellular localization DcR2 was mostly seen in the cytoplasm of the 
nodular BCC when compared to expression in the nucleus. For the variant BCC types 
DcR2 weakly positive in the cytoplasm. Results of visual analogue scoring of staining of 
these tumours were analysed (as shown in Table 5.1).   
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Figure 5.5  Representative images showing DcR2 expression in Mouse skin tissues (A) 
Mouse skin negative control (B) Ptch1 wild-type (+/+) Mouse skin (C) Mouse skin 
lacking one Ptch1 allele (+/-). The staining was very weak and cytoplasmic on all tissues 
of mouse skin samples.   
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Figure 5.6: Representative images showing DcR2 expression in Mouse BCC derived 
from irradiated Ptch1 +/- Mice (A, B and C) Mouse Nodular BCC (D) Mouse BCC variant. 
DcR2 expression was seen in mouse nodular BCC and was seen as moderate in 
intensity, but on mouse BCC variant it was weakly positive. The cellular localization of 
staining was mostly seen in cytoplasm.  
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5.4 Expression of DEC1 in Ptch1 wild-type (+/+) and Mouse skin lacking one Ptch1 
allele (+/-) and in Mouse BCC derived from  x-ray irradiated Ptch1 +/- Mice. 
A panel of mouse skin and mouse BCC were stained for DEC1. The tissues included 
both Ptch1 wild-type (+/+) and Ptch1 null (+/-) skin as well as  nodular BCC and BCC 
variant tumours derived from the Ptch1 null mice following irradiation, (see Figure 5.7 
and 5.8). The intensity of staining was assessed by visual analogue scoring. 
In both the Ptch1 wild-type (+/+) mice and Ptch1 null (+/-) mice DEC1 in non-irradiated 
skin (Figure 5.7) was weakly expressed in the cytoplasm of both the epidermis and in 
the hair follicles and sebaceous glands of both Ptch1 wild-type (Figure 5.7B) and Ptch1 
null (Figure 5.7C) mice. 
In irradiated mouse skin DEC1 stained positive and was moderate in intensity on all 
nodular mouse BCC tissue sections (see Figure 5.8 A, B and C), however in mouse BCC 
variant tumours the staining was very weak (see Figure 5.8 D). In nodular mouse BCC 
staining is quite clearly seen in epithelial compartment when compared with the 
stroma. With regards its subcellular localization DEC1 was mostly seen in the 
cytoplasm of the nodular BCC when compared to expression in the nucleus. For the 
variant BCC types DEC1 remained weakly cytoplasmic and was not observed in the 
nucleus. Results of visual analogue scoring of staining of these tumours were analysed 
(as shown in Table 5.1). 
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Figure 5.7: Representative images showing DEC1 expression in Mouse skin tissues  (A) 
Mouse skin negative control (B) Ptch1 wild-type (+/+) Mouse skin (C) Mouse skin 
lacking one Ptch1 allele (+/-). The staining was very weak on these samples of mouse 
skin. The staining was seen mostly seen in epidermis and hair follicles. 
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Figure 5.8: Representative images showing DEC1 expression in Mouse BCC derived 
from irradiated Ptch1 +/- Mice (A, B and C) Mouse Nodular BCC (D) Mouse BCC variant. 
DEC1 expression was more strongly seen in nodular mouse BCC when compared with 
mouse BCC variant tumours. In both nodular and variant tumours expression was 
cytoplasmic.    
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5.5 Expression of p16INK4a in Ptch1 wild-type (+/+) and Mouse skin lacking one 
Ptch1 allele (+/-) and in Mouse BCC derived from x-ray irradiated Ptch1 +/- Mice. 
A panel of mouse skin and mouse BCC were stained for p16INK4a. The tissues included 
both Ptch1 wild-type (+/+) and Ptch1 null (+/-) skin as well as  nodular BCC and BCC 
variant tumours derived from the Ptch1 null mice following irradiation, (see Figure 5.9 
and 5.10). The intensity of staining was assessed by visual analogue scoring. 
In both the Ptch1 wild-type (+/+) mice and Ptch1 null (+/-) mice, p16INK4a in non-
irradiated skin (Figure 5.9) was weakly expressed in the cytoplasm of both the 
epidermis and in the hair follicles and sebaceous glands of both wild-type (Figure 5.9B) 
and Ptch1 null (Figure 5.9C) mice. 
In irradiated mouse skin p16INK4a stained positive and was very strong on all nodular 
mouse BCC tissue sections (see Figure 5.10 A, B and C), however in mouse BCC variant 
the staining was negative (see Figure 5.10 D). In nodular mouse BCC staining is quite 
clearly seen in epithelial compartment when compared with the stroma of tumour 
type. With regards its subcellular localization p16INK4a was mostly seen in the cytoplasm 
of the nodular BCC when compared to expression in the nucleus. Results of visual 
analogue scoring of staining of these tumours were analysed (as shown in Table 5.1).   
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Figure 5.9  Representative images showing p16INK4a expression in Mouse skin tissues 
(A) Mouse skin negative control (B) Ptch1 wild-type (+/+) Mouse skin (C) Mouse skin 
lacking one Ptch1 allele (+/-). The p16INK4a expression was very weak on all tissues 
investigated.   
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Figure 5.10: Representative images showing p16INK4a expression in Mouse BCC derived 
from irradiated Ptch +/- Mice (A, B and C) Mouse Nodular BCC (D) Mouse BCC variant. 
p16INK4a staining was seen in nodular mouse BCC but staining was absent in the mouse 
BCC variant apart from some weak possibly stromal staining. The cellular localization of  
p16 INK4a was seen in cytoplasm of nodular mouse BCC.    
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5.6 Expression of p15INK4b in Ptch1 wild-type (+/+) and Mouse skin lacking one 
Ptch1 allele (+/-) and in Mouse BCC derived from x-ray irradiated Ptch1 +/- Mice. 
A panel of mouse skin and mouse BCC were stained for p15INK4b. The tissues included 
both Ptch1 wild-type (+/+) and Ptch1 null (+/-) skin as well as  nodular BCC and BCC 
variant tumours derived from the Ptch1 null mice following irradiation, (see Figure 
5.11 and 5.12). The intensity of staining was assessed by visual analogue scoring. 
In both the Ptch1 wild-type (+/+) mice and Ptch1 null (+/-) mice p15INK4b in non-
irradiated skin (Figure 5.11) was expressed in the cytoplasm of both the epidermis and 
in the hair follicles and sebaceous glands of both wild-type (Figure 5.11B) and Ptch1 
null (Figure 5.11C) mice. 
In irradiated mouse skin p15INK4b stained positive and was very strong on all nodular 
mouse BCC tissue sections (see Figure 5.12 A, B and C), however in mouse BCC variant 
the staining was very weak (see Figure 5.12 D). In nodular mouse BCC staining is quite 
clearly seen in epithelial compartment when compared with the stroma of tumour 
type. With regards its subcellular localization p15INK4b was mostly seen in the 
cytoplasm of the nodular BCC when compared to expression in the nucleus. For the 
variant BCC types p15INK4b remained weakly cytoplasmic and was not observed in the 
nucleus. Results of visual analogue scoring of staining of these tumours were analysed 
(as shown in Table 5.1).   
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Figure 5.11: Representative images showing p15INK4b expression in Mouse skin (A) 
Mouse skin negative control (B) Ptch1 wild-type (+/+) Mouse skin (C) Mouse skin 
lacking one Ptch1 allele (+/-). The staining of p15INK4b was seen in all samples of skin 
sample investigated. The staining was mostly seen epidermis and hair follicles. 
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Figure 5.12: Representative images showing p15INK4b expression in  Mouse BCC derived 
from irradiated Ptch +/- Mice (A, B and C) Mouse Nodular BCC (D) Mouse BCC variant. 
p15INK4b expression was seen in all nodular mouse BCC and also very weak staining was 
seen in mouse variant BCC.   
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5.7 Expression of p21WAF1 in Ptch1 wild-type (+/-) and Mouse skin lacking one 
Ptch1 allele (+/-) and in Mouse BCC derived from x-ray irradiated Ptch1 +/- Mice. 
Multiple tissues of mouse BCC and mouse skin were stained for p21WAF1. The tissues 
includes nodular BCC, BCC variants, Ptch1 Wild type Mouse skin (+/+) and Mouse skin 
lacking on Ptch1 allele (+/-) (see Figure 5.13 ). The intensity of staining was assessed by 
visual analogue scoring. 
There was no staining of p21WAF1 on all nodular mouse BCC tissue sections and also no 
staining in mosue BCC variant along with Ptch1 Wild type Mouse skin (+/+) and Mouse 
skin lacking on Ptch1 allele (+/-)(see Figure 5.13 C & D). I have used mouse colon 
tissues as positive control for p21WAF1 and it shows staining in nucleus (see Figure 5.13 
B) These data therefore, indicate no staining of p21WAF1  in the mouse BCCs and mouse 
skin. Results of visual analogue scoring of staining of these tumours were analysed (as 
shown in Table 5.1). 
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Figure 5.13: Representative images showing p21WAF1 expression in Mouse skin and BCC 
tissues (A) Negative control (B) Mouse colon tissues as positive control (C) Mouse 
Nodular BCC (D) Mouse BCC variant. The staining of p21WAF1 was negative on all 
samples investigated apart from the positive control which showed staining for 
p21WAF1 in the colon and thus confirming the antibody staining was working. 
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Discussion 
The aim of this study was to examine the presence of senescence markers in mouse 
BCC and mouse skin to determine whether senescence is also a characteristic of these 
mouse tumours. The immunohistochemical expression and localization of senescence 
markers was investigated in wild type Ptch +/+ mouse skin, Ptch +/- mouse skin and 
mouse BCC derived from irradiated Ptch +/- mouse skin (Mancuso et al., 2004).  My 
experiments shows marked increased in cell senescence markers in mouse BCC when 
compared to control wild type Ptch  +/+, Ptch +/- mouse skin. It was interesting to note 
however, that in general more intense staining for senescence markers was observed 
in the nodular mouse BCCs compared to the more aggressive variant BCCs. This may 
suggest that in the variant BCCs the tumour cells have been able to escape senescence 
or have not undergone senescence.  
Cellular senescence is an age-related process where cells remain metabolically active 
but in a growth-arrested state at the G1 phase. p53, p21WAF1, p15INK4b and p16INK4a, 
which are known to regulate G1 cell cycle arrest, and the tumour necrosis factor 
receptor super family member decoy receptor 2 (DCR2) and DEC1 have been recently 
identified as senescence markers (Xu et al., 2012).  
Overall in this study the expression of senescence markers were higher in mouse 
nodular BCC (benign type of BCC) compared to mouse BCC variants (aggressive type of 
BCC). This data suggests that senescence is a feature of the benign mouse tumours but 
not in the more aggressive or malignant type. This data is different to that observed in 
human BCC where similar levels of senescence markers were observed in both benign 
nodular and more aggressive morphoeic BCC. Although senescence in mouse models 
of BCC have not been previously reported senescence has been demonstrated in 
chemically induced skin papillomas in mice which have H-ras oncogenic mutations 
(Collado et al., 2005). Senescence has also been reported in mouse lung and colorectal 
tumours (Serrano and Blasco, 2001, Serrano et al., 1997, Floyd et al., 2005, Bennecke 
et al., 2010).  
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With regards p53 this has previously been shown to be expressed in BCC before and 
cellular localization was mostly in the nucleus (Eshkoor et al., 2008). Also in my study 
p53 is mostly expressed nucleus of mouse BCC. This data correlates with previous data. 
p53 has also been reported in mouse basal cell carcinomas in mice over expressing GLI-
1 (Nilsson et al., 2000a) and also in Ptch1 deficient mice (Mancuso et al., 2004). 
Bolshakov et al. (2003) in his study on human BCC also showed no difference in 
staining for p53 in aggressive and non aggressive BCC (Bolshakov et al., 2003) which 
supports my data. Inactivating mutations in p53 are found in most tumour types, and 
so contribute to the complex network of molecular events leading to tumour 
formation (Levine, 1997). The p53 gene exerts anti-proliferative effect in response to a 
variety of different stimuli, such as DNA damage telomere shortening, oxidants, 
hypoxia and a variety of stresses. Loss of functional p53 may also inhibit apoptotic 
pathways and hence enhance survival of abnormal cells (Levine, 1997).  
In this study I observed p16INK4a and p15INK4b expression in mouse BCC that was 
predominately localised in the cytoplasm.  It has been reported that there is structural 
and functional homology between p15INK4b and p16INK4a and that p15INK4b is 
transcriptionally activated by transforming growth factor-B (TGF-β) (Rahimi and Leof, 
2007, Hannon and Beach, 1994).  Human BCCs have previously been reported to 
express p16INK4a in human BCC and has been reported as a senescence markers in 
adenoma and adenocarcinoma (Collado et al., 2005, Eshkoor et al., 2008). The 
expression of p16INK4a is reported to be induced in response to DNA damage, 
oncogenic Ras expression and by other cellular stresses. Under normal physiological 
conditions p16INK4a is expressed in low levels but if cells are under stress such as 
oncogenic stress p16INK4a levels increase. The p16INK4a protein is often highly expressed 
in senescent cells in culture and inactivated in a variety of human cancers (Eshkoor et 
al., 2008, Michaloglou et al., 2005, Serrano et al., 1997). In cancer the influence of 
p15INK4b is not clear and work with p15INK4b deficient mice has only shown a subtle 
predisposition to tumours whereas loss of p16INK4a causes a wide range of tumours 
(Eshkoor et al., 2008). Staining for p15INK4b has been reported in human premalignant 
lung tumors, nodular hyperplasia and PIN tissues (Zhang et al., 2006). Therefore 
expression of p15INK4b in mouse BCC may not play important role in senescence. 
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However, the fact that these tumours also express p16INK4a suggest a role for the 
protein in BCC senescence.      
DcR2 expression has been reported to protect cells from trail induced apoptosis  and is 
regulated by p53 (Liu et al., 2005). DcR2 expression is often silenced or down-
regulated by promoter hypermethylation in multiple cancer types, including cervical 
cancer, breast cancer, neuroblastoma, malignant mesothelioma, and prostate cancer 
(Liu et al., 2005). The expression of the DcR2 has been previously reported in 
adenomas and carcinomas. Both adenomas and carcinomas exhibited cytoplasmic 
staining for DcR2. Meng et al (2000) found DCR2 overexpression in human colon 
cancer cells and studies have shown that some chemotherapy agents caused DCR2 
over expression in a human lung cancer cell lines (Meng et al., 2000). However, my 
current study is the first time this has been reported in either human or mouse BCC. 
DEC1 expression is reported to be induced in response to hypoxia (Chakrabarti et al., 
2004).  The expression of DEC1 has been reported in the nuclei of a number of human 
tumours including breast, colon, lung, and head and neck cancers (Ehata et al., 2007). 
The expression pattern in tumour cells was   much stronger than that in surrounding 
non-neoplastic tissue or that seen previously in normal tissues. However, there are no 
reports so far of DEC1 expression in either mouse or human BCC.   
In summary, my study demonstrated that there is an increased protein expression of 
senescence-associated molecular markers indicating that cellular senescence might 
play a role in mouse BCC cancer. In particular my data showed that in the more 
aggressive mouse BCCs p53, DcR2, DEC1, p16INK4a and p15INK4b were only weakly 
expressed when compared to nodular BCC types. These data suggest that the more 
aggressive mouse BCC may have overcome cell senescence and this may explain the 
more aggressive nature of these tumours. This is however, different from human BCCs 
in which I observed similar levels of expression of senescent markers in both the 
benign nodular BCCs and in more aggressive morphoeic tumours. The mechanism by 
which the variant mouse BCCs overcome senescence is not clear from my studies 
however, understanding how cancer cells are able to evade senescence is of 
considerable interest but poorly understood. In general there are two possible 
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mechanisms of tumour reversion or avoidance involving either reversal of senescence 
involving inactivating mutations of essential senescence-maintenance genes or 
avoidance of senescence through low levels of oncogene expression (McDuff and 
Turner, 2011). 
My data may indicate that in the variant mouse BCC senescence avoidance is achieved 
via low levels of expression of proteins associated with senescence. However, for my 
studies the mechanism of action is not clear. 
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    Chapter 6: Discussion 
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Discussion 
BCC is the most common skin cancer in humans which accounts for approximately 80% 
of all NMSC with incidence of BCC increase by 10% annually. Although BCC very rarely 
metastasise they can be locally very destructive of surrounding tissue and can be 
divided into two groups. The first group of BCC include less aggressive (superficial and 
nodular BCC) and second group includes the more aggressive BCC subtypes such as 
morphoeic and infiltrative. Cellular senescence is an important tumour suppressor, 
limiting cell lifespan and removing damaged cells from a proliferative state preventing 
the formation of clonal tumours. The aim of the work carried out in this thesis was to 
investigate senescence in human BCC. I hypothesised that senescence may be a 
characteristic the more benign nodular and superficial BCC subtypes and that there 
may be down regulation of senescence in the more aggressive morphoeic and 
infiltrative types of BCC. Cellular senescence is an important tumour suppressor, 
limiting cell lifespan and removing damaged cells from a proliferative state preventing 
the formation of clonal tumours. To study this I have used a number of models and 
have investigated cell senescence in human BCC tissues, in an in-vitro model BCC 
developed in my laboratory by another PhD student Muhammad Rahman (Rahman, 
2013) and in mouse BCCs. To characterise senescence in these models I have used a 
number of well known and well characterised markers of cell senescence. The major 
well defined markers include senescence associated β-galactosidase assay, DcR2 
(Decoy Receptor 2), DEC1 (differentially embryo-chondrocyte expressed gene), p53, 
p16INK4a and p21WAF1 genes. . Overall the techniques I have used in this thesis have 
been straightforward and with the exception of immunohistochemistry using the 
p21WAF1 antibody I have experienced very few problems.  
In Chapter 3 of this thesis I carried out β-galactosidase staining on the frozen tissue 
sections of basal cell carcinoma and also looked at the expression of DcR2, DEC1, 
p16INK4a, p53, p21WAF1 and p15INK4b in formalin fixed BCC from the archives of the Royal 
London Hospital. These experiments were carried out in formalin fixed sections as 
morphoeic BCCs are not very common and therefore, would have taken considerable 
time to collect fresh morphoeic tumours. I therefore, carried out the β-galactosidase 
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assay on fresh frozen samples as the β-galactosidase assay will not work on formalin 
fixed sections for the reasons described in Chapter 2. The senescence markers used in 
my study have previously been in a number of pathological conditions, includes 
chronic ulcers, benign prostate hypertrophy, atherosclerotic plaques, osteoarthritis, 
and tissue damage by radiation or chemotherapy (Campisi, 2005, Jeyapalan and 
Sedivy, Kahlem et al., 2004). In my study β-galactosidase staining was in all human BCC 
samples investigated, however, expression was mainly restricted to the stromal cells of 
the tumour and only occasional epithelium cells showed positive β-galactosidase 
staining. In contrast DcR2, DEC1, p16INK4a, p53, p21WAF1 and p15INK4b were detected in 
both the stroma and epithelium of BCCs. The reason why the epithelium of BCC did not 
stain for β-galactosidase when it was positive for the other senescence markers is not 
clear. However, although β-galactosidase is widely used and accepted as  a marker of 
senescence there was some reservation about its use. Dimri et al., (Dimri et al., 
1995a) in experiments with cultured fibroblasts, first described lysosomal beta-
galactosidase activity, which is expressed ubiquitously in most cells when assayed at a 
pH of 4.0 as a marker for senescent cells which stain positively for beta-galactosidase 
when assayed at a pH of 6.0. This novel staining capacity was ultimately referred to as 
senescence-active beta-galactosidase (SA-β-gal) activity. Although, SA-β-Gal is widely 
used as a marker of senescence in some human cells (Choi et al., 2000). We do not yet 
know the origin or function of SA-β-Gal. Moreover, it is not known whether this is a 
distinct enzyme active at pH 6, and differentially expressed in senescence, or reflects 
an increase in the classic acid lysosomal β-galactosidase. The speciﬁcity and selectivity 
of this assay have been disputed by other groups (Kurz et al., 2000). β-galactosidase 
activity at pH 6 has been shown in immortalised cell lines following either serum 
starvation or phorbol ester-induced macrophage-like differentiation (Yegorov et al., 
1998), or have detected pH 6 activity, using a sensitive high-pressure liquid 
chromatography assay, in various proliferating cell lines and in liver homogenates 
(Krishna et al., 1999). However, despite the reservations senescence-associated β-
galactosidase (SA-β-gal) is still the most widely used biomarker for senescent or ageing 
cells. However, it is advisable to use this marker in parallel with established markers. 
Therefore, in my thesis as well as using senescence-associated β-galactosidase (SA-β-
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gal) I have also used the panel of senescence markers described by (Collado et al., 
2005). 
In my research I observed that there was no significant difference in the expression of 
senescence markers between different BCC types as I had originally hypothesised. This 
suggests that while senescence is a characteristic of BCC the difference between 
benign and aggressive BCC does not appear to be due to differences in the level of 
senescence i.e. aggressive BCC do not appear to be any less senescent than benign 
BCC. Perhaps this is not totally surprising as it has recently been reported that human 
BCC have one of the highest rates of mutations in any human tumour (Jayaraman et 
al., 2013). Therefore, while PTCH may be the initial driver mutation the subsequent 
biology of BCC may be influenced by many other pathways.  
In Chapter 4 of my thesis I went on to investigate whether the senescence markers 
detected in BCC in Chapter 3 were direct targets of HH signalling. To investigate this I 
used two different in vitro models of BCC developed by my group. The first of these 
models was NEB-1 keratinocytes transduced by retrovirus to over express GLI-1. The 
second model was NEB-1 keratinocytes in which the PTCH1 receptor has been knocked 
down by shRNA. As outlined in Chapter 4 the disadvantage of using cells over 
expressing GLI1 is that although this reflects the increase in GLI1 seen in BCC these 
cells have wild type PTCH1. In these keratinocytes over expression of GLI1 will activate 
a negative feedback loop in which GLI1 up-regulates its target gene PTCH1 and then 
PTCH1 then is able to repress the GLI1 response. This may result in damping down of 
any possible effect of GLI1. In contrast PTCH1 knockdown recapitulates the events 
seen in BCC in which PTCH1 is mutated and as a result GLI1 is up regulated. Because I 
used shRNA this also results in a stable heritable knockdown of the target gene. In 
Chapter 4 I showed that at both the mRNA and protein level that there is increase in 
senescence markers in my in-vitro model at protein and mRNA level. However, I did 
observe marked differences in levels of expression both at the mRNA and protein level 
between the PTCH knockdown and GLI overexpressing cells. The reason for this 
variation can most probably be explained by the fact that in the NEB1 GLI-1 cells, GLI-1 
is overexpressed in cells containing the wild type PTCH1 gene. As PTCH1 is a direct 
target of GLI-1 and act as a negative feedback loop it is highly likely that in these cells 
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PTCH1 is able to damp down the effects of GLI-1 overexpression. In contrast in the 
NEB1-189A cells in which PTCH1 has been knocked down using shRNA the subsequent 
increase in GLI1 expression may be a better reflection of what happens in BCC. 
However, for the reasons explained above and the high burden of mutations in BCC 
the PTCH knockdown cells may only reflect early events in BCC development. However, 
such models are essential for understanding early events in BCC development and 
Harrison et al (2013) have used human keratinocytes to over express GLI1 and GLI2 
and shown that these cells are resistant to apoptosis but do not form colonies in soft 
agar indicating that they are not transformed. However, on treatment with known 
mutagens colonies of cells survive and grow in soft agar suggesting cellular 
transformation. It would be important to see if similar changes occur with PTCH1 
knockdown cells and whether exposure to UV or carcinogens can then be used to 
model subsequent events in BCC tumour development. Finally, it is also important to 
highlight that BCC is associated with an extensive stroma and that this stroma is likely 
to play an important role in growth and development of the BCC. Further working 
using PTCH1 knockdown cells and BCC derived stroma would be important although as 
mentioned in Chapter 3 these cells are also senescent and have proven difficult to 
maintain in vitro. 
Finally in Chapter 5 I have investigated whether the cell senescence I observed in 
human BCC in Chapter 3 and which I showed in Chapter 4 is associated with HH 
signalling can also be observed in mouse BCCs. This is important as murine models of 
BCC are widely used to investigate BCC biology (See Section Chapter 1). The mouse 
model of BCC I used was that developed by Mariateresa Mancuso from Biotechnology 
Unit and Radiation Protection Unit, ENEA-Ente per le Nuove Tecnologie, l’Energia e 
l’Ambiente, Centro Ricerche, Casaccia, Rome, Italy. This group have generated Mice 
lacking one Ptch1 allele, through targeted disruption of exons 6 and 7 in 129/SV ES 
cells and maintained on CD1 background (Mancuso et al., 2004). Mancuso et al 
performed X-ray irradiation (HVL _ 1.6 mmCu) on these mice using a Gilardoni CHF 
320G X-ray generator (Gilardoni S.p.A.; Mandello de Lario Lecco, Italy) operated at 250 
kVp, 15 mA, with filters of 2.0 mm of A1 and 0.5 mm of Cu. PTCH1neo67/+ mice and wild-
type littermates of both sexes were whole-body irradiated with 3 Gy of X-rays as 
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newborns (4 days of age) or adults (90 days of age). In addition, 2-month-old mice 
were subjected to local irradiation of the dorsal skin with a single dose of 4 Gy of X-
rays. I carried out staining for β-galactosidase as well as DcR2, DEC1, p16INK4a, p53, 
p21WAF1 and p15INK4b  on Ptch1 Wild-type (+/+) and Ptch1 (+/-) mouse skin as well as on 
BCC derived from irradiated Ptch1 +/- Mice. Although I did not detect β-galactosidase 
in any mouse tumours the staining for most markers was moderate in intensity in all 
nodular BCC except for p53 which was very strong on nodular mouse BCC (non 
aggressive type). In contrast I only observed very weak or no staining for these markers 
on mouse BCC variant (aggressive type). These data suggest that mouse nodular BCC 
are similar to human nodular BCC and are highly senescent. In contrast the aggressive 
mouse variant BCC have much lower levels of senescence and this is in direct contrast 
with the situation in human morphoeic BCC. The data from the mouse variant BCCs 
suggest that these mice have either overcome senescence or perhaps levels of 
senescence were lower to start with and which may explain why these variant tumours 
develop. 
Lack of senescence associated β-galactosidase activity in mouse tumours is not clear. 
However, it may be related to the early stages of BCC development with the mouse 
tumours harbouring fewer mutations. It has also been shown in a mouse model of 
bladder tumorigenesis that up-regulation of senescence associated molecules 
including Dec1 and DcR2 was not associated with senescence associated β-
galactosidase activity (Mo et al., 2007). Lack of  senescence associated β-galactosidase 
activity may also be linked to lack of expression of p21 as this protein has been 
associated with cell senescence and decreased senescence associated β-galactosidase 
activity has been reported in v-Ha-ras transduced keratinocytes cells lacking p21 
(Weinberg and Denning 2002 for review). Finally senescence associated β-
galactosidase activity is associated with the lysosome  but is itself not essential for 
senescence to occur (Lee et al., 2002) 
Although much is known about BCC in regards to their histopathological structure, 
clinical features and to an extent their cause, much remains undefined with regards 
the molecular mechanisms that regulate BCC development and in particular the 
differences between benign and aggressive BCC. It is also worth noting that in most 
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other tumours aberrant HH pathway activation is associated with highly aggressive and 
metastatic tumours (Kasper et al., 2006a). It is therefore striking that in skin aberrant 
HH pathway activation is rarely associated with metastasis. While mouse models of 
skin carcinogenesis have been very informative and a number of murine models for 
BCC have been developed these mouse BCC models may be more indicative of hyper 
proliferation of the epidermis resulting in tumour formation. It would be very useful to 
carry out exome sequencing of some of these mouse BCC to see how closely they 
resemble human BCC. 
Understanding the molecular mechanisms that regulate BCC development has been 
difficult in part due to the fact that culture of primary human BCC and its cell types in 
vitro has proven very difficult, thereby making the study of this cancer and its 
molecular changes challenging. There are few papers in the literature that report 
success in culturing BCC keratinocytes usually with fibroblasts derived from the same 
tissue sample (Dicker et al., 2002, Lacina et al., 2007). However, currently there are no 
commercially available BCC cell lines and BCC keratinocyte cell culture is still generally 
regarded by workers in the field as extremely complicated. My data showing that BCC 
epithelium and stroma express senescence markers and hence my conclusion that BCC 
are a highly senescent tumour may well explain why BCC cells are difficult to culture in 
vitro and hence why there are no cell lines. Indeed a previous PhD student Jane Elliot 
(Elliot, 2011) in my supervisor Professor Philpotts group attempted to culture BCC 
keratinocytes from BCC using fibroblasts derived from the same BCC as feeder layers. 
However, she observed that while it was possible to explant some keratinocytes from 
BCC these rapidly senesced in vitro. Moreover, she also showed that fibroblasts from 
BCC also grew very slowly and also senesced as determined by expression of β-
galactosidase, DEC1, DcR2 and p16INK4a. 
Inactivation of more than one pathway is required to bypass senescence. Senescence 
caused by telomere dysfunction and maintained by p53 is a reversible state, however 
p16INK4a expression in this scenario is a dominant irreversible effect that forms a 
second barrier against cell proliferation (Beausejour and Campisi, 2006). Although 
p16INK4a up regulation can be seen at the same time as p53 and p21WAF1, it is triggered 
and acts independently. If one pathway is up regulated (i.e. p16INK4a) this doesn’t 
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prevent the cells from responding to the other pathways (i.e. p53/p21WAF1) at a 
subsequent time (Herbig and Sedivy, 2006). Therefore, my observation that BCC 
expressed both p16INK4a as well as p53 supports my hypothesis that BCC has high levels 
of senescence and supports both the data from Jane Elliots PhD thesis but also 
probably explains why BCC keratinocytes have been so difficult to culture. To 
overcome this senescence would presumably involve both p16INK4a and p53 being 
mutated. 
Mutation in the p16INK4a gene have been previously identified in sporadic melanomas 
and NMSC resulting in breakdown of tumour suppression mechanisms. Under 
conditions of stress, and oncogenic stimuli, expression of p16INK4a increases and does 
p15INK4b expression. The increase expression of these genes results in the suspension of 
cell cycle and counteracts the excessive proliferation or the replication of damaged 
DNA. It would be of great interest to know whether rare metastatic BCC have 
mutations in p16INK4a and or p53 which allows them to overcome senescence. 
However, these tumours are very rare and were not available for this current study. It 
would also have been interesting to have been able to look at the basal-squamous skin 
tumours to see whether they expressed components of the HH pathway and if so 
whether they also expressed senescence markers. 
As previously described the presence of DcR2 BCC cells may protect them from the 
actions of TRAIL induced apoptosis. In my study immunocytological investigation for 
the receptor DcR2 showed a strong positive stain in human BCC , in my in vitro model 
of BCC and in mouse BCC. This has also been reported in melanoma cell lines and it is 
suggested that the expression of this receptor may involve regulated movement from 
the intracellular compartments to the membrane. In that study by Zhang et al, 2000, 
DcR2 was shown to be localized to the nucleus but then sub cellular localization to the 
cytoplasm was seen in the melanoma cells on their exposure to the TRAIL ligand 
(Zhang et al., 2000). Apoptotic cells have been observed in BCC (Erb et al., 2005, 
Orlandi et al., 2004, Harrison, 2013) however, this is at a relatively low level. Moreover, 
GLI1 and GLI2 expressing cells have been shown to have up-regulated Bcl-2 an 
important anti apoptotic protein and to be resistant to apoptosis (Pantazi, 2010, 
Harrison, 2013). 
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Senescent cells, whilst also acquiring altered gene expression, often become resistant 
to cell death signals and therefore apoptosis. Another senescence associated marker 
observed in this initial study was DEC1. DEC1 is abundant in carcinomas and usually 
expressed when cells are in a hypoxic state. It has been previously demonstrated that 
DEC1 transcriptionally activates a gene called survivin which is a member of the 
Inhibitor of the Apoptosis family (IAF) and inhibits caspase and therefore negatively 
regulates apoptosis (Chakrabarti et al., 2004). In my study DEC1 has also shown 
increase level in human BCC, in my in vitro model of BCC and in mouse BCC. There is a 
correlation between DEC1 expression and tumour grade and prevention of apoptosis 
in mouse mammary epithelial cells. Like DcR2, DEC1 has an anti apoptotic role in 
senescence and cancer. 
The hypothesis of my thesis was that cell senescence may explain the more benign BCC 
subtypes and that more aggressive BCCs may either escape senescence or have lower 
levels of senescence markers. This does not appear to be the case and similar levels of 
cell senescence were observed in both nodular and morphoeic BCC 
In conclusion I have shown that cell senescence is seen in human BCC as well as in a 
mouse model of BCC although in the mouse model used in my study aggressive variant 
BCCs had much lower levels of senescence than nodular BCC and this contrast with 
human BCC. I also showed  in an in-vitro model of BCC that the senescence markers 
used in my study are up regulated by GLI1 and hence I conclude are targets of HH 
signalling. My data  suggests that while up-regulation of senescence in BCC is 
characteristic of this tumour and may explain why they rarely metastasise; cell 
senescence does not explain difference between BCC subtypes. 
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6.2 Future work 
This research presented in this thesis forms the foundations for future study of 
senescence in BCC and its role in BCC biology. As such there is a wide scope of future 
experiments that can be performed across a range of topics. Initially, some of the data 
presented here needs to be confirmed by doing some other experiments. Key among 
these would be to knockdown GLI-1 in the PTCH null cell line using shRNA to confirm 
that the increase in cell senescence markers is directly associated with Gli1. By 
knocking down GLI-1 we would expect to see down regulation of DcR2, DEC1, p16INK4a, 
p53, p21WAF1 and p15INK4b thus further confirming that  DcR2, DEC1, p16INK4a, p53, 
p21WAF1 and p15INK4b are targets of HH signalling. 
One of the key questions remaining from my work relates to the mechanism by which 
BCC may overcome senescence to allow tumor growth. It is known that p53 is mutated 
in many BCCs and therefore, it would be interesting to knockdown p53 in our PTCH 
null cell line and indeed in the GLI1 over-expressing cells, again using shRNA and see if 
this overcomes cell senescence. However, it is also likely that the local tumour 
environment plays a crucial role in the growth of BCC tumours and the balance 
between proliferation and senescence and therefore investigating the role of the 
stroma in BCC formation would also be important (see below). 
Although I have shown no apparent quantifiable differences in senescence between 
benign and aggressive BCC it would be interesting to further investigate senescence in 
metastatic BCCs as it would be expected that these tumors would not be senescent. 
However, metastatic BCC are very rare and I am not aware of any having been seen at 
the Royal London Hospital in the past 5 years. However, it may be possible by 
collaborating with other groups to collect a small sample of these tumors from 
pathology archives. As all of our antibodies work on formalin fixed tissues we could 
carry out a retrospective study. It would also be interesting to look at senescence in 
basosquamous tumors as these BCC also have the ability to metastasise. 
basosquamous tumours have an incidence rate of between 1.2 to 2.7% (Garcia et al 
2009) and so it is more likely we could obtain sufficient samples from pathology 
archives for a retrospective study. It is not known whether these tumors express 
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components of the HH pathway and so this could be investigated along with 
senescence. 
Gene arrays on epithelial and stromal tissue from nodular and morphoeic  BCC should 
also be carried out to try and identify differences  that may explain more aggressive 
nature of morphoeic BCC. Two approaches could be used the first would be to carry 
out gene arrays on cultured cells from these tumours. However, while this would be 
possible on early passage BCC derived fibroblasts it would represent a major challenge 
with BCC keratinocytes. However, comparing fibroblasts would be  a very valuable 
approach and may help identify stromal differences that may explain some differences 
between BCC subtypes. It would also be useful to carry out Exome sequencing of 
human morphoeic BCC and to compare these data with Exome sequencing of nodular 
BCC. In addition Exome sequencing of mouse BCC would provide valuable information 
with regards similarities and differences between the human disease and mouse 
models. 
It is well established that the local tumour environment plays an important role in 
tumour growth and indeed it is known that senescent cells although they no longer 
proliferate are metabolically active and secrete a range of cytokines. Fibroblasts could 
be cultured from nodular and morphoeic BCC to investigate the kind of cytokines they 
secrete. However, as already mentioned in this thesis previous workers in my 
supervisors laboratory have also found these cells difficult to culture. However, they 
were able to maintain fibroblasts over several passages and were able to measure TGF-
 and SHH secretion using ELISA and a SHH activity in tissue culture serum using a cell 
based reporter assay (Elliott 2011). Therefore, it is possible to measure cytokines 
produced by BCC derived fibroblasts by ELISA.  
The data generated by Elliott (2011) also suggested that the BCC keratinocytes were 
required for optimum BCC fibroblast culture and that BCC keratinocytes were required 
for optimum fibroblast culture. This data was based on explant culture. An additional 
approach would be to make organotypic models with early passage before senescent 
but also possibly senescent fibroblasts from nodular and morphoeic BCC and 
investigate effects on both normal keratinocytes but also the GLI-1 and GLI-2 
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expressing cells and the PTCH1 knockdown cells. This would allow us to investigate the 
influences of the stroma and in particular fibroblasts on BCC formation as 
keratinocytes expressing GLI1 and GLI2 are widely used in BCC research in the absence 
of suitable BCC keratinocyte cell lines. Recently Dr Wesley Harrison a postdoctoral 
scientist in my group has published a paper in Oncogene (Harrison et al 2013) showing 
that both GLI1 and GLI2 confer apoptosis resistance on human keratinocytes and that 
when exposed to known carcinogens this promotes cellular transformation and cell 
invasion in collagen gels. Cell invasion  can be quantified using ImageJ software both in 
terms of depth of invasion but also average number of detached invasions per field of 
view (Harrison et al 2013). 
Currently there are no BCC cells lines and this may be for the reasons identified in this 
thesis. However, not all cells in the BCC can be senescent and the work carried out in 
my group by a previous PhD student, Jane Elliott showed that both BCC keratinocytes 
and fibroblasts could be grown as explant culture although on passage they rapidly 
senesce (Elliott 2011). It would be worth trying to make immortalised cell lines from 
BCC keratinocytes and fibroblasts while in explant culture or following early passage. 
My supervisors group has considerable experience in making immortalised cell lines 
from human hair follicles using either the catalytic subunit of human telomerase 
(hTERT) or the HPV E6/E7 proteins and indeed have recently made an immortalised 
line for the secretory coil of human eccrine sweat glands (unpublished data). Both 
hTERT and HPV E6/E7 are accepted methods of immortalisation (Storey and Banks 
1993; Dickson et al 2000). 
The experiments outlined above would help further understand the differences 
between benign and aggressive BCC and the role of senescence and as proof of 
principle all of the approaches suggested have  been shown to be viable although as 
outlined above some are much more technically challenging than others. 
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Appendix 
Appendix 1 
 
Details of Patients Demographics (Age and Sex) 
Paraffin Tissues   
Patients 
Number 
Nodular 
BCC 
Patient 
Number 
Morphoeic 
BCC 
                                     Age           Sex 
 
                                       Age               Sex 
 
1 
 
54  
          M 
1 
 
75            M 
2 
 
69  
          M 
2 
 
69            M 
3 
 
37  
          M 
3 
 
58             F 
4 
 
75  
           F 
4 
 
54            M 
5 
 
81  
           F 
5 
 
60             F 
6 
 
52  
          M 
6 
 
52            M 
7 
 
54  
           F 
7 
 
84             F 
8 
 
59  
           F 
8 
 
59             F 
9 
 
82  
           F 
9 
 
59             F 
10 
 
68  
           F 
10 
 
68             F 
11 
 
91  
          M 
11 
 
91            M 
12 
 
56  
          M 
12 
 
56            M 
13 
 
51  
           F 
13 
 
59             F 
14 
 
49  
          M 
14 
 
49            M 
15 
 
76  
           F 
15 
 
30             F 
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Appendix 2 
Details of Patients Demographics (Age and Sex). Frozen  Tissues   
Patient Number 
 
            Age           Sex                          Type BCC 
SM 120 
 
54           M Nodular 
SL A01 
  
69            F Nodular 
SW M68  
 
37           M Nodular 
LA 107  
 
75           M Nodular 
EL 652  
 
81            F Nodular 
MA 4BT 
  
52           M Nodular 
GJ 106  
 
54            F Nodular 
BD 641  
 
59           M Nodular 
JW 611 
  
82           M Nodular 
JK 959 
  
68           M Nodular 
WJ 140 
  
91             F Nodular / Micronodular 
MJ 120 
  
56           M Micronodular 
DF 572 
  
51            F Superficial 
HP 115 
  
49           M Superficial 
AC 636 
  
76             F Superficial 
RF M75 
  
75           M Infiltrative 
MN 108 
  
69             F Infiltrative 
MJ F26 
  
58            F Infiltrative 
JS 668 
  
54           M Morphoeic 
JG 138 
  
60            F Morphoeic 
NJ 646  
 
52            F Morphoeic 
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Appendix 3 
 
The commercial kit contain the following reagents:- 
  • 10X Fixative Solution (15ml) 
• X-Gal (150mg) 
• 10X Staining Solution (15ml) 
• 100X Staining Solution Supplement A (1.5ml)  
• 100X Staining Solution Supplement B (1.5ml)  
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Appendix 4 
Materials used for β-galactosidase staining made in our own laboratory. 
 
Solution Stock Concentration Working 
Concentratio
n 
Volume (to make 
10ml) 
X-gal 
 
20 mg/ml 1mg/ml 0.5ml 
NaCl 
 
5M 150mM 0.3ml 
MgCl 
 
1M 2mM 20µL 
K3Fe(CN)6 
 
100mM 5mM 0.5mL 
K4Fe(CN)6 
 
100mM 5mM 0.5mL 
NaPi pH6.0* 
 
100mM 40mM 4mL 
    
dH2O 
 
  4.18mL 
 
* NaPi (pH6.0), 100mM, consists of; 
      1M Disodium Hydrogen Phosphate (Na2HPO4)       12mL 
      1M Sodium Dihydrogen Phosphate (NaH2PO4)       88mL 
      Distilled water (dH2O)                                                   900mL 
      Glutaraldehyde 0.2% (v/v)                                           1ml in 125ml PBS 
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Appendix 5 
KGM Media which is consists of :  
  AlphaMEM from BioWhittaker/Lonza  
  Penicillin/Streptomycin  
  10% Foetal bovine serum (FBS)  
  L-glutamine  
  KGM supplement which is made up of:  
   Adenine  
   Cholera toxin  
   Insulin  
   Hydrocortisone  
   Epidermal growth factor.  
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Appendix 6 
Trypsin EDTA include;  
  Trypsin 0.5 mg/ml  
  EDTA (Titriplex III) 0.22 mg/ml  
  Solvent PBS, without Ca & Mg  
  Phosphate Buffer Saline (PBS)(Dulbecco’s PBS (1x) PAA Laboratories 
  GmbH) 
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Appendix 7 
Components of qPCR Kit 
 
Component Volume(μl) 
2X (SYBER Green PCR Master Mix) 10 
50mM MgCl2  
(comes to a final conc. of 7mM in 20μl of total reaction) 
 
1 
Primers at 1μM (Forward and Reverse)  
(comes to final concentration of 100nM per 20 of total 
reaction) 
 
2+2 (F+R) 
Nuclease free water (NF-H2O) (Ambion) X (4) 
cDNA (0.5μg/μl) (comes to a final of 25ng/μl) 1 
X-refers to variable volume of NF-H2O. Total = 20 
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Appendix 8 
 
DcR2 (Decoy Receptor) 
 
                                                           DcR2 (Decoy Receptor) 
                                          Nodular Basal Cell Carcinoma   
Normal 
Skin 
DcR2   
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
1048/2000A 2 2 2 1 1.5 1 
1059/2009 2 2 1 2 2 0.5 
1092/1999 3 3 1 3 3 0.5 
1090/2000 3 3 2 3 3 0.5 
1056/1998 2 2 2 2 2 0.5 
1156/2009 2 2 1 2 2 0.5 
1075/2007 0 2 1 1 1 0.5 
1172/2008 0 0 0 0 0  
104/1999 2 2 1 2 2 
1022/1999 1 1 1 1 1 
1073/2007 2 2 2 1 1.5 
1019/2007 2 3 3 2 2 
1003/1999 3 2 1 3 3 
1123/2002 2 2.5 2 1 1.5 
1024/2007 2 3 3 2 2 
                                        Morphoeic Basal Cell Carcinoma 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
2103/2004 2 2 1 3 2.5 
761/1997 3 3 3 3 3 
118/2000 2 3 2 2 2 
406/1998 2 3 3 3 2.5 
2353/2006 3 3 2 3 3 
696/1997 2 3 2 2 2 
836/1997 2 3 2 2 2 
357/1998 3 3 1 3 3 
307/2001A 1 1 0 1 1 
49/2002 3 3 3 3 3 
391/1996A 2 3 1 3 2.5 
252/1999 3 2 1 3 3 
307/2001B 2 2 2 2 2 
306/2000 1 1 1 1 1 
637/1996 2 2 1 1 2.5 
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DEC1 (Differentially Embryo-chondrocyte Expressed Gene) 
 
                                   DEC1 (Differentially Embryo-chondrocyte Expressed Gene) 
                                          Nodular Basal Cell Carcinoma   
Normal 
Skin 
DEC1 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
1048/2000A 2 2 1.5 1 2.5 1.5 
1059/2009 3 3 2 3 3 1.5 
1092/1999 2 2 1.5 1 1.5 0.5 
1090/2000 2 2 1 2 2 1 
1056/1998 2 2 1 1 1.5 0.5 
1156/2009 0.5 3 2 0.5 0.5 0.5 
1075/2007 3 2 2 2 2.5 0.5 
1172/2008 3 3 2 3 3  
104/1999 0.5 1 1 0.5 0.5 
1022/1999 2 2 1 2 2 
1073/2007 2 2 1.5 2 2 
1019/2007 3 2 2 3 3 
1003/1999 3 3 1 3 3 
1123/2002 3 3 2 1 2 
1024/2007 3 3 2 3 3 
                                        Morphoeic Basal Cell Carcinoma 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
2103/2004 2 2 1 2 2 
761/1997 3 3 2 3 3 
118/2000 3 3 2 3 3 
406/1998 2 3 2.5 2 2 
2353/2006 1 1 2 1 1 
696/1997 2 2 1.5 2 2 
836/1997 1 1 0.5 1 1 
357/1998 3 3 0 3 3 
307/2001A 0 0 0 0 0 
49/2002 3 3 2 3 3 
391/1996A 3 3 2 3 3 
252/1999 2 2 2 2 2 
307/2001B 3 2 1 3 3 
306/2000 2 1 1 2 2 
637/1996 2 2 1.5 2 2 
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p53 
 
                                                                  p53 
                                          Nodular Basal Cell Carcinoma   
Normal 
Skin p53 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
1048/2000A 1 0 1 0 1 0 
1059/2009 3 0 1 0 3 0 
1092/1999 3 1 0 0 3 0 
1090/2000 1 0 1 0 1 0 
1056/1998 0 0 1 0 0.5 0 
1156/2009 0 0 0 0 0 0 
1075/2007 1 0 0.5 0 0.5 0 
1172/2008 1 1 1 0 1  
104/1999 1 1 0 0 1 
1022/1999 0 0 0 0 0 
1073/2007 3 0 1 0 3 
1019/2007 1 0 0 0 0.5 
1003/1999 1 1 0 0 1 
1123/2002 0.5 0 0 0 0.5 
1024/2007 1 0 0 1 1 
                                        Morphoeic Basal Cell Carcinoma 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
2103/2004 1 0 1 0 1 
761/1997 1 0 1 0 1 
118/2000 2 0 0 0 2 
406/1998 2 0 0 0 2 
2353/2006 0 0 0 0 0 
696/1997 1 0 0 0 1 
836/1997 2 0 0 0 2 
357/1998 3 0 2 0.5 3 
307/2001A 2 1 0 0 2 
49/2002 1 0 1 0 1 
391/1996A 2 0 0 0 2 
252/1999 0 0 0 0 0 
307/2001B 2 0 1 0 2 
306/2000 1 1 0 0 1 
637/1996 3 0 1 0 3 
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p16INK4a 
 
                                                               p16INK4a 
                                          Nodular Basal Cell Carcinoma   
Normal 
Skin 
p16INK4a 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
1048/2000A 2 1.5 1 1 1.5 1.5 
1059/2009 3 2 1.5 2 2.5 0.5 
1092/1999 2 2 1 2 2 0.5 
1090/2000 2 2 2 2 2 0.5 
1056/1998 2 2 1 2 2 0.5 
1156/2009 2 3 0.5 1 2 0.5 
1075/2007 2 3 2 2 2 1 
1172/2008 2 0 0 3 2.5  
104/1999 2 2 0.5 2 2 
1022/1999 1 0.5 0.5 1 1 
1073/2007 1 2 2 1 1 
1019/2007 2 2 2 2 2 
1003/1999 3 3 1 2 2.5 
1123/2002 2 2 1.5 2 2 
1024/2007 3 2 1.5 3 3 
                                        Morphoeic Basal Cell Carcinoma 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
2103/2004 3 2 1 2 2.5 
761/1997 3 3 1 3 3 
118/2000 1 2.5 1.5 2 1.5 
406/1998 3 2 3 3 3 
2353/2006 3 2 1.5 2 2.5 
696/1997 2 2 1.5 2 2 
836/1997 2 2 2 2 2 
357/1998 1 2.5 0 1 1 
307/2001A 2 0 0 2 2 
49/2002 1 2 2 1 1 
391/1996A 1 2 1 1 1 
252/1999 0 3 0.5 0 0 
307/2001B 2 2 1.5 2 2 
306/2000 2 1 1.5 2 2 
637/1996 2 1 1 2 2 
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p15INK4b 
 
                                                                              p15INK4b 
                                          Nodular Basal Cell Carcinoma   
Normal 
Skin 
p15INK4b 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
1048/2000A 3 2 2 2 2.5 1.5 
1059/2009 3 2 1.5 2 2.5 1.5 
1092/1999 2 1.5 1.5 3 2.5 1 
1090/2000 3 2 2 3 3 1 
1056/1998 2 2 1 3 2.5 1.5 
1156/2009 1 1 1 2 1.5 1.5 
1075/2007 2 2 1.5 3 2.5 1 
1172/2008 1 2 1 2 1.5  
104/1999 1 2 2 2 1.5 
1022/1999 0 1 2 2 1 
1073/2007 2 2 0 2 2 
1019/2007 0 1.5 1.5 3 2 
1003/1999 2 2 1 2 2 
1123/2002 1 1.5 1.5 2 1.5 
1024/2007 1 1.5 1.5 1 1 
                                        Morphoeic Basal Cell Carcinoma 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
2103/2004 3 2 2.5 3 3 
761/1997 3 2 1 3 3 
118/2000 3 2 1.5 3 3 
406/1998 3 2 2 3 3 
2353/2006 3 2 2 2 2.5 
696/1997 1 1.5 1 1 1 
836/1997 2 1 2 2 2 
357/1998 1 2 1 2 1.5 
307/2001A 1 1 1 2 1.5 
49/2002 3 2 2 1 2 
391/1996A 2 3 1 3 2.5 
252/1999 1 2 2 1 1 
307/2001B 2 2 2 3 2.5 
306/2000 3 2 2 3 3 
637/1996 2 2 1.5 2 2 
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GLI-1 
 
                                                        GLI-1 
                                          Nodular Basal Cell Carcinoma  
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
1048/2000A 2 1 0 0 2 
1059/2009 2 2 1 1 2 
1092/1999 2 1 1 1 2 
1090/2000 1 0 1 1 1 
1056/1998 3 3 1 0 2 
1156/2009 2 1 1 1 1.5 
1075/2007 0.5 1 0 0.5 1 
1172/2008 3 2 1 1 2 
104/1999 2 1 0.5 0 1.5 
1022/1999 3 3 2 2 2.5 
1073/2007 3 3 2 1 2.5 
1019/2007 2 1 1 0 1 
1003/1999 2 1 1 1 1.5 
1123/2002 0.5 0.5 1 0 0.5 
1024/2007 2 1 2 0.5 2 
                                        Morphoeic Basal Cell Carcinoma 
Patient 
Number 
Nuclear 
Staining 
Cytoplasmic 
Staining 
Epithelial 
Staining 
Stromal 
Staining 
Overall 
Staining 
2103/2004 1 1 1 0 1 
761/1997 3 2 0.5 0.5 2 
118/2000 2 1 0.5 0.5 1 
406/1998 3 3 3 1 2.5 
2353/2006 1 1 0 0 0.5 
696/1997 1 0 0 0.5 0.5 
836/1997 2 2 0.5 1 1.5 
357/1998 2 1 0 0.5 1 
307/2001A 2 2 2 2 2 
49/2002 2 2 2 2 2 
391/1996A 1 0.5 1 1 1 
252/1999 3 3 1 0.5 2 
307/2001B 2 1 0.5 0.5 1 
306/2000 2 3 1 2 2.5 
637/1996 0.5 1 0 1 1 
 
 
